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Abstract 
When a drug is given orally, one of the major factors that impacts safety and efficacy is 
dissolution rate. Two important in vivo parameters that impact dissolution that are not well 
accounted for in current dissolution methods are the physiological buffer species bicarbonate and 
hydrodynamics. This work explores important aspects of each of these.  
Dissolution of pure drug using rotating disk dissolution methodology was used to 
evaluate the accuracy of several physically realistic simultaneous diffusion and chemical reaction 
schemes for CO2-bicarbonate buffer. Experimental results for ibuprofen, ketoprofen, 
indomethacin, 2-napthoic acid, benzoic acid, and haloperidol dissolution confirmed that the CO2 
hydration reaction is sufficiently slow that it plays an insignificant role in the hydrodynamic 
boundary layer. Therefore the reaction scheme of the CO2-bicarbonate buffer becomes 
           
  
       
   
    
         
  .  Dissolution experiments were also performed in 
the USP 2 (paddle) apparatus using suspended ibuprofen particles and tablets to demonstrate that 
the CO2-bicarbonate transport analysis can be successfully applied to pharmaceutical dosage 
forms. This transport analysis allows for predictions of phosphate buffers that more closely 
simulate dissolution in vivo. In the case of weak acid and weak base BCS class 2 drugs 
phosphate buffer concentrations are typically 1-15mM at pH 6.5.  
The role of hydrodynamics on particle dissolution was studied using the USP 4 (flow 
through) apparatus because it provides relatively well-defined fluid velocity profiles that may 
simulate in vivo conditions. Experimental results showed that increasing the fluid velocity 
xvi 
 
resulted in increased particle dissolution rates. The impact of fluid velocity can only be 
accurately predicted with knowledge of particle Reynolds number and the void space of the solid 
particles suspended in solution  The suspensions studied were consistent with predictions 
assuming a void fraction of 0.25 
  The impact of hydrodynamics was also studied for erodible HPMC tablets using the USP 
4 apparatus. In vitro erosion studies using bulk fluid velocities that simulate average intestinal 
flow rates (~0.1cm/sec) resulted in erosion rates that were 2-4.5 times slower than erosion rates 
observed for the same formulations in humans. It was concluded that the USP 4 apparatus may 
not provide hydrodynamics that accurately simulate in vivo tablet erosion. 
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Chapter 1 
 
The Impact of In Vivo Buffer and Hydrodynamic Parameters on In Vitro 
Dissolution 
 
Abstract  
A number of physiological parameters can impact the rate at which the drug dissolves in 
vivo. Two parameters that can play critical roles in the dissolution of oral drugs are the buffer 
species and the hydrodynamics. Bicarbonate is the main buffer present in the gastrointestinal 
tract and it can have a significant impact on the dissolution of ionizable drugs but current 
dissolution testing protocols do not accurately account for its effect on drug dissolution.  Also, 
the hydrodynamics in the intestine can play a major role in dissolution and current in vitro testing 
methods typically do not account for this specifically with regards to fluid flow rate. This chapter 
will give a comprehensive overview of the literature that is currently available and discuss each 
of these factors. The role of bicarbonate buffer and fluid velocity in dissolution will be analyzed 
as well as how a better understanding of them can increase our knowledge to develop a more in 
vivo relevant dissolution methodology. The literature analysis will provide a background for both 
the experimental work and the transport analysis used to develop mathematical models to predict 
dissolution that can be used to improve our knowledge in the science of in vivo predictive 
dissolution.   
Introduction 
Dissolution testing is a key aspect for predicting the in vivo performance of an oral drug 
because the drug must go into solution before it will reach the systemic circulation.  There are 
2 
 
numerous physiological conditions and physicochemical properties of the drug that have an 
effect on dissolution. Some of the most important factors that affect dissolution and their effect 
are listed in Table 1.1.  
The conditions used in current dissolution testing methods do not accurately reflect the 
physiological environment that a drug encounters in the body.  Having a dissolution 
methodology that can simulate conditions the drug and dosage form will see in the body before it 
is absorbed will create a valuable tool to evaluate a drug’s performance in vivo.  Two areas 
where current dissolution tests fail to achieve physiologically relevant conditions are the choice 
of buffer composition and strength as well as the hydrodynamic conditions the dosage form and 
drug will observe in vivo. 
The primary buffer throughout the gastrointestinal tract is bicarbonate buffer.  However, 
it is not commonly used as a buffer for dissolution testing because preparing bicarbonate buffer 
in the laboratory is a complicated process.  It requires the control of carbon dioxide gas partial 
pressure      g   . The carbon dioxide gas must be continuously pumped into the water because 
reacts with water to form bicarbonate.  Without a constant supply of     g , the carbon dioxide 
present in the aqueous system will be lost to the atmosphere and the buffer concentration will 
decrease.  For this reason, the process of obtaining a bicarbonate buffer at equilibrium and at a 
physiologically relevant pH is time consuming and not an ideal method by which to perform 
dissolution testing.  
 In addition, this process is dependent on a number of chemical reactions taking place in 
the buffer solution and depends on the kinetics of these reactions.  The rates of these chemical 
reactions add further complexity to bicarbonate buffer and this will be discussed in greater detail.  
It would be advantageous to use a more stable buffer that could more accurately depict 
3 
 
dissolution conditions in the gastrointestinal tract.  A suitable substitute to bicarbonate buffer 
will provide a more practical way to achieve a physiologically relevant dissolution test.  This will 
be accomplished by using predictions of dissolution rates of drugs in different buffers that match 
the dissolution rate in physiologically relevant bicarbonate buffer. 
The first portion of this research will focus on characterizing the bicarbonate system 
through mathematical modeling using transport analysis to predict dissolution.  The 
mathematical modeling will be verified experimentally by using rotating disk dissolution 
methodology.  The mathematical model will then be applied to more practical buffers (e.g. 
Phosphate) to match the dissolution rates between more stable buffer systems and 
physiologically relevant concentrations of bicarbonate buffer that can then be verified 
experimentally.  Lastly dissolution using the USP 2 apparatus will be investigated to see if the 
transport analysis can be applied to predict dissolution of drug particles in a non-static system 
with a diffusion layer thickness that is not clearly defined.  
The hydrodynamic boundary layer has an important role in the mathematical modeling of 
the simultaneous diffusion and chemical reaction of particles. It is a convenient way in which to 
characterize the impact of hydrodynamic conditions that drug particles encounter and can be 
modeled using dimensionless numbers 
1,2
.  The current hydrodynamic conditions in standard 
USP dissolution apparatuses do not appear to accurately describe the stress and hydrodynamic 
conditions experienced by dosage forms and drug particles in the gastrointestinal tract.  One way 
to better understand this is by considering physiologically appropriate flow rates and Reynolds 
numbers (Re) versus what is seen in current USP dissolution systems.   
The second phase of this research will focus on developing an in vitro dissolution 
methodology that will incorporate more physiological hydrodynamic conditions (i.e. 
4 
 
Hydrodynamic boundary layer) to achieve conditions that resemble that of the gastrointestinal 
tract.  This will be approached through the use dimensionless numbers (Sherwood number, 
Reynolds number, and Schmidt number) to identify experimental conditions that are more 
physiologically representative of the GI tract.  The focus of this research will be concentrated on 
the USP 4 apparatus (flow through cell) as a potential system that permits adequate control of the 
hydrodynamics and specifically the fluid flow rate.    
The review that follows discusses in detail the importance of buffer composition, 
bicarbonate buffer, and its role physiologically as well as the associated simultaneous diffusion 
and chemical reactions. This will lead to a discussion on how dissolution predictions will be 
modeled for the bicarbonate buffer system. Next, physiological modeling for the dissolution of 
particles with a focus on the hydrodynamic boundary layer will be examined as well as how 
dimensionless numbers can be incorporated to attain physiologically relevant dissolution 
conditions.  
Physiological Importance and Relevance of Buffer Species: Bicarbonate Buffer 
As shown in table 1.1, there are a number of in vivo parameters that affect the dissolution 
of drugs and an extensive study of these was reviewed by 
3
Mudie et al.  In terms of media 
throughout the gastrointestinal tract, efforts have been made to simulate fluid in the fed state 
(FESSIF) and fasted state (FASSIF) of the human intestine 
3, 5, 4,  
. These buffers typically contain 
bile salts, which have been shown to affect the solubility of drugs, based upon bile salt levels in 
the intestinal tract.  The presence of bile acids in the GI tract alters the buffer capacity and can 
have a large impact on the dissolution rate of drugs 
10
.  The main buffer component used in these 
fluids is phosphate buffer.  However, the concentration and buffer capacity of phosphate used 
experimentally does not give an accurate depiction of the buffer in the gastrointestinal tract.  
5 
 
Moreno et al. tested human intestinal fluid (HIF) against FASSIF and observed that HIF had a 
lower buffer capacity than FASSIF.  The pH change caused by selected drugs was 5 times 
greater in HIF compared to FASSIF 
6
.  The buffer capacity of HIF was found to range from 4-13 
mmol L
-1
/pH in this study of the fasted state 
13
. These values are roughly in the range of the 
reported values by Persson et al. who reported a buffer capacity of 2-3 mmol L
-1
/pH in the fasted 
state and 13 – 15 mmol L-1/pH in the fed state 7.  
A difference in buffer capacity could have a large effect on the dissolution of drugs in the 
body.  Past work in dissolution has shown that the properties of buffers and buffer concentrations 
can have a large effect on the dissolution of drugs 
8,9,10,11
.  In these studies, as the pH and buffer 
concentration are increased, the dissolution rate of weakly acidic drugs is also increased.  
McNamara and Amidon looked at the commonly used buffers acetate (pKa = 4.6), citrate 
(pKa=5.93), and phosphate (pKa=6.6) with respect to dissolution rates in each buffer at its 
maximum buffer capacity at pH 7-8 
10
.  In the pH range of 7-8, the dissolution rate was found to 
be highest in the phosphate buffer and the lowest in acetate buffer 
10
.   The reason for this is that 
the buffer will reach its maximum buffering capacity when the pKa of the buffer becomes two 
units or more higher than the pKa of the drug 
10
.Therefore a strong emphasis needs to be placed 
on buffer species and concentration when evaluating the dissolution of ionizable drugs.  
The main buffer in the small intestine of humans and other small animals is bicarbonate 
buffer. Bicarbonate plays a key role in neutralizing secreted acids in the mucosal layer which 
contributes to retaining a pH that is close to 7 
12
.  This function is of particular relevance at the 
mucosal surface in the stomach and duodenum 
12
.  This occurs by bicarbonate reacting with HCl 
secretions to form carbonic acid which then can form carbon dioxide and water 
13
.  Bicarbonate 
is secreted throughout the GI lumen and it occurs at different rates throughout the GI tract 
11,14
. 
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For example, basal bicarbonate secretions have been shown at a steady rate of ~150 µmol cm
-1
 h
-
1
 in the proximal duodenum and ~25 µmol cm
-1
 h
-1
 in the distal duodenum 
14
.  The first step for 
the secretion of bicarbonate into the duodenum has been shown to occur through uptake of 
sodium bicarbonate into the enterocyte via a cotransporter 
12
. Once in the enterocyte, bicarbonate 
will be secreted through exchange with Cl
- 
ions.  In addition, bicarbonate can undergo 
paracellular migration. A simplified version of the secretion process of bicarbonate into the GI 
lumen and the diffusion of carbon dioxide from the lumen into the cells is illustrated in figure 
1.1.  
Bicarbonate concentrations vary based on location in the GI tract and other factors such 
as food and stress 
14,15
. For example, the partial pressure of carbon dioxide has been shown to 
vary from 4% in arterial blood to up to 37% in the lumen during the duodenal fed state 
15
.  This 
variation in percent carbon dioxide in the body correlates with variations in the bicarbonate 
concentration (reaction description discussed in detail below).  Therefore dissolution testing 
should be done at a wide variation of bicarbonate buffer concentrations to evaluate the impact of 
buffer concentration on drug dissolution. 
McNamara et al. performed dissolution testing in systems with various percent carbon 
dioxide (5-20%) buffer compositions (and hence different bicarbonate buffer strengths) and 
compared these dissolution rates to FESSIF and FASSIF.  McNamara et al. found that the 
dissolution rates obtained in FASSIF and FESSIF were greater for both weakly acidic drugs 
(indomethacin) and weakly basic drugs (dypyridamole) when compared to the bicarbonate 
buffer.  Sheng et al. obtained similar results when using FASSIF and simulated intestinal fluid 
(SIF) without bile salts and with different phosphate concentrations. The dissolution study results 
of McNamara et al. and Sheng et al. correlate well with the data described above obtained by 
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Moreno et al. in which it was shown that the buffer capacity was higher for FASSIF than HIF.  
Thus current dissolution testing conditions must be reevaluated to obtain a more physiologically 
relevant buffer.  In order to do so, more knowledge about the entire CO2-bicarbonate buffer 
system must be obtained to accurately describe the impact this complicated buffer has on the 
dissolution of ionizable drugs. 
The Reactions and Kinetics of the Bicarbonate Buffer System  
Conversion of C      to C        
                   (Rxn. 1.1) 
The first reaction to be considered is the first step in the process of preparing bicarbonate 
buffer in the lab which requires     g  conversion into its aqueous form.  The solubility of 
    g  can be calculated using Henry’s Law to calculate the concentration of carbon dioxide 
           in the medium by using the partial pressure of     g  used in the different 
experiments.  The Henry’s law constant is dependent on the temperature of the system and the 
ionic strength.  The effect of temperature can be described by equation 1.1   
           
                                 
                       
         
 
 
 
 
  
     (Eq. 1.1) 
    
           ;         ;                          ;           
Harned and Davis also showed experimentally (see the table 2  that Henry’s law  onstant will be 
affected by the ionic strength, I, of the solution.  Below are the equations to calculate    to 
correct for the presence of species that will affect the ionic strength of the solution 16.     
      
       
 
        (Eq. 1.2) 
   
     
  
           (Eq. 1.3) 
                          (Eq. 1.4) 
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                     (Eq. 1.5) 
                (Eq. 1.6) 
                  (Eq. 1.7) 
  
 
 
     
                  (Eq. 1.8) 
Experimentally, 0.9% NaCl may be used to obtain ionic strength near physiologic conditions. 
  
 
 
                
                               
 
 
        
                     
       
        
     
       (Eq. 1.9) 
Using equations 1.1-1.9 to calculate the Henry’s law constant for 37oC and an ionic 
strength based on an isotonic solution gives a value of 0.02403.  This value closely approximates 
the experimental values obtained shown in table 1.2 by Harned and Davis
17
.  
Based on the equations and experimental values for Henry’s law constant, the solubility 
of carbon dioxide in water will decrease as the temperature and ionic strength increase.  The 
Henry’s law constant can be used along with the partial pressure of carbon dioxide (P(CO2)) 
being used to give the concentration of carbon dioxide in the buffer as shown below.  
                     (Eq. 1.10) 
                              
                                                  
The Reaction Between          and        
The carbon dioxide in solution is free to react with water. This reaction ultimately leads 
to the formation of bicarbonate buffer.  The complete reaction that takes place is shown below. 
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    (Rxn. 1.2) 
Reaction 1.2 can be broken down into two parts to determine the overall reaction constant 
(Ka).  The first part is the reversible reaction of the aqueous carbon dioxide to form carbonic acid 
as shown below.  
           
  
  
         (Rxn. 1.2a) 
The value for    is equal to the ratio for the hydration reaction of carbon dioxide and the 
dehydration of carbonic acid.   
   
  
  
   (Eq. 1.11a) 
   
       
         
   (Eq. 1.11b) 
The hydration (kh) and dehydration rate constants (kd) are significantly different and vary 
with temperature and ionic strength. The hydration rate constant (kh ) value varies from 0.06s
-1
 to 
0.16s
-1
 and the dehydration rate constant’s (kd) value varies from 50s
-1
 to 80s
-1
 in literature in the 
range of 30-40
o
C at different ionic strengths 
18-21
. A comprehensive list of these values is given 
in table 1.3. 
The concentration for carbonic acid at equilibrium is very low as evidenced by the values 
for the hydration rates and dehydration rates shown in the Table 1.3.  Based on the constants 
given in Table 1.3, the hydration reaction is at least several hundred times slower than the 
dehydration reaction such that the concentration of carbonic acid in aqueous solutions is low 
relative to the other buffer species.       
The Ionization of Carbonic Acid (     ) to form Bicarbonate (    
  ) 
The first ionization constant of carbonic acid (   ) plays a role in determining the rate of 
the overall reaction.   
10 
 
     
   
    
         
    (Rxn. 1.2b) 
The value for     is comprised of the forward reaction rate       for the ionization of carbonic 
acid to form bicarbonate and the reverse reaction rate        where the bicarbonate ion reacts 
with a hydrogen ion to form carbonic acid.  
    
   
   
   (Eq. 1.12) 
    
          
  
       
   (Eq. 1.13) 
The value of     is also affected by temperature and ionic strength.  Table 1.4 presents values 
reported around 37
o
C. 
There is little information regarding exact values for the forward and reverse reaction 
rates at 37
o
C.  However, values for the reaction rate constants have been given by 
26
Eigen and 
Hammes at 25
 o
C of        
  and          
    .  The values at 25
 o
C show that these 
rate constants are 6 to 10 orders of magnitude greater than the hydration (Kh) and dehydration 
rate (Kd) constants. This difference indicates that the hydration and dehydration reactions may be 
occurring too slowly to allow for an assumption of instantaneous chemical equilibrium. In 
comparison, the ionization reaction rates are so large that it can be assumed that the ionization of 
carbonic acid happens so rapidly that the chemical equilibrium is achieved instantaneously.   
The Overall Reaction Constant   
In the literature, usually the entire reaction is assumed to be at equilibrium where    and 
    are combined to give an overall pKa value (    ).  The chemical equilibrium and equation 
for equilibrium are shown below. 
           
  
  
      
   
    
         
  
              (Eq. 1.14) 
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   (Rxn. 1.2c) 
   
       
         
 
          
  
       
 
          
  
         
  (Eq. 1.15) 
The Ka value has been studied at different temperatures and different ionic strength’s. Using 
experimentally obtained data, it is possible to calculate    based on the temperature and ionic 
strength of the solution.  An equation for the temperature effect was developed by Millero et al.   
               
        
 
                                     (Eq. 1.15) 
Corrections to adjust for ionic strength are given by 
16
Butler . 
       
               (Eq. 1.16) 
    
                                                                               
      
    
      
       
   
     
 
   
  (Eq. 1.17) 
                     
This function above for      can only be applied to a temperature range of 0 to 50o C. 
Applying these equations, the value for     can be estimated based on the experimental 
conditions (eg: 37
o
C and a 0.9% NaCl solution) to be 6.04 which fits nicely with the 
experimental data given in table 1.5 for the overall reaction rate constant. Additionally this 
parameter was measured experimentally for our system and is consistent with this calculated 
value (see chapter 2)  
The value for    is used below to calculate the bicarbonate concentration in solution. 
   
          
  
         
   (Eq. 1.18) 
          
-
                (Eq. 1.19) 
     
-
  
            
     
             (Eq. 1.20) 
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Using the above equation, the bicarbonate concentration can be calculated in the bulk solution at 
equilibrium by monitoring [CO2 (aq)] and [H
+
].  A carbon dioxide monitor can be used to 
measure the percent carbon dioxide present in aqueous solution which can be converted to a 
value in atmospheric pressure (atm). The aqueous carbon dioxide concentration,            , 
can then be found by multiplying this measured value by the Henry’s Law constant under the 
experimental conditions of the system. In the above equation at equilibrium,    is constant and 
the      can be monitored using a pH meter.   
However, due to the solubility of carbon dioxide and the effect of hydrogen ions on the 
concentration of bicarbonate there are limitations in using bicarbonate buffer for dissolution.  
Dissolution testing at high bicarbonate buffer concentrations cannot realistically be performed at 
bulk solution pH values much below a pH of 5.5.  This is shown in the Table 1.6 for the percent 
carbon dioxide needed to produce bicarbonate buffers of various strengths. 
These values in Table 1.6 show that dissolution testing throughout the entire range of 
physiologically relevant pH in the small intestine (where weak acid dissolution primarily occurs) 
requires a wide range of %CO2 in solution.  The pH varies throughout the intestine and is lowest 
in the duodenal bulb which is closest portion to the stomach which will be receiving the low pH 
gastric secretions. The pH of the intestinal fluid is becomes higher as the fluid moves through the 
jejunum and the ileum.  When the bulk pH is below 6, only very low concentrations of 
bicarbonate buffer can be made and below pH 5.5 creates situations where virtually no 
bicarbonate buffer can be produced because the solubility of     g  is too low to allow 
bicarbonate to form at these pH values. In addition, as the pH increases over 7, a buffer at low 
bicarbonate concentrations is difficult to prepare accurately because such a low partial pressure 
of     g  is required.  This makes dissolution testing with physiological bicarbonate buffer 
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concentrations in the pH range of the small intestines (5-8) impractical. The pH values that are 
observed in the different portions of the small intestine are shown in Table 1.7.  Table 1.7 shows 
an average pH range in the upper small intestines is 6 – 7. At these pH values, dissolution testing 
with physiologically relevant concentrations of bicarbonate buffer can be done. 
Ionization of Bicarbonate (    
  ) to form Carbonate    
   
The bicarbonate ion (     
  ) can undergo ionization to form carbonate.  However, at 
physiologically relevant pH the bicarbonate ion would not dissociate to form any significant 
concentrations of carbonate. 
    
-
   
    
        
     (Rxn. 1.2d) 
This reaction, like the bicarbonate reaction discussed above occurs essentially instantaneously 
30
. 
The value for     varies with temperature and ionic strength. The effect of temperature on Ka2 
was studied by Millero et al. and is shown below. 
               
       
 
                          (Eq. 1.21) 
Using the above equation, the value for      at 37
o
 C is 10.249. The effect of Ionic strength can 
also be taken into account. The Davies equation can be modified to calculate the value of     as 
shown below 
16
. 
         
            (Eq. 1.22) 
 The final value for      after taking temperature and physiological ionic strength (assuming 
isotonic conditions) into account is 9.94.   
           
  
  
      
   
    
         
 
   
    
        
    (Rxn. 1.2e) 
The value for      is sufficiently greater than the pKa so that at physiologically relevant pH 
values, essentially no carbonate will form.  
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Carbonic Anhydrase catalytic effect and physiologic relevance: 
The presence of the enzyme carbonic anhydrase has been shown to catalyze the hydration 
and dehydration of    .  Carbonic anhydrase is a zinc containing metalloenzyme that has an 
acid form and a basic form with a pKa ~7 
31
.  There are 11 known carbonic anhydrase 
isoenzymes that have been found to be present in mammals 
32
.  A number of these carbonic 
anhydrase isoenzymes are throughout the gastrointestinal tract (CA I,II,III,IV, and VI).   
The enzymatic activity of carbonic anhydrase and the effect it has on hydration and dehydration 
has been studied extensively.  Roughton and Booth showed that the activity of the enzyme 
increases as pH increases 
33
.  However, as Khalifah states, the equilibrium constants would not 
change, only the forward and reverse rate constants kh and kd would change 
34
.  This means that 
the uptake and output of carbon dioxide are equally catalyzed by carbonic anhydrase.  This was 
discussed by Roughton and Booth and can be viewed as shown below.   
   
  
  
 
     
   
     
     
   (Eq. 1.23) 
                         
                         
 The ratio 
    
  
 provides a way to compare how effective an enzyme is towards a substrate. 
A ratio on the order of magnitude of 10
8
 means every collision between carbonic anhydrase and 
carbon dioxide will result in the formation of a complex that will lead to bicarbonate being 
formed.  The turnover number varies with each enzyme and pH  and CA II has the largest at 
1x10
6
 s
-1
  
35
. Additionally, Koeing and Brown obtained a 
     
   
 value for carbonic anhydrase of 
2.1x10
8
 while Khalifah obtained a value 1.35x10
8
  
37 36.  These large values of turnover numbers 
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and 
     
   
 for carbonic anhydrase demonstrate that this enzyme can convert carbon dioxide into 
its product essentially instantaneously. With these values, the rate limiting step in the presence of 
carbonic anhydrase becomes the diffusion of the molecules and not the reaction of carbon 
dioxide with water to produce carbonic acid.   
However, of the isoenzyme’s listed above, the one that seems to be most plausible for 
catalyzing the hydration/dehydration reaction of carbon dioxide in the gastrointestinal tract liquid 
media is CA VI.  This isoenzyme is located in the human salivary glands and CA VI is the only 
isoenzyme among the isoforms that is secreted which allows for the case to be made that 
carbonic anhydrase is present in the luminal fluid of the intestines 
38,39
.  The other isoenzymes 
are located in the cyptoplasm, mitochondria, or are membrane associated 
32
.  These isoenzymes 
would theoretically not have a direct effect on the hydration/dehydration of carbon dioxide in the 
intestinal fluid.  However, they would play a role in the overall bicarbonate equilibrium.     
It has been reported that 10-14 mg of the CA VI isoenzyme are swallowed every day 
38
.  
The concentration of CA VI fluctuates depending on the health of the person and disease state 
(eg: gastrointestinal disorders).  In healthy patients, the average concentration of CA VI in saliva 
was found to be 23 mg/liter 
38
.  This suggests that CA VI could be present in the gastrointestinal 
tract.  Parkkilla et al. also showed that CA VI is able to survive the highly acidic conditions of 
the stomach.  Parkkilla et al. exposed CA VI enzyme to a pH of 2.2 for up to 30 minutes and 
showed there to be little reduction in enzyme activity.  Since CA VI could survive the acidic 
conditions in the stomach, then it may be active in the fluid of the small intestine and available to 
catalyze the hydration/dehydration reaction of carbon dioxide. However, the presence of 
carbonic anhydrase has not been confirmed in the intestinal tract. Therefore the hydration and 
dehydration reactions are assumed to occur at their non-catalyzed rates in the lumenal fluid of 
16 
 
the intestines. This will be an important point to consider when evaluating dissolution 
experiments in the CO2-bicarbonate buffer system and applying a mathematical model that uses 
a simultaneous diffusion and chemical reaction approach. 
Modeling diffusion and simultaneous chemical reaction to predict dissolution rates 
Background on Rotating Disks Dissolution and Diffusion Layer Gradients 
Mathematical modeling will be implemented following the model formulated by Mooney 
et al. 
40,8
 that assumes simultaneous diffusion and chemical reaction in the hydrodynamic 
boundary layer ( or diffusion layer) adjacent to the dissolving surface of the tablet using a 
rotating disk.  The model permits the estimation of the pH at the surface of the tablet by taking 
into account the properties of the drug and buffer system while assuming simultaneous diffusion 
and chemical reaction in the hydrodynamic boundary layer.  These properties include the pH of 
the buffer, pKa of the drug and buffer, drug solubility, and the diffusion coefficient of all of the 
species involved.  In this model the dissolution of a drug is assumed to take place by a diffusion 
layer-controlled process 
8
.    
This model has been applied to rotating disk hydrodynamics which has been 
characterized in terms of dissolution and diffusion layer thickness 
41
. The hydrodynamic 
boundary layer exists because as the liquid flows along the solid surface its velocity is decreased 
due to friction 
42
. This decrease in velocity near the solid surface creates a boundary layer where 
the fluid’s velocity will change abruptly 42.   Within this layer transport occurs primarily by 
diffusion based on the concentration of all of the species present.  This diffusion layer controlled 
process takes place through a boundary layer of a constant thickness across the solid surface 
42
.  
The diffusion layer is a valid assumption based on the bulk solution being a homogenous well 
mixed mixture where no concentration gradients are present 
43
.   Levich characterized this 
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boundary layer thickness based on the liquid’s physical properties, velocity, and diffusion 
coefficient of the solid being dissolved 
41,42
.  Levich applied this theory to obtain the boundary 
layer thickness that is seen with a rotating disk by using equation 1.24.  
                     (Eq. 1.24) 
                                    
                                      
                                                
The correlation between the diffusion layer thickness and flux is evident by examining the 
equation for flux in a rotating disk system (equation 1.25).  It is a function of all of the same 
variables with the addition of the solubility of the drug. 
       
 
   
 
  
 
      (Eq. 1.25) 
                                                                                    
The above equation assumes that no natural convection is occurring and that the system is 
operating under laminar hydrodynamic conditions 
44
.   
Reactions and Equations for Obtaining flux in a buffered system 
The reactions that are taken into account in the simultaneous diffusion and chemical 
reaction model developed by Mooney et al. are shown below 
8
: 
      
  
       (Rxn. 1.3) 
  
  
 
         (Rxn. 1.4) 
      
  
 
      
   (Rxn. 1.5) 
    
  
         (Rxn. 1.6) 
   
  
 
           (Rxn. 1.7) 
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         (Rxn. 1.8) 
In reactions 1.3-1.8, HA is the unionized form of the drug and BH
+ 
is the unionized form of the 
buffer.  Any change that is caused by chemical reactions in the diffusion layer will lead to a 
change in one of the products or reactants in the reactions given above 
8. Fick’s laws can be 
applied to all of the elements involved in the above reactions to give the differential equations 
shown below. 
     
  
    
      
   
        (Eq. 1.26) 
     
  
   
      
   
        (Eq. 1.27) 
     
  
   
      
   
        (Eq. 1.28) 
      
  
    
       
   
       (Eq. 1.29) 
    
  
   
     
   
        (Eq. 1.30) 
      
  
    
       
   
       (Eq. 1.31) 
In this model, these equations are assumed to be at steady state.  Using the above 
equations and reactions, a number of mass balance relations can be made to obtain a cubic 
polynomial equation to solve for the pH at the surface of the tablet in a rotating disk.  This 
equation can easily be solved with computer software or using Newton’s method. A higher pH at 
the surface of the tablet for weak acid drugs corresponds to a faster dissolution rate.  
As reaction 1.4 illustrates, an ionizable drug acts to buffer the pH at the dissolving 
surface.   In order to better understand how different drugs behave as self buffers, figure 1.2 
shows the relative flux of drugs as pH is increased in an unbuffered dissolution medium.  Figure 
1.2 shows that the pH will not affect the dissolution rate of a highly soluble drug (benzoic acid) 
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unless it reaches a very high pH value.  This is because benzoic acid is so soluble that it is able to 
buffer the pH at the surface of the tablet very well and resist the changes in pH.  The opposite is 
seen with a very insoluble drug (indomethacin). A large increase in the relative dissolution rate is 
observed with indomethacin at a much lower pH because its solubility is sufficiently low that it 
is not able to buffer the surface pH as well, allowing the pH at the surface to rise and approach 
the bulk pH, thereby increasing dissolution rate.   
The impact of adding a buffer into the bulk solution is examined in Figure 1.3. Figure 1.3 
compares the pH gradient in the diffusion layer of ibuprofen when a 50mM phosphate buffer 
concentration is present in a pH 6.50 bulk solution to the gradient when no buffer is present in 
the bulk solution at pH 6.50. The high concentration of phosphate buffer helps to maintain a 
fairly constant pH across the diffusion layer so the pH at the surface is similar to the pH in the 
bulk solution. However, when no buffer is present, there is a sharp decrease in pH due to the 
drug forming H
+
 ions at its surface that are not being consumed by a buffer species. Therefore 
the surface pH is much less than the bulk pH when no buffer is present for a dissolving weak 
acid drug.  
Solving for the pH at the surface allows for all of the other unknown surface 
concentrations to be calculated. These calculated surface concentrations allow for the total flux 
of the drug to be predicted. 
                    
 
 
               
      
            
       
                    (Eq. 1.32a) 
                                     (Eq. 1.32b) 
Theoretical predictions using the film model have been shown to be accurate for various drugs 
(with different  physicochemical properties) over a range of buffer concentration and pH ranges 
8
.   
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The work presented so far assumes a buffer with only one pKa. However, this is usually 
not the case with buffers such as bicarbonate and phosphate.  To determine the impact of buffers 
with multiple pKa’s on drug dissolution, Aunins et al. 9 did work with polyionizable buffers. One 
of the buffer’s that was studied in this work was phosphate buffer which is commonly used in 
dissolution testing and is the main buffer component of FASSIF and FESSIF.  Aunins et al. 
applied the same model to include the different reactions and mass balances that occur with a 
buffer that has more than one pKa like phosphate.  The accuracy of including these additional 
parameters was studied by Aunins et al. by comparing predictions to experimental data and good 
agreement was found depending on the drug, buffer concentration, and pH of the solution.  In 
addition, this model was compared to the more simplistic model for a monoprotic buffer.  When 
compared, these models predicted nearly identical values as long as the pH of the solution was 
not within the range of the smallest or largest pKa. In the case of phosphate buffer, which has 
three pKa’s (1.86, 6.60, 11.5), the first and third pKa would only change the shape of the 
dissolution predictions over the buffer concentration used if the pH used was relatively low or 
high 
9
.  This result indicates that the monoprotic buffer system would be appropriate to be used 
for predictions for physiologically relevant dissolution testing based on the pH of the small 
intestine (see table 8) where dissolution primarily occurs.  Figure 1.4 specifically examined this 
by comparing the monoprotic and triprotic model predictions at pH 6.5 for ibuprofen over a 
range phosphate buffer concentration. Figure 1.4 shows that the same prediction for flux is 
obtained using either model at each buffer concentration. Therefore the simpler monoprotic film 
model will be used when predicting experimental dissolution results. 
Figure 1.5 applied the monoprotic model for phosphate buffer to show predictions of flux 
for ibuprofen at different phosphate buffer concentrations and different bulk pH values.  The 
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figure illustrates the major role that both bulk pH and buffer concentration play as the drug is 
dissolving. In order to develop an in vivo predictive dissolution test, these in vitro parameters 
must be as close to physiologically relevant as possible.  If not, the results could be significantly 
different from what is occurring in intestinal tract. This makes bicarbonate buffer and the ability 
to predict how it impacts the dissolution of drugs so important. 
Applying the model to Bicarbonate buffer: 
The overall equilibrium constant (pKa = 6.04) for bicarbonate buffer and the pH range 
for the dissolution experiments allows for the assumption that a monoprotic buffer model can be 
applied to bicarbonate. However, one problem with using the film model proposed by Mooney et 
al. is that it may not adequately take into account the reaction kinetics of the bicarbonate buffer 
system in the aqueous diffusion layer.  The model discussed above does not take into account the 
forward and reverse rate constants of each reaction. Instead it assumes the reactions are at 
equilibrium and it uses the overall equilibrium constant.  However, as previously discussed, the 
uncatalyzed reaction rate for the hydration of carbon dioxide to carbonic acid is a very slow 
process relative to the ionization reactions.   This means the assumption of equilibrium within the 
bulk solution may not translate into what is actually occurring in the diffusion layer.  A similar 
situation was examined by Mooney et al. in which the drug phenylbutazone, which has non-
instantaneous ionization kinetics, was studied.  In this study Mooney et al. showed that non-
instantaneous ionization kinetics of the drug can affect the observed dissolution rate 
45
.  In the 
pH range of 5-8 (roughly that seen throughout the intestines) the dissolution rate of d-
phenylbutazone was noticeably slower than phenylbutazone.   The ionization of each compound 
is not spontaneous but the stronger bond between carbon and deuterium was hypothesized by 
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Mooney et al. to slow the reaction to a greater extent 
45
. This would make the forward rate 
constants for d-phenylbutazone smaller 
45
.   
If the time the diffusing molecule spends in the diffusion layer is much less than the 
reaction time, then the reaction would presumably only be occurring in the bulk solution
45
.  A 
way for determining whether a reaction will take place in the diffusion layer is to compare the 
average lifetime of a diffusing molecule in the diffusion layer using the equation by Higuchi for 
the residence time in the diffusion layer 46.  The average lifetime in the diffusion layer is based 
on its thickness, the diffusivity of the molecule, and the rotational speed of the rotating disk 
45
.  
The reaction time depends on the first order rate constant and it defines the time needed for the 
reaction to be 63% complete 
45
.   
   
  
   
 
       
 
 
   
 
  (Eq. 1.33) 
                                                                    
   
 
 
  (Eq. 1.34) 
                 
                            
Predicting extreme cases of the bicarbonate buffer reaction kinetics 
Based on the hydration rate of carbon dioxide, it is possible that the hydration of carbon 
dioxide does not occur in the diffusion layer.  In fact, Roughton and Booth showed that no 
bicarbonate ion is present after 1 second in a carbon dioxide saturated solution at 0
o
C.  Using 
Roughton’s value of 0.131s-1 at 37oC, Parsons describes that only 50% of the reaction would take 
place in 5.3 seconds and it would take 35 seconds for the reaction to be 99% complete.  These 
times are significantly longer than the calculated time in the diffusion layer for CO2 of 0.5 
second or less depending on the thickness of the diffusion layer. Thus, the hydration reaction in 
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the absence of any catalyst may not be going to completion in the aqueous diffusion layer around 
the tablet during the dissolution test.  If the hydration reaction does not occur within the diffusion 
layer, this would have a large affect on the chemical equilibrium in the diffusion layer. Therefore 
the film model of Mooney and Stella would need to be adjusted to take into account the slow 
reaction kinetics of the hydration reaction in order to accurately predict the dissolution of drugs.  
How exactly this is done and the steps that need to be taken will be examined in further detail in 
chapters 2-4. One hypothesis was that the only buffer reactions taking place in the diffusion layer 
would be the ionization reaction of carbonic acid to form bicarbonate.  
     
   
    
         
  
Based on the chemical equilibrium that was previously discussed, the pKa of the above 
reaction would be 3.55.  This pKa is much smaller than if the hydration of carbon dioxide was 
assumed to be going to completion in the diffusion layer (pKa =6.04). However, the only time 
the hydration/dehydration reaction could be assumed to be at equilibrium is when the reaction 
time is very large (i.e. in the bulk solution) or if a catalytic species such as the enzyme carbonic 
anhydrase were present to speed up these reactions. This difference in overall equilibrium 
constants could have a large effect on the predictions of the dissolution rate depending on drug 
physicochemical properties.  Additionally, it could act as an upper and lower limit for predicted 
dissolution rates using bicarbonate buffer.  Figure 1.6 shows the predicted flux (dissolution rate) 
of ibuprofen is ~6 times slower when assuming no hydration/dehydration is occurring in the 
diffusion layer compared to when the hydration/dehydration reactions are assumed to be 
instantaneous.   
The predictions in figure 1.6 also show that there is a clear difference in the flux when 
dissolution is performed in bicarbonate buffer (both models) and when dissolution is performed 
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in phosphate buffer. This is consistent with literature where a difference in dissolution rates in 
bicarbonate buffer and in 50 mM phosphate buffer was observed by both McNamara et al. and 
Sheng et al.  This difference will be the focus of chapters 2-4 where a third model will be 
identified to take into account the slow reactions involved in the formation of bicarbonate buffer. 
This model will be shown to accurately predict dissolution in bicarbonate buffer and predict 
equivalent phosphate buffer concentrations.  
The importance of being able to incorporate physiologically relevant media in dissolution 
testing can become evident when determining the dissolution profile of a new drug product or 
evaluating the bioequivalence of reference and generic drug products.  The significance of 
dissolution media and bioequivalence has been studied by Alvarez et al. In their study the current 
USP recommended dissolution testing protocol for drug products was analyzed and compared to 
in vivo results. These drug products were shown to not be equivalent in vivo. However, the USP 
in vitro dissolution protocol was not able to determine the differences between brand name and 
generic drugs that were shown to occur in vivo 
47
.  Applying a more physiologically relevant 
buffer in dissolution testing should better simulate in vivo conditions and this will be one of the 
aspects studied in chapter 4. As the data will show, the buffer species and buffer concentration 
are critical parameters but not the only physiologic parameters that would need to be 
incorporated to provide an in vivo predictive dissolution test.  However, a better buffer system 
should aid in predicting in vivo bioequivalence and assist in guiding decisions with new drug 
products.   
Hydrodynamic Considerations for Physiologic Conditions and Parameters: 
Hydrodynamics in the gastrointestinal tract are governed primarily by peristalsis.  
Peristalsis involves the motor patterns in the gastrointestinal tract where the lumen undergoes 
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partial or total occlusion as content moves through the gastrointestinal tract 
48
.  In vivo studies 
have been performed using MRI to look at the contraction amplitudes within the intestine 
49
. 
When these contractions are not strong enough to completely occlude the lumen, backflow of the 
digesta in the lumen may occur 
50
.  Abrahamsson et al. observed that greater occlusion in the 
stomach led to increased rates of mixing.  Froelich et al. showed that the mean minimal cross 
sectional diameter was 9.95mm and the mean maximal diameter was 20.5mm.  These 
contractions and peristalsis occur because of the intake of calcium into smooth muscle cells and 
the contractions have been shown to occur at a rate of 10.96/minute 
49,
 
48
.  For matter in the 
intestine to be transported down the intestine, the contractions must create enough pressure to 
overcome the fluid friction that is present in the gastrointestinal tract 
50
. Flow rates and velocities 
have been measured throughout the gastrointestinal tract using MRI based imaging.  These 
values are shown in the table 1.8.   
The values in table 1.8 can be applied to the diffusion layer thickness equation to obtain a 
similar hydrodynamic boundary layer for particles in a dissolution test.  A similar theory could 
be applied to dimensionless numbers such as the Re number.   The Re number compares the 
effects of viscous and inertial forces.  Laminar flow is assumed to be present in the 
gastrointestinal tract based on low Re numbers that are obtained when looking at the properties 
of the fluid and flow velocities in the GI tract 
50
.  Abrahamsson et al. used these properties to 
predict Re numbers around a 1cm tablet to vary between 0.01-30 in the stomach 
53
.  However, 
these Re numbers are difficult to accurately predict because it depends on the physical 
conformation, the extent and mode of the contraction, and the properties of the fluid in the 
gastrointestinal tract 
50
.   
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In the body, a dosage form will undergo both normal and shear stress 
53
.  Dosage forms 
have been shown to undergo destruction within the stomach due to contractions 
54
.  These 
destructive forces vary depending on whether a person is in the fed or fasted state 
54
. The greatest 
destructive forces occur in the fed state 
54
.  The force a tablet undergoes due to shear stress is 
difficult to measure however.  Using data from the human stomach, Abrahamsson et al. predicted 
shear stress values as high as 500 dyne/cm
2
 and an average of 10-70 dyne/cm
2
. 
Modeling the Hydrodynamic Boundary Layer of Particles 
Theories and Equations: 
As discussed previously in reference to the rotating disk, the diffusion layer thickness 
affects the dissolution rate of compounds.  In vivo dissolution typically involves the 
disintegration of tablet dosage forms leading to the dissolution of particles.  The diffusion layer 
thickness can be assumed to be constant for very large particles (approaching infinite curvature) 
or tablets that undergo little change in size (eg. Rotating disk) during the dissolution process 
55
.  
Modeling of the hydrodynamic boundary layer (or diffusion layer) of particles may be based on 
the Noyes Whitney equation to describe dissolution.  
  
  
                                        (Eq. 1.35) 
                                       (cm
3/sec) 
                                   (cm/sec) 
                    (cm2) 
                                  (mass/cm
3) 
                                      (mass/cm
3) 
The mass transfer coefficient in the Noyes Whitney equation is equal to the diffusion coefficient 
of the drug divided by the diffusion layer thickness.   
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   (Eq. 1.36) 
  
  
           
        
    
   (Eq. 1.37) 
The effect of the mass transfer coefficient on spherical particle dissolution has been 
modeled by Hixson and Crowell, Higuchi and Hiestand, Niebergall et al, and Wang and 
Flanagan.   The Hixson and Crowell model is equivalent to the Noyes Whitney equation shown 
above.  In this model, it is assumed that the mass transfer coefficient is a constant and that the 
diffusion layer thickness is a constant 
56
.  This equation is shown below. 
  
  
            (Eq. 1.38) 
           
Higuchi and Hiestand modeled the dissolution of spherical particles assuming that 
dissolution is diffusion controlled, the bulk solution concentration is negligible at all times, and 
particle shape was assumed to be a sphere 
57
. In addition, the diffusion layer thickness was 
assumed to be equivalent to the particle radius (or greater) which is shown in their model for 
particle dissolution 
57
. 
  
  
      
  
  
    (Eq. 1.39) 
Equation 1.39 (Higuchi and Hiestand equation) shows that dissolution is dependent on the radius 
of the dissolving particle.  
  The Niebergall et al. model differs from the other two models by describing the diffusion 
layer thickness to be proportional to the square root of the particle diameter 
55
. This is shown in 
equations 1.40 and 1.41. 
       
       (Eq. 1.40) 
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      (Eq. 1.41) 
Wang and Flanagan derived a variation of the Noyes Whitney equation where the 
diffusion layer thickness is based on the radius of curvature of the dissolving surface which gave 
equation 1.42 shown below 
58
. 
  
  
       
 
 
 
 
  
                                                    (Eq. 1.42) 
                                
           
According to Wang and Flanagan, the value of α in this equation,  
 
 
 
 
  
  , is a constant.  
This equation shows that as the radius goes to zero  when α >> r , the diffusion layer thickness 
depends on the particle radius.  When the radius is large  when r>> α , the diffusion layer 
thickness is dependent on the constant α.   
The idea of a constant diffusion layer thickness above a critical particle size was 
proposed by Hintz and Johnson.  According to the Hintz and Jonson model, the diffusion layer 
thickness is equal to the radius of the particle until it reaches a critical value when it becomes 
constant 
59,2
 .  Multiple studies have been done to evaluate the critical particle size at which a 
constant diffusion layer thickness applies and what constant diffusion layer thickness fits the data 
the best. Hintz and Johnson theorized the diffusion layer thickness is equal to 30μm for particles 
with a radius larger than 30μm and becomes equal to the radius of the particle when the radius is 
less than 30μm through fitting dissolution data obtained using a rotating paddle on various sizes 
of disks of compressed drug.   Sheng et al. looked at the diffusion layer thickness for the BCS 
Class II drug fenofibrate using the Paddle method at both 50 RPM and 100 RPM. The test was 
performed on suspensions of varying particle size to observe the affect of particle size. When the 
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paddle was rotated at 100 RPM, the diffusion layer thickness was found to have a constant value 
of 43.5µm for particles with radius’s greater than  3.7µm 60.  However, when the paddle was 
rotated at 50 RPM, the diffusion layer thickness continued to slowly increase as the radius of the 
particle increased 
60
.  The Sheng et al. results differ somewhat from the Hintz and Johnson model 
because the dissolution rate obtained is smaller than what would be expected based on the Hintz 
and Johnson model.  A comparison of these models is shown in n figure 1.8. 
Diffusion Layer Thickness and Dimensionless Numbers: 
 The mass transfer coefficient and diffusion layer thickness can be expressed through the 
use of dimensionless numbers 
2
.  The dimensionless numbers of most relevance for 
characterizing dissolution are the Reynolds number (Re) and the Schmidt number (Sc).  The Re 
number compares the ratio of momentum forces to viscous forces.  In a laminar flow (low Re 
numbers with no disruption to parallel flow) case, the viscous forces dominate. For turbulent 
flow (high Re numbers where there is chaotic flow), inertial forces dominate.  Sc is a ratio of 
kinetic viscosity and molecular diffusivity and is assumed to be constant (under experimental 
conditions) 
61
.    
              (Eq. 1.43) 
                  
                  
                
                  
              (Eq. 1.44) 
                                                 
The Sherwood number (Sh) is a combination of the Re and Sc numbers that is used to 
equate the differing characteristics observed in mass transfer through molecular diffusion and 
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fluid flow 
1,2
. The Sherwood number defined in equation 1.45 is based on data from Ranz and 
Marshall.  Ranz and Marshall looked at the evaporation of drops in terms of mass and heat 
transfer and fit the data to a ratio of Re and Sc.  It was assumed that when the Re number was 
equal to zero, the mass transfer would need to have a value of two to obtain the vapor diffusivity 
in air 
1
.  Using this assumption and the experimentally fitted data, equation 1.45 was obtained. 
                                                    
The mass transfer coefficient can be defined in terms of dimensionless numbers 
1,2
.  
      
        
  
   (Eq. 46) 
                     
Using the above equations, it is possible to relate the mass transfer coefficient above to the 
effective diffusion layer and put it in terms that would take into account the particle size and 
fluid velocity experienced by the particles.  The dimensionless numbers defined above are 
incorporated into the diffusion layer thickness and the mass transfer coefficient.    
  
  
      
  
  
                                                   (Eq. 1.47) 
Equation 1.47 allows for the dissolution rate to be expressed in terms of experimental 
parameters that can be inserted into the Re and Sc numbers for the Sh number definition.  These 
parameters include the velocity the particle experiences in vivo and can be adjusted to meet 
physiologically relevant properties and allow for a more accurate dissolution tests to be 
performed based on conditions in the GI tract.  Therefore large fluid velocities observed in a 
USP 2 apparatus make the value for Sh much larger which leads to a small diffusion layer 
thickness that is much smaller than what would be expected physiologically. This is shown in 
figure 1.7. 
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Based on the Sh values, the diffusion layer thickness can be calculated for and compared 
to the other models proposed by Hintz and Johnson and Sheng et al.  When the diffusion layer 
thickness is calculated using dimensionless numbers (assuming fluid velocity in the intestine 
(0.13cm/s)), the initial thickness is similar to both the Sheng et al. (at 100 RPM) and the Hintz 
and Johnson model.  However, the diffusion layer thickness does continue to vary with radius 
and will not become a constant for particles less than 100 µm. A comparison of these models is 
shown in figure 1.8. 
 Conditions in Different Dissolution Apparatus’: 
As described above, the physiological conditions in the gastrointestinal tract vary.  When 
the agitation around a tablet and/or drug particles is increased, the rate of dissolution will 
increase.  However, if the agitation is large, drugs with different properties may exhibit similar 
dissolution rates even though they behave differently in the body 
62
.  Therefore, it would be 
advantageous to have a dissolution apparatus that can mimic physiologic hydrodynamic 
conditions.  The apparent diffusion layer thickness for particles of different size derived above 
can be used along with physiological parameters to create a dissolution test that is more 
physiologically relevant in a hydrodynamic sense.  For example, the relative velocity that a 
particle experiences in the GI tract could be used in an apparatus and applied to a suspension of 
particles. This would create a situation where the particles would have hydrodynamic conditions 
similar to the GI tract and therefore have a diffusion layer thickness similar to particles in the GI 
tract. A similar situation could be obtained through the use of the Reynolds number.  If a 
physiologically relevant Re number could be achieved in a dissolution apparatus, the diffusion 
layer thickness would be expected to be comparable to the expected value in the body. 
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USP 2 Apparatus (Paddle Method): 
When choosing an apparatus for dissolution testing of particles, the most common 
method is the USP apparatus 2 (Paddle) method.  However, it does not appropriately depict 
physiologic conditions based on the known hydrodynamic environment of the system.  As 
described above, the Re numbers experienced throughout the Gastrointestinal tract are quite low 
(0.01 – 30).  However, the Re numbers in the USP 2 paddle apparatus are much larger.  Figure 9 
shows how much the Re numbers vary depending on the rotational speed and that they are on the 
order of magnitude of 5x10
3 – 1x104 using the equation shown below. 
                                        
  
 
  (Eq. 1.48)63 
                                
                          
                         
In addition to the high Re numbers, there is a large the variation in agitation and shear 
rates throughout the USP 2 apparatus.  It has been observed that, at a rotational speed of 50 
RPM, the agitation rate varies and reaches a minimum at the bottom of a USP vessel when using 
the paddle method 
64,65
.  The USP 2 apparatus shows that the shear rates throughout the vessel 
are heterogeneous and that the lowest shear strain can be seen in areas where a tablet would be 
located 
65
.  The highest shear rates occurred around the impeller and at the walls while the lowest 
are seen between the shaft of the impeller and the wall of the dissolution apparatus 
65
.  Shear rate 
quantities are affected by rotational speed (the distribution stays constant) and were as high as 
185s
-1
 with a rotational speed of 100 RPM 
65
.  The variability in the hydrodynamics of the USP 2 
apparatus does not make it an ideal system for physiologically relevant dissolution testing. This 
heterogeneous stress in the USP 2 system has been looked at with respect to a tablet and it has 
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been shown to cause uneven dissolution across the tablet’s surface 66.  This would affect particles 
as well as they would be undergoing different conditions throughout the apparatus.  
USP 4 Apparatus (flow through cell) 
The USP 4 apparatus (flow through cell) is a possible alternative to be used for obtaining 
more physiologically relevant dissolution because of the experimental conditions it provides.  
The flow rate can be varied to a large extent to mimic those seen in the body and Re numbers can 
be obtained that fit the estimated values by Abrahamsson et al.  The properties seen in the flow 
through cell vary with the width of the flow through cell and the fluid flow rate 
67
.  By varying 
the size of the flow through cell and the flow rate, Cammarn et al. obtained Re numbers that 
varied in the range of 3.7 – 292.   As experimental conditions lead to increased Re numbers in 
the USP 4 apparatus, Cammarn et al. showed that the dissolution rate increased 
61
.  This data was 
taken from Cammarn et al. and made into a plot (Figure 1.10) to show the relationship between 
the experimental Re number and the observed dissolution rate. 
The flow in the USP 4 flow through cell can be made much more homogenous than that 
seen in the paddle method when the appropriate conditions are used. Shiko et al. observed that a 
homogenous flow could be obtained in a 12mm cell using a flow rate of 4-8 ml/min but the flow 
will start to deviate when the flow rate is increased to 16 ml/min.  However, when a 22.6 mm 
cell is used, the flow becomes heterogeneous starting at a flow rate of 8 ml/min and the 16 
ml/min flow rate is much more heterogeneous than that seen in the 12mm cell 
67
.  Additionally, 
the flow characteristics can be affected by the presence of no beads, open column (a single bead), 
or a packed bed where the fluid enters the flow through cell.  Kakhi showed that an open column 
or packed bed increases the area for flow by an order of magnitude when compared to a situation 
with no beads present.  The flow is similar in both the open and packed bed conformation 
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because it is flat and symmetrical in each case 
68
.  In addition, the shear stress profile is quite 
similar and it is proposed that differences in dissolution observed by the open and packed bed 
would not be related to the fluid dynamics of the vessel 
68
.  This creates a better defined system 
for dissolution testing with properties that could produce hydrodynamic conditions more similar 
to those seen in the gastrointestinal tract. 
The flow rates used in the flow through cell can be converted to linear velocity and 
applied to the derived equation for diffusion layer thickness by applying the equation of 
Cammarn et al. for linear velocity in a flow through cell. 
                
 
  
  (Eq. 1.49) 
             
                
                
                                                                                                
Applying Equation 1.49 will allow for fluid velocities to be achieved within the flow-through 
cell dissolution apparatus which can more closely match physiologically relevant conditions.  
This will help in creating a more appropriate hydrodynamic condition and corresponding 
hydrodynamic boundary layer (i.e. diffusion layer thickness) that drug particles will experience 
in vivo and should provide a more realistic set of conditions in which to evaluate dissolution rate.   
Conclusion 
The effect of buffer species and concentration as well as the hydrodynamics employed in 
dissolution testing play a major role in the dissolution rate of drugs.  The purpose of this research 
is to increase the physiological relevance of dissolution testing with respect to each of these 
aspects.  This will provide greater reliability in characterizing how a drug product will act in the 
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gastrointestinal tract.  In addition, the mathematical modeling of buffer and diffusion layer 
thickness of particles should offer insight into what parameters should be used for the current 
buffer and apparatus used for dissolution testing.  This will assist in providing a more meaningful 
way for determining bioequivalence for generic drugs.   
Chapters 2-4 will address the complex bicarbonate buffer system.  This will be done by 
considering the reaction kinetics involved with the buffer and applying these to a model to 
accurately describe their affect on the chemical reactions that occur at the surface of the tablet 
and within the diffusion layer during dissolution.  The successful modeling, when applied to pure 
drug in a rotating disk system, will allow for the experimental exploration of the model to other 
buffer systems and dosage forms in the USP 2 dissolution apparatus.  This will allow for 
qualifications to be made on the effectiveness of physiologically relevant buffers to provide 
meaningful dissolution results that are predictive of in vivo results 
Chapters 5-6 will address dissolution and erosion studies in the USP 4 apparatus. These 
chapters will address incorporating the velocities a dissolving particle or eroding tablet will see 
in vivo into an in vitro study and how this can impact each of the respective processes.  Accurate 
modeling of the effect velocity has on the diffusion layer thickness of particles will allow for 
physiologically relevant parameters to be used to approximate the rate at which particles will 
dissolve in the GI tract.   
Two of the most important factors for a dissolving drug in vivo are the dissolution media 
and the hydrodynamics. If modeling bicarbonate buffer effects and hydrodynamic effects on the 
diffusion layer separately are successful, then this would enhance our knowledge of two critical 
factors in dissolution testing and will give a more complete view of drug dissolution in the 
intestinal tract. 
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Tables 
Table 1. 1 Physiological and physicochemical factors that affect dissolution rate in the body and 
their corresponding Parameters in the body. 
Factor Affect on Dissolution Rate  Physiologically Relevant Data 
Drug Properties: 
Solubility 
 
pKa 
 
Diffusion Coefficient 
   
  Solubility     dissolution rate 
 
Depends on the pH of the system 
 
Larger  diffusion coefficient 
corresponds to a     dissolution 
rate 
The physiological properties 
can have an impact on each of 
the drug properties listed 
pH Weak acid:    pH       dissolution 
rate 
Weak base:     pH     dissolution 
rate 
3pH range in GI Tract 
(stomach through intestine) 
1.5 – 8.0  
Volume of the fluid    volume causes a    in the bulk 
concentration and      dissolved 
drug effect on the bulk solution 
which leads to an    dissolution 
rate 
Stomach (ml): Fasted state 
4 
13-
72,  
3 
300; Fed state 
4
 534-859, 
5 
500; 
Small intestine (ml): fasted state       
4 
45-319, 
4 
200; Fed state 
4
 20-
256,   
5
1000; 
Buffer Species Can      dissolution rate of an 
ionizable by limiting pH change 
at the surface of the drug 
particle or tablet depending on 
buffer pKa 
Bicarbonate is the buffer species 
present in the gastrointestinal 
tract 
Buffer concentration    Buffer concentration     
dissolution rate for ionizable 
drugs 
6 
Bicarbonate Concentrations 
(mM): 
Stomach: 9 – 20; 
Duodenum: 3-15; 
Jejunum: 2-20, 30; 
Ileum: 40, 50, 70, 74, 75; 
Presence of bile salts    drug solubility/wetting effect 3 Concentrations (mM): 
Duodenum:  
fasted state  = 6.4±1.2; 
fed state = 14.5±9.4; 
Upper Jejunum: 
fasted state = 5 
fed state = 15 
Lower Jejunum: 
fasted state = 6; 
Hydrodynamics Motility and contractions affect 
stress placed on the 
tablet/particles 
7 Contractions occur at a rate 
~11/minute in the small intestine 
Flow rate   Flow rate     dissolution rate 
8
 Stomach (ml/min): 4.8 - 34.8 
9
 Small intestine (ml/min): 1.62 – 
30.96 
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Table 1. 2. Measured values from literature and estimated values of Henry’s Law  onstant for 
Carbon Dioxide at different temperature and ionic Strength  
Solvent Temperature (
o
C) Henry’s Law  onstant 
Water 35 0.02678 
17
 
Water 40 0.02407 
17
 
0.2 M NaCl Solution  35 0.02553 
17
 
0.2 M NaCl Solution 40 0.02289 
17
 
Isotonic solution (0.0154 M) 37 0.02403 
* 
*Estimated using the van’t Hoff Equation for temperature dependence and ionic strength 
dependence from Butler
16
 
 
Table 1. 3. Experimental values from literature obtained for the hydration and dehydration rate 
constant of carbonic acid, carbon dioxide and water. 
Temperature 
(
o
C) 
Solvent Kh (s
-1
) Kd (s
-1
) 
38 Buffer mixture with Gaseous     0.161 
19
  
40 Water 0.143 
94
  
38 Phosphate Buffer 0.062 
95
  
37 Water 0.145 
23
 49.5 
23
 
32.5 HCl and Sodium Bicarbonate Mixture (made to 
ionic strength of 0.65 with NaCl) 
0.057 
18
 50.2 
18
 
36.7 Water  80  
20
 
36.9 HCl and Sodium Bicarbonate Mixture  49.04 
21
 
37 HCl and Potassium Bicarbonate Mixture (0.1 M 
Ionic Strength) 
 72 
22
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Table 1. 4. Experimental values from literature obtained at different experimental conditions for 
the equilibrium constant Ka1 (ratio of the forward and reverse ionization reaction). 
Temperature 
(
o
C) 
Solvent Ka1 pKa1 
35 Buffer with NaCl (Ionic 
Strength =0.143) 
            24 3.55 
35 Aqueous Solution           25 3.78 
38 Aqueous Solution           25 3.80 
 
Table 1. 5. Experimental values from literature obtained at different experimental conditions for 
the overall equilibrium reaction constant    
Temperature 
(
o
C) 
Solvent pKa 
35 Aqueous Solution 6.3094  
17
 
35 Aqueous Solution 6.3086  
27
 
35 Aqueous solution made to ionic strength 0.1 with NaCl 6.0683  
27
 
35 Aqueous solution made to ionic strength 0.2 with NaCl 6.0091  
27
 
40 Aqueous Solution 6.2978  
17
 
40 Aqueous solution made to ionic strength 0.1 with NaCl 6.0529  
27
 
40 Aqueous solution made to ionic strength 0.2 with NaCl 5.9935  
27
 
38 Phosphate buffer with sodium bicarbonante (ionic 
strength = 0.12) 
6.09  
28
 
32.5 HCl and Sodium Bicarbonate Mixture (made to ionic 
strength of 0.65 with NaCl) 
5.9354  
18
 
37 Isotonic solution (ionic strength =0.154) 6.045  
Calculated 
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Table 1. 6. % CO2 needed to produce various bicarbonate buffer concentrations at a range of 
physiologic pH values.   
pH 5.0 %CO2 10 %CO2 15 %CO2 20 %CO2 40 %CO2 60 %CO2 
5 0.11 0.22 0.33 0.44 0.88 1.31 
5.5 0.35 0.69 1.04 1.39 2.77 4.16 
6 1.10 2.19 3.29 4.38 8.77 13.15 
6.5 3.47 6.93 10.40 13.86 27.72 41.58 
7 10.96 21.92 32.87 43.83 87.66 131.49 
7.5 34.65 69.30 103.95 138.61 277.21 415.82 
 
Table 1. 7. pH values inside the different portions of the intestinal tract (recreated from 
29
Dressman et al 1998). 
Location  Fasted State pH Fed state pH  
Mid-distal duodenum 4.9 5.2 
 6.1 5.4 
 6.3 5.1 
 6.4  
Jejunum 4.4-6.5 5.2-6.0 
 6.6 6.2 
Ileum 6.5 6.8-7.8 
 6.8-8.0 (range) 6.8-8.0 
 7.4 7.5 
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Table 1. 8. Experimentally determined flow rates and velocities of fluid in the GI tract 
Measured Value Location Flow Rate (ml/min) Velocity 
51Stomach Fully open pylorus = 4.8 
Peak retropulsive velocity= 34.8 
Peak velocity = 0.74 cm/s 
52Small intestine Range = 1.62 – 30.96 
Average = 11.28 
Mean velocity = 0.129 cm/s 
50Ileum and Jejunum Fasted state = 0.73 
Fed state = 3.0 
 
- 
 
Figures 
 
Figure 1. 1. Jacob stewarts cycle depiction for the formation of bicarbonate in the GI epithelial 
cells and in the GI lumen.  
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Figure 1. 2. The relative flux (total drug flux/unionzed drug flux) of weak acid drugs with 
varying physicvochemical properties at different bulk pH values . Predictions for indomethacin       
(         ) ; Predictions for Ibuprofen (            ); Predictions for Benzoic Acid (          ) at different 
pH’s.  
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Figure 1. 3. A comparison of the predicted pH gradient in the diffusion layer of a 50mM 
phosphate buffer at pH 6.5 versus when no buffer is present at pH 6.5.  Predictions for 50mM 
phosphate buffer (          ); Predictions when no buffer is present (          ) 
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Figure 1. 4. Comparing predictions of ibuprofen flux over a wide variation in phosphate buffer 
concentration at pH 6.5 when using a monoprotic and triportic buffer system model. Predicted 
ibuprofen flux made using the monoprotic buffer model (          ); Predicted ibuprofen flux using 
the triprotic buffer model (            ); 
 
Figure 1. 5. Predicted flux of ibuprofen vs. phosphate buffer concentration. Predictions  at bulk 
pH 5.0 (         ); Predictions at bulk pH 6.0 (         ); predictions at bulk pH 7.0 (         ).  
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Figure 1. 6. Predicted dissolution rate of ibuprofen in bicarbonate buffer and in phosphate buffer 
at different buffer concentrations. Predictions in bicarbonate when the hydration/dehydration 
reaction of carbon dioxide with water is instantaneous (           ); Predictions in bicarbonate when 
the hydration/dehydration reactions do not occur (          ); Predictions in Phosphate (          ) 
 
Figure 1. 7.  Comparison of diffusion layer thickness predictions using Ranz and Marshall Sh#  
based on stomach fluid velocity, intestinal fluid velocity, and the USP 2 apparatus fluid velocity. 
Predictions based on the fluid velocity in the intestine (          ), Predictions based on fluid 
velocity in the stomach (         ); Predictions based on the fluid velocity observed in a USP 2 
Apparatus (          ); 
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Figure 1. 8.  omparison of the diffusion layer thickness at different particle size radius’ based on 
the different approaches to predicting diffusion layer thickness.  Predictions using the Sheng et 
al. Model using a USP 2 apparatus at 50 RPM(           ) and 100 RPM(          ), Predictions using 
the Hintz and Johnson model (          ) Predictions using dimensionless numbers following 
sugano and the Ranz and Marshall Sh# (          ). 
 
Figure 1. 9. Plot of Re numbers obtained in a USP 2 apparatus assuming the tablet is undergoing 
the maximum velocity at the impeller tip. 
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Figure 1. 10. Experimental dissolution rates obtained in a flow through system vs the Re 
numbers in the apparatus based on the experimental parameters. (data from Cammarn et al
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Chapter 2 
 
In Vivo Predictive Dissolution: Transport Analysis of the CO2, Bicarbonate In 
Vivo Buffer System 
 
Abstract 
Development of an oral in vivo predictive dissolution medium for acid drugs with a pKa 
in the physiological range (eg: BCS Class IIa) requires transport analysis of the complex in vivo 
CO2/bicarbonate buffering system.  In this chapter the bicarbonate buffer system using 
hydrodynamically defined rotating disk dissolution will be examined.  Transport analysis of 
Drug flux was predicted using the film model approach of Mooney et al
1
  based on equilibrium 
assumptions as well as accounting for the slow hydration reaction, CO2 + H2O  H2CO3.  The 
accuracy of the models was compared with experimentally determined results using the rotating 
disk dissolution of ibuprofen, indomethacin, and ketoprofen.  The weak acid drugs were studied 
at a variety of experimental conditions to analyze the ability of the model to predict dissolution 
in bicarbonate buffer at conditions the drugs may encounter in vivo.  The equilibrium and slow 
hydration reaction rate models predict significantly different dissolution rates. The experimental 
results are more accurately predicted by accounting for the slow hydration reaction under a 
variety of pH and hydrodynamic conditions.  While the complex bicarbonate buffering system 
requires further consideration given its dynamic nature in vivo, a simplifying irreversible reaction 
transport (IRR) analysis accurately predicts in vitro rotating disk dissolution rates of several 
carboxylic acid drugs.  This IRR transport model provides further insight into bicarbonate buffer 
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and can be useful in developing more physiologically relevant buffer systems for dissolution 
testing.   
Introduction 
When a drug product is administered orally, the absorption may be limited by the rate at 
which the drug dissolves in the gastrointestinal tract. For BCS Class II low solubility drugs, 
dissolution can be the rate limiting step 
2
.  The composition of the intestinal fluid plays a critical 
role in determining this rate.  One of the main components of intestinal fluid is the bicarbonate 
buffer species that controls lumenal pH.  Buffers can have a large effect on the dissolution of 
ionizable drugs by affecting the pH at the solid liquid interface (surface) of the dissolving drug 
1,3,4,5,6
.    
Bicarbonate (HCO3
-
) is secreted by epithelial cells and the pancreas into the small 
intestine where it is the main buffer in the lumen and acts to maintain a relatively constant pH in 
the intestinal tract.  Bicarbonate is thought to follow the Jacobs Stewart Cycle in the small 
intestine
7-9.  Bicarbonate (HCO3
-
) present in the intestinal lumen can react with hydrogen ions 
(H
+
) to form carbonic acid (H2CO3) which then produces carbon dioxide (CO2 (aq)) and water 
(H2O) through the dehydration reaction.  This process is reversible (see Rxn 2 below) and carbon 
dioxide can diffuse into the intestinal cells or react with water to form carbonic acid through the 
hydration reaction.  Carbonic acid can also ionize to form hydrogen ions and bicarbonate. In the 
intestinal cells, the same reversible process can occur, resulting in the formation of CO2 (aq) and 
HCO3
-
 .  The HCO3
-
 formed in the intestinal cells can be transported back into the intestinal 
lumen.  The concentration of each of the species formed is dependent on the corresponding 
equilibrium constants. 
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Concentrations of aqueous carbon dioxide and bicarbonate are directly related in the 
luminal fluid of the GI tract 
10,11,12
.   In the stomach of healthy humans, the percent CO2 typically 
ranges between 4-10 % CO2 (30-76 mmHg) and similar values are observed in the proximal 
jejunum 
12,13
.  McGeese and Hastings measured an average of 13.2 %  (100 mmHg) CO2 in the 
jejunum at an average pH of 6.5 
14
.  In the proximal duodenum, where there is a lower pH, these 
values are typically significantly higher and can be as high as 66% CO2  (500 mmHg) 
15
.  These 
%CO2 levels can be compared to normal atmospheric conditions which are approximately 
0.04%.  The stomach secretes about 400 mmol of  H
+
 per day
16
 (17mmol/h) which enters the 
duodenum. Therefore bicarbonate must be secreted at a rate in the duodenum that is high enough 
to neutralize the incoming H
+
. This increase in bicarbonate and H
+
 will result in an increase in 
the concentration of CO2 partial pressure in the duodenum.  Bicarbonate secretions have been 
shown to range from approximately 150-600 µmol cm
-1
 h
-1
 (~6mmol/h) in the proximal 
duodenum to approximately 25-200 µmol cm
-1
 h
-1
 (~2mmol/h) in the distal duodenum depending 
on the H
+ 
concentration 
11
.  The differences in the H
+
 stomach secretions and duodenal 
bicarbonate secretions results in the pH of the proximal duodenum  fluctuating  up to 5 pH units 
transiently
16
.  
An important consideration in more fully understanding the bicarbonate system are the 
individual reaction rates associated with the equilibrium constants Kc and Ka1 in Rxn 1 below. In 
particular, the hydration and dehydration reactions associated with Kc are six to ten orders of 
magnitude slower than the reaction rates associated with Ka1.  The enzyme carbonic anhydrase is 
present in the intracellular fluid and membranes of the epithelial cells of the intestinal tract 
8,17
. It 
functions to significantly accelerate the hydration and dehydration reactions in these regions.  
However, there is no evidence that carbonic anhydrase is secreted or present in the luminal fluid.  
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Therefore, it is likely that the hydration and dehydration reactions occur at their slow rates in the 
bulk lumenal fluid.   
Understanding the role of bicarbonate buffer and the reactions involved in its formation is 
essential to understanding the dissolution of weak acid and weak base drugs in the intestinal tract 
and, ultimately, to creating a more physiologically relevant dissolution medium.  While the 
impact that certain buffers have on a dissolving drug has been modeled accurately and is well 
understood, there has been little consideration to the effect of bicarbonate buffer on drug 
dissolution in the intestine 
1,3,4,5,18
.  There have been several studies characterizing the effect 
bicarbonate buffer has on drug dissolution and attempts have been made at modeling the 
process
5,10,19-21
 .  However, a thorough examination of how the CO2 reaction chemistry of 
bicarbonate buffer affects drug dissolution has not been explored though this is an area that has 
been studied rigorously and applied in geology and other sciences
22-26
. It is anticipated that a 
better understanding of the impact of bicarbonate buffer on the pH at the surface of a dissolving 
ionizable drug will provide the foundation for creating buffer systems that more closely resemble 
in vivo conditions and dissolution. 
  The significant role the slow hydration and dehydration rates have on the formation of 
bicarbonate and its ability to function as a buffer and alter the pH at the surface of dissolving 
drug (i.e at the solid liquid interface) has been investigated in this study.   The simultaneous 
convective diffusion and chemical reaction within the boundary layer model assuming either: (a) 
instantaneous chemical equilibrium, or (b) slow hydration and dehydration will be compared to 
experimental results using the defined hydrodynamics of the rotating disk dissolution system for 
weak acid drugs.  Our analysis and experimental results demonstrate that the slow irreversible 
reaction rate (IRR) model best matches the experimental rotating disk dissolution rate of the 
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weak acid drugs studied.  This analysis can be helpful in developing buffering systems that are 
more physiologically relevant for in vivo dissolution predictions and testing. A similar analysis 
may be applied to weak base and amphoteric drugs.  This analysis has been successfully applied 
to weak base drugs and this is detailed in chapter 3 
Reactions and Kinetics of the Bicarbonate Buffer System: 
Conversion of        to          
 Bicarbonate buffer can be produced experimentally by controlling the partial pressure of 
CO2 (g) equilibrated with water as shown in reaction 2.1. 
         
  
   
             
  
  
      
   
    
         
  (Rxn. 2.1) 
           
  
  
      
        (Rxn. 2.2) 
Chapter one described each of these reactions and reaction rates in detail. Reaction 1 outlines the 
entire chemical reaction process that leads to the formation of bicarbonate in the dissolution 
media and reaction 2.2 outlines the chemical equilibrium in the bulk solution. Therefore the 
bicarbonate concentration can be written as a function of the partial pressure of carbon dioxide 
(PCO2) using KH, assuming equilibrium. 
 
                                                 
-
  
         
     
          (Eq. 2.1) 
The values for PCO2 and [H
+
] can be adjusted to yield a desired bicarbonate buffer 
concentration.  At low pH values the total buffer concentration, when CO2 (aq) concentration is 
included, is relatively high due to high CO2 (g) partial pressures found in vivo in the duodenum.  
Due to solubility limitations of carbon dioxide and the effect of [H
+
] on the concentration of 
bicarbonate, the presence of bicarbonate is most significant for pH values in the range: 5.5  pH 
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 7.5.  For pH below 5.5, only very dilute bicarbonate buffer concentrations can be produced 
even at high CO2 (g) partial pressures.  At pH values above 7.5, only low CO2(g) values are 
required to achieve relevant bicarbonate buffer concentrations though the buffer capacity is 
substantially reduced.  The relationship between CO2(g), CO2(aq), [H
+
], and [HCO3
-
] is shown in 
Figure 2.1. Typical physiologic conditions of pH and carbon dioxide levels result in total buffer 
concentrations (CO2(aq) +  [HCO3
-
]) in the duodenum and jejunum in the range of 3-20 mM as 
shown in Figure 2.1.  Figure 2.1 also compares the total buffer concentration to the bicarbonate 
concentration as a function of pH.  The bicarbonate concentration present is significantly less 
than the total buffer concentration especially at low pH values. 
Simultaneous Diffusion and Reaction Model  
Dissolution of drugs from a solid surface are generally accurately predicted by 
considering the simultaneous diffusion and chemical reactions as described by Mooney et al. 
1,
 
27. Applying this to a rotating disk dissolution apparatus permits the estimation of pH at the 
surface of a compacted drug by taking into account the properties of the drug and buffer system 
and assuming simultaneous and instantaneous diffusion and chemical reaction in the 
hydrodynamic boundary layer near the surface of the rotating disk. Levich characterized this 
boundary layer thickness for a rotating disk based on liquid viscosity, rotational speed, and 
diffusion coefficient 
28,29
: 
                      (Eq. 2.2) 
When the Levich theory is applied to rotating disk drug dissolution, h is the thickness of 
the diffusion layer, D is the diffusion coefficient of the drug in the dissolving medium (aqueous 
buffer),  is the kinematic viscosity (water = 0.007 cm2/s) and  is the rotational speed (100RPM 
= 10.47 radians/sec).  The diffusion layer thickness is a constant for each specific drug under 
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fixed conditions of rotational speed (see Table 1). Following Mooney and coworkers
1
, the 
simultaneous diffusion and chemical reaction model assuming instantaneous reaction was 
applied to the bicarbonate buffer system.   
Applying a simultaneous diffusion and reaction model to bicarbonate buffer 
The reaction rate for the hydration of carbon dioxide to carbonic acid is a slow process as 
described above.  If the time the diffusing molecule spends in the diffusion layer is less than the 
reaction time, then the reaction would  primarily be occurring only in the bulk solution and not in 
the diffusion layer 
30
.  The average residence time of a molecule in the diffusion layer is 
determined by diffusion layer thickness and the diffusivity of the molecule
30
 (Equation 2.3).   
The reaction time depends on the first order rate constant and it defines the time needed for the 
reaction to be 63% complete 
30
 (Equation 2.4).  Equations 2.3 and 2.4 can be used to assess the 
extent that a reaction will go to completion within the diffusion layer:  
 
   
  
   
 
       
 
 
   
 
  (Eq. 2.3) 
 where tD is the average residence time of a diffusing molecule in the diffusion layer.  The 
reaction time, tr, is given by equation 2.4 where k is the first order rate constant. 
   
 
 
              
If the hydration reaction between CO2 (aq) and H2O does not occur sufficiently fast, the 
reaction will not go to completion in the diffusion layer and the flux of bicarbonate throughout 
the diffusion layer will be less than predicted.  Table 2.1 compares the ratio of tr (~8s
-1
) and tD at 
different diffusion layer thickness values (based on ibuprofen) calculated at different rotational 
speeds.   These values were calculated according to the Levich equation for boundary layer 
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thickness at the surface of a rotating disk (Eq. 2.2). The table shows that tr  > tD even at large 
diffusion layer thickness values (low RPM) and that tr can vary between an order of magnitude to 
two orders of magnitude greater than tD.   This analysis indicates that the hydration reaction is 
occurring to a very limited extent in the diffusion layer while the dehydration reaction appears 
sufficiently fast that it may be assumed to be occurring rapidly enough that this difference in 
reaction rates will impact the buffer capacity of bicarbonate in the diffusion layer. It is worth 
noting that these differences are relevant in the diffusion layer but not in the bulk aqueous phase 
where all the reactions occur sufficiently fast to be considered instantaneous and Rxn 2 and Ka 
apply because the reaction time is unlimited. 
As the results will show, this slow reaction has a large effect on the experimental flux in 
comparison to predictions applying the instantaneous reaction film model
1
 to bicarbonate buffer. 
Initially, two different chemical equilibrium approaches were applied.  The first approach was to 
assume that all of the reactions in the formation of bicarbonate buffer are sufficiently fast so that 
the chemical equilibrium that  is assumed to occur in the bulk solution (and displayed in Rxn. 
2.2) can be applied to the boundary layer in the film model (pKa = 6.04; Bulk Chemical 
Equilibrium Model ).  When applying the bulk chemical equilibrium (BCE) model, CO2 is the 
nonionized form of the buffer and HCO3
-
 is the ionized form of the buffer.  The second approach 
assumed that both the hydration and dehydration reaction are so slow in comparison to the 
ionization reactions that the formation of bicarbonate is dependent only on Rxn. 2.3 (pKa1 = 
3.55, Carbonic Acid Ionization Model).   
     
   
    
         
                
In the case of the carbonic acid ionization (CAI) model, H2CO3 is the nonionized form of 
the buffer and HCO3
-
 is the ionized form.  It is notable that the concentration of CO2(aq) is 300 
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times greater than carbonic acid. Therefore, the total buffer concentration used in the CAI model 
is less than that used in the BCE model which includes the CO2 (aq) concentration. However, the 
results show that these two assumptions do not accurately describe experimental results. 
Therefore a modification to the transport analysisis that incorporates the slow reaction rates for 
the hydration and dehydration reactions is necessary.   
Incorporating Reaction Rates into a Simultaneous Diffusion and Chemical Reaction Model 
The experimental results (see below) indicate that when reactions occur non-
instantaneously, the film model needs to account for the slow reactions.  There are multiple 
species reacting in the diffusion layer during the dissolution of a weak acid or weak base drug 
which makes adding reaction rates into the film model challenging.  Therefore, to follow the 
same steps using the simultaneous diffusion and chemical reaction model, two assumptions were 
made to simplify the process.  The first assumption is that only the hydration and dehydration 
reaction rates need to be considered and all other reactions can be assumed to take place 
instantaneously.  The second assumption is that since the hydration reaction (kh) happens very 
slowly, it can be assumed to not be taking place at all in the diffusion layer (though it will occur 
in the bulk solution) and the only reaction rate that needs to be included in the modeling process 
is the dehydration reaction rate (kd).  These assumptions describe a situation where the protons 
formed at the surface of the dissolving weak acid drug will react with HCO3
-
 to form H2CO3 
which can then form CO2 and H2O through an irreversible chemical reaction (Irreversible 
reaction model, IRR). This assumption, when applied to the film model changes the resulting 
equation for calculating the surface pH. The surface pH is no longer independent of reaction 
rates and diffusion layer thickness because the dehydration reaction rate and the diffusion layer 
thickness remain included in the equation for surface pH. The experimental results show that 
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using the irreversible reaction model (IRR model) allows for accurate predictions of drug flux in 
bicarbonate buffer.  The derivation of the IRR model is presented in the appendix and the cubic 
equation needed to solve for surface pH and drug flux are shown in appednix equations 33 and 
34d.   
Materials and Methods 
Ibuprofen (Albermarle, Lot#11550-0005 , indomethacin  Alexis Biochemicals  ≥ 98%, 
Lot# L25666, and ketoprofen (Sigma Aldrich, Lot# 044K0790) were used as received and all 
other chemicals used were of analytical grade.  Distilled water was used for all experiments.  
Mineral oil USP grade was used for the titration experiment to prevent the escape of CO2(g). All 
dissolution runs were performed in a jacketed beaker at 37
o
C.  Two runs were done for each 
experimental condition described below. Samples were analyzed using a UV spectrophotometer 
(Agilent Technologies, Model# 61103A).  The samples were obtained using a flow through 
system that recycled the analyzed solution back into the dissolution vessel.  The standard curves 
were also made using the UV flow through system.   
Ibuprofen solubility was measured by agitating a suspension of ibuprofen particles in 
50mM acetate buffer at pH 4.5 while being kept at 37
o
C. The pH of the saturated solution at 
37
o
C was measured to be 4.5. Samples were taken from the solutions and filtered before they 
were diluted with 50mM acetate buffer at pH 4.5. The measured solubility was 0.150 mg/ml and 
based on the the pH-solubility profile this solubility is in good agreement with an intrinsic 
solubility of 0.068mg/ml used in this paper and reported by Karl et al.
31
  
The intrinsic solubility of indomethacin was measured by agitating a suspension of 
indomethacin particles in 0.1N hydrochloric acid solution while being kept at 37
o
C. Samples 
were taken from the solutions and filtered before they were diluted with 0.1N hydrochloric acid. 
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The intrinsic solubility of ketoprofen was measured by agitating a suspension of ketoprofen 
particles in 0.1N hydrochloric acid solution while being kept at 37
o
C. Samples were taken from 
the solutions and filtered before they were diluted with pH 6.7 25mM phosphate buffer. 
The pKa of the bicarbonate buffer was measured by adjusting 100% dry compressed air and 
100% carbon dioxide (at appropriate ratios to give physiologically relevant conditions) in a 100 
ml 0.9%NaCl solution in a jacketed beaker at 37
o
C.  Solid NaOH and a 5N NaOH solution were 
used to adjust the buffer pH to ~7.0.  Next, the sources of the gas mixture were eliminated from 
the solution and USP grade mineral oil (heated to 37
o
C) was added to the buffer solution where it 
produced an oil layer on top of the aqueous buffer to limit the escape of carbon dioxide gas.  
1.0M HCL solution was added in 0.1ml increments to the aqueous phase and the pH was 
monitored until it dropped to ~5.0.  In addition, the %CO2 in the aqueous phase was monitored 
throughout using a CO2 monitor (YSI 8500 CO2 monitor).   
For the dissolution experiments in bicarbonate buffer, different concentrations of 
bicarbonate buffer were prepared by adjusting quantities of 100% dry compressed air and 100% 
carbon dioxide in a 0.9%NaCl solution at appropriate ratios to make pgysiologically relevant 
concentrations of bicarbonate buffer.  See Table 3 for the experimental parameters used for the 
dissolution tests  The %CO2(aq) in solution was determined using a CO2 monitor (YSI 8500) and 
pH was monitored using a pH meter (Beckman  40).  The mixture of carbon dioxide gas and 
air was continuously pumped in throughout the dissolution runs to maintain bulk equilibrium. 
Solid sodium hydroxide and sodium hydroxide solution was added to adjust pH.  The volume of 
the bicarbonate buffer dissolution medium for ibuprofen and indomethacin was 100ml and for 
ketoprofen it was 200ml. Differences in volume used for the experiments were made according 
to the solubility and predicted flux of each drug to achieve desirable experimental conditions 
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(sink conditions and adequate sensitivity for UV analysis). All experiments were carried out at 
100RPM. However, dissolution tests for ibuprofen were also done at rotational speeds of 50, 
250, and 500RPM. Ibuprofen was also performed at bulk pH values 5.5, 6.0 and 7.0 (see table3 
for buffer concentration at each pH).   
The flux of the drug was predicted by applying the mathematical models outlined in this 
paper and the parameters that are given in Table 2 using MATLAB (MathWorks). 
Results  
Bicarbonate Buffer Measured pKa 
Figure 2.2 shows the measured pH as a function of the amount of 1.0M HCl added during 
the titration and the experimental buffer capacity (dn/dpH) as a function of pH.  This titration 
data suggests that the pKa of the bulk solution is ~ 6.  A statistical analysis was performed by 
comparing the residual sum of squares and the result was a best fit bulk pKa of 6.04.  This value 
was used for calculating the bulk bicarbonate buffer concentrations for all of the rotating disk 
dissolution experiments.  Additionally, this was the pKa that was used in the BCE model for 
predicting drug flux in bicarbonate buffer.  One factor to note is that bicarbonate concentration is 
continuously changing throughout the titration because the %CO2 increases as the pH decreases.  
However, it was observed in the bulk solution that CO2 (aq) acts as a buffer component and 
therefore the total buffer concentration remains relatively constant.  The measured value of 6.04 
for the pKa of the overall reaction (Rxn. 2.2) is consistent with experimentally determined values 
in the literature which were given in chapter 1. 
Ibuprofen Results 
Figure 2.3 shows the predicted impact of rotational speed (change in diffusion layer 
thickness) on the surface pH and the relative buffering ability of bicarbonate based on the 
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different model approaches for ibuprofen. Assuming instantaneous hydration/dehydration 
reactions ( BCE model: pKa =6.04) predicts bicarbonate to have the greatest buffer capacity and 
highest surface pH. When it is assumed that the hydration/dehydration reactions do not occur at 
all in the diffusion layer (CAI model:  pKa 3.55), bicarbonate is predicted to have a low buffer 
capacity and low predicted surface pH. Assuming carbonic acid undergoes the irreversible 
dehydration reaction (IRR model) the predictions of buffer capacity and surface pH fall between 
the BCE and CAI models. Additionally, Figure 2.3 shows that the predicted surface pH 
decreases using the IRR model as the rotational speed increases.  The thickness of the diffusion 
layer has no effect on surface pH for the BCE and CAI models because it is assumed that 
chemical equilibrium is achieved instantaneously in each case.   
Figure 2.4 shows the calculated Damkohler numbers (Diffussion time/reaction time = 
  
  
 
 
) 
for the dehydration and hydration reactions as a function of diffusion layer thickness. This plot is 
consistent with figure 2.3, because as the diffusion layer thickness decreases, the reaction time 
becomes the rate limiting step in the case of the dehydration reaction. This explains why the IRR 
model starts to converge with the CAI model in figure 2.3 as the diffusion layer thickness 
decreases.  In the case of the hydration reaction, the Damkohler number is always at least an 
order of magnitude less than one which is consistent with the assumption that it does not 
contribute to buffering the pH in the diffusion layer.  
Figure 2.5 shows the experimental and predicted results for the flux of ibuprofen in 
bicarbonate buffer at different rotational speeds.  As will be seen with all of the experimental 
data, the BCE model overestimates the effect bicarbonate buffer has on increasing the surface pH 
and the flux of ibuprofen.  The CAI model underestimates the effect of bicarbonate buffer and 
the flux of ibuprofen. The flux predictions for the BCE and CAI models in Figure 4 are 
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influenced only by the changing diffusion layer thickness as the rotational speed is changed 
because the surface pH is constant and independent of diffusion layer thickness (see figure 2.3).   
The predicted flux in the IRR model also depends on diffusion layer thickness but in a more 
complicated fashion.  The surface pH is dependent on the residence time of the diffusing species, 
H2CO3,  and this impacts the consumption of H+ through the irreversible dehydration reaction  
(see Figure 2.3 and Appendix: Eq. 33).  The IRR model more accurately predicts the effect of a 
changing diffusion layer thicknessas as well as the diffusing species residence time in the 
diffusion layer on the ability of bicarbonate to buffer the pH at the surface of the dissolving drug.  
Figure 2.6 shows the predicted and experimental flux of ibuprofen in bicarbonate buffer 
over a range of buffer concentrations at pH 6.5.    There is a large difference in flux predictions 
when comparing the BCE versus CAI models. The experimental flux of ibuprofen in bicarbonate 
buffer falls between predictions assuming instantaneous hydration/dehydration reactions (BCE 
model) or no hydration/dehydration reactions (CAI model).  When the hydration reaction is 
assumed to not occur and the dehydration reaction rate is incorporated into the mathematical 
analysis (IRR model), the predicted flux matches the experimental flux very well. 
Figure 2.7 shows the effect bulk pH has on the flux of ibuprofen in 10-11mM bicarbonate 
buffer at pH values of 6, 6.5, and 7 as well as 3.5mM bicarbonate buffer at pH 5.5.  The 
experimental flux shows little variation as bulk solution pH is changed.  The BCE model 
overestimates the effect that bulk pH and bicarbonate buffer have on increasing the pH at the 
surface of the dissolving drug and the flux of ibuprofen.  The CAI model underestimates the 
effect that bulk pH and bicarbonate buffer have on increasing the pH at the surface of the 
dissolving drug and the flux of ibuprofen.  The flux of ibuprofen in bicarbonate buffer over 
different bulk pH values is accurately predicted using the IRR model.   
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Ketoprofen Results  
Figure 2.8 shows the experimental and predicted flux of ketoprofen in bicarbonate buffer 
over a range of buffer concentrations at pH 6.5.  The predictions show that an increase in buffer 
concentration results in a significant increase in the flux.  In comparison to ibuprofen, the 
solubility of ketoprofen is similar but it has a lower drug pKa.  Therefore ketoprofen acts as a 
similar self-buffer to ibuprofen but will be impacted by increasing buffer concentrations more 
under the experimental conditions. As was seen with ibuprofen, the experimental flux of 
ketoprofen in bicarbonate buffer is not predicted accurately by the BCE and CAI models and is 
only accurately predicted when the dehydration reaction rate is incorporated by applying the IRR 
model. 
Indomethacin Results 
Figure 2.9 shows the experimental and predicted flux of indomethacin in bicarbonate 
buffer over a range of buffer concentrations at pH 6.5.  In comparison to ibuprofen and 
ketoprofen, the solubility of indomethacin is much lower.  Therefore indomethacin does not 
serve as an effective self-buffer which leads to the surface pH approaching the bulk pH at low 
buffer concentrations. As was seen for with the other weak acid drugs, the experimental flux of 
indomethacin in bicarbonate buffer is not predicted accurately by the BCE or CAI models and is 
only accurately predicted by applying the IRR model.  
To provide further confirmation for the accuracy of the IRR model, previous 
experimental work involving rotating disk dissolution in bicarbonate buffer was evaluated.  A 
specific example is work by McNamara et al. 
10
 that also looked at the weak acid drug 
indomethacin using rotating disk dissolution.  Their work focused on dissolution at different 
bicarbonate buffer concentrations (different bulk PCO2) at a bulk pH of 6.8. Figure 2.10 shows 
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that the IRR model gives accurate predictions for the flux of indomethacin that was interpolated 
from the rotating disk experiments of McNamara et al. (Figure 3 in their paper) using the 
parameters in Table 6 as well as the pKa for indomethacin that was reported in their paper (pKa 
= 4.17).  
Discussion 
The results show that the ability of bicarbonate to buffer the surface pH of a dissolving 
drug is dependent on the hydration/dehydration reaction kinetics.  The boundry layer IRR model 
predicts the pH at the surface of the dissolving drug and allows for accurate predictions of drug 
flux consistent with the mass transport analysis. The success of the boundry layer IRR model 
indicates that H2CO3 will form CO2 and H2O through an irreversible reaction in the diffusion 
layer while undergoing its instantaneous, reversible ionization reaction to form bicarbonate. The 
IRR model, in effect, means that bicarbonate buffer behaves differently at the solid surface and 
in the boundary layer of a dissolving drug than it does in the bulk dissolution medium where the 
hydration/dehydration reaction is at equilibrium.  In effect, bicarbonate has a “dynamic buffer 
capacity” represented by the IRR model at the dissolving surface and boundary layer where the 
hydration reaction can be assumed to not occur while it has the standard buffer capacity expected 
of bicarbonate buffer in the bulk. 
Based on drug solubility and drug pKa, each drug studied has a different self-buffering 
effect at its dissolving surface.  The results show that the IRR model accurately predicts surface 
pH and drug flux even when large differences in drug properties exist.  For example, 
indomethacin has an intrinsic solubility ~100 times lower than ibuprofen and ketoprofen but this 
does not impact the accuracy of the predictions. Additionally, the ibuprofen and indomethacin 
data from this paper and from McNamara et al. shows the robustness of the IRR model to 
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changes in experimental conditions and the accuracy of the IRR model to be replicated in 
different laboratories.  The IRR model can accurately account for surface pH changes when the 
bulk pH and diffusion layer thickness is altered. When the diffusion layer thickness decreases, 
less time is available for the protons that have formed H2CO3 to undergo the dehydration 
reaction and form CO2 and H2O. This changes the ability of bicarbonate to function as a buffer 
and it becomes similar to a situation where only the ionization reaction occurs. Therefore 
changing the rotational speed of the disk will change the surface pH and this can be well 
accounted for by the IRR model.  The impact on surface pH that results from the changing 
diffusion layer thickness in the IRR model is one of the many factors taken into account in the 
cubic equation (Appendix: Equation 33) that calculates the pH at the surface of the dissolving 
drug.   The only difference between the CAI and the IRR  models is the mass transfer coefficient 
for the flux of carbonic acid: IRR =            and CAI = 
      
 
  . When the ratio of the mass 
transfer coefficients equals one (h = 5.4 µm) then the pH at the surface becomes equal to the CAI 
model because the irreversible reaction is no longer consuming protons that will allow for an 
increase in the buffer capacity beyond the CAI model.  Conversely, figures 3 and 4 show that as 
the diffusion layer thickness becomes larger, the proton consumption caused by the irreversible 
chemical reaction increases which allows for the IRR model to provide a similar buffer effect 
that is seen in the BCE model, However, this effect would only occur at unrealistically large 
diffusion layer thickness values. 
Although bicarbonate is the buffer present in the GI tract, using it as a buffer in 
dissolution testing is challenging because of long preparation times and hydrodynamic concerns 
(i.e. presence of air and CO2 gas bubbles in the apparatus) that make it less than ideal. However, 
the accuracy of the IRR model in predicting drug flux in bicarbonate buffer using known 
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physicochemical parameters allows for the possibility of predicting a more physiologically 
relevant buffer based on the physicochemical properties of the drug.  Aunins et al. demonstrated 
that the dissolution of  of weak acid drugs can be accurately predicted in standard buffers (i.e.: 
phosphate) using the standard film model
3
.  The accuracy of these models creates the basis for 
the development of an in vitro dissolution buffer system with more standard buffers that would 
be more predictive of the in vivo buffer conditions. However, the work done in this paper and by 
Aunins et al. applies only to rotating disk dissolution with fixed experimental conditions in the 
bulk solution.  A dissolving ionizable dosage form could have an effect on the bulk pH or 
introduce additional ionic or buffering species that could impact experimental and predicted 
dissolution rates .  Additionally, the dynamic nature of the in vivo environment with dynamic 
intestinal secretion of bicarbonate, the absorption of water, and transit through the intestine 
continues to make prediction of in vivo dissolution complex.  
 Conclusions 
Applying the boundary layer model with the assumption of instantaneous bulk chemical 
equilibrium (BCE model) does not accurately predict the buffer capacity of bicarbonate in the 
diffusion layer of a dissolving drug.  Assuming that the hydration and dehydration reactions 
happen instantaneously overestimates the ability of bicarbonate to buffer the pH at the surface of 
the dissolving drug.  On the other hand, assuming that both the dehydration and hydration 
reactions are too slow to occur in the diffusion layer (CAI model) underestimates the impact of 
bicarbonate buffer in the diffusion layer and at the surface of the tablet.  
 The predicted and experimental flux in bicarbonate buffer indicates the importance of 
the reaction kinetics in the bicarbonate buffer system.  The effect of the slow hydration reaction 
in the diffusion layer has a significant impact on the buffer capacity of bicarbonate at the surface 
68 
 
of a dissolving drug and drug dissolution. The assumption that CO2 does not react with H2O in 
the diffusional boundary layer, and thus assuming that H2CO3 undergoes an irreversible chemical 
reaction forming CO2 and H2O in addition to its ionization reaction (pKa=3.55), accurately 
predicts the effect that bicarbonate buffer has on the pH in the diffusion layer.  The IRR model is 
intermediate between the BCE and CAI models and most accurately describes the experimental 
results.  In effect, bicarbonate has:  a  a “dynamic buffer capacity” represented by the IRR model 
at the dissolving surface where the hydration reaction can be assumed to not occur and, (b) the 
standard buffer capacity expected of bicarbonate buffer in the bulk where the hydration reaction 
can be assumed to occur sufficiently quickly to appear to be instantaneous (ie. is at equilibrium).  
The irreversible reaction in the diffusion layer where H2CO3 forms CO2 and H2O allows protons 
to be consumed and assists in buffering the pH at the surface of the tablet.  The protons 
consumed by the irreversible reaction is a function of the time H2CO3 spends in the diffusion 
boundary layer and is therefore dependent on the thickness of the diffusion layer.  Unlike the 
film models, assuming instantaneous chemical equilibrium (BCE and CAI), the pH at the surface 
in the IRR model is a function of diffusion layer thickness. 
 The IRR model has been shown to accurately predict the rotating disk dissolution rate of 
the weak acid drugs studied.  More experimental work is needed to assess its applicability to 
weak bases and amphoteric drugs.  However, for ionizable drugs, the pH at the surface is a key 
component in determining the rate at which the drug will dissolve, and the IRR model is accurate 
at predicting surface pH under various experimental conditions examined in this paper. 
Therefore, the IRR model may be used to identify buffers that more closely resemble the 
bicarbonate buffer of the luminal fluid and provide an approach for the development of more 
relevant in vivo dissolution media.  
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Appendix 
Irreversible Reaction (IRR) model for the dissolution of weak acid drugs (HA = unionized form 
of the weak acid drug; A
-
 = ionized form of the weak acid drug) in bicarbonate buffer.  Below 
are the the equilibrium reactions before the irreversible dehydration reaction assumption is 
introduced: 
      
  
  
           
  
  
 
  
          
       
  
 
 
      
   
       
 
  
  
        
   
       
  
  
       
       
   
    
      
     
      
 
   
    
      
   is not considered because research has shown that this reaction would 
not play a role at the pH the experiments were performed at 
32
. 
Chemical equilibrium constant equations: 
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  (Eq. A3) 
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Differential equations defining the flux of the different species: 
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Defining   1-7 for the differential equations: 
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Setting up relations for   and the diffusion terms based on assumptions from mooney et al. 
1981: 
The first relation is that the amount of components reacting as acids must equal the amount of 
components acting as bases. 
               (Eq. A14) 
Eq. 14 based on the definitions for phi above: 
            
        
                  
               
               
  1  +   3−=−      +     + −− 1   [  −]+ 1  −− 2   [   3−]+ 2 [ 
2  3] −+      −     + −+  1  2  3−  1  +   3−  (Eq. A15) 
The like terms cancel on each side of the above equation which leads to Eq.15 becoming:     
The second assumption is that the acid drug in solution is neither created nor destroyed. 
          (Eq. A16) 
Eq. 16 based on the definitions for phi above: 
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Equation 16 allows for the relation made in equation 17 based on the assumption of steady state. 
   
      
   
   
      
   
     (Eq. A17) 
The third assumption is that since kh is so small (~0.1-0.16s
-1
) it is going to be assumed that it is 
not playing a role in formation of any      in the diffusion layer. Therefore       is 
undergoing an irreversible chemical reaction to form CO2 and H2O in addition to the reversible 
ionization reaction that forms H
+
 and HCO3
-
 .  The change in carbon dioxide concentration has no 
effect on the other buffer components leading to the Irreversible Reaction Model (IRR Model).  
           
  
       
  
  
        
  
Therefore it is assumed that the only two buffer components are H2CO3 and HCO3
-
 . The change 
in bicarbonate is based only upon the change in carbonic acid. This assumption leads to equation 
18: 
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All of the like terms cancel and equation 18 simplifies to equation 19. 
     
       
  
   
         
         
   
             (Eq. A19). 
At this point, all of the second order differential equations can be solved.  For all of the terms 
that are diffusion controlled the boundary conditions and general solution are shown below. 
  
     
   
   (Eq. A20) 
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The general solution to the second order differential is shown below. 
  
        
 
          (Eq. A21) 
      is not only diffusion controlled because it also undergoes an irreversible chemical 
reaction. The boundary conditions are the same for the species but its general solution is 
different. 
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The general solution to the second order differential for carbonic acid is shown below. 
 
 
 
 
          
 
   
       
 
         
 
 
 
 
   
       
 
 
   
       
 
  
 
   
       
 
  
 
 
                  
   
       
 
 
 
 
 
 
   
       
 
 
   
       
 
  
 
   
       
 
     (Eq. A23a) 
The diffusion coefficient of carbonic acid is a constant (      =14.6 x 10
-6
cm
2
/s) and so is the 
dehydration rate constant (      
-1
).  The diffusion layer thickness changes based on the 
Levich equation but it is on the order of 0.001-0.005.  Therefore     
 
   
       
 
 is so small (~4 x 
10
-5
) in comparison to  
   
       
 
(~2.5 x 10
4
) that it can be assumed that  
 
   
       
 
 and 
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-9
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 (~ 10
-9
-10
-10
) is equal to zero and 
equation 23a becomes Eq. 23b. 
         
   
       
 
 
   
       
 
  
 
 
         
   
       
 
 
 
 
 
 
   
       
 
 
   
       
 
       (Eq. A23b) 
In order to apply the rest of the assumptions to the film model, the derivative to all of the general 
solutions must be obtained in order to define all of the species in terms of flux. 
Taking the derivative of all of the diffusion controlled species gives the equation below: 
    
  
 
       
 
 (Eq. A24) 
Equation 24 must be multiplied by the diffusion coefficient to give the flux of the species. 
 
    
  
  
       
 
 (Eq. A25) 
Taking the derivative of the general solution for        (Eq. 23b) gives equation 26. 
            
   
       
 
        
   
       
 
 
            
 
   
       
 
       
               
In order to solve for the flux from x=h to x=0, the h and x must be inserted into equation 26. 
At x= 0 
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is equal to 1 which simplifies the above equation: 
           
        
   
       
 
 
           
       
 
   
   
       
 
(~ 0.4)              (~10
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) that 
           
   
   
       
 
 is considered to be zero 
which leaves: 
 
           
       
 
At x= h 
            
   
       
 
        
   
       
 
 
            
 
   
       
 
       
 
 
 
 
   
       
 
 is so small (~4 x 10
-5
) that it can be assumed that it and 
             
 
   
       
 
   
 
           
       
 
Therefore 
        
  
 from x=h (bulk solution) to the surface of the tablet (x=0) is 
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If you multiply each side by the diffusion coefficient of carbonic acid, then that will give the flux 
of carbonic acid. 
      
        
  
                                          
It is assumed that electric neutrality is maintained at every point in the diffusion layer so the 
positively charged species flux must be equal to the negatively charged species flux. 
           (Eq. 29) 
  
         
    
 
    
           
    
 
   
         
    
 
      
      
         
    
 
   (Eq. A30) 
Another assumption is that since no boundary or internal sources of buffer exist, then the total 
buffer flux must be equal to 0. 
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Equation 32 can be used to find the concentration of bicarbonate at the surface of the tablet. First 
it must be put in terms of known values and H
+ 
at the surface of the tablet as shown below. 
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The above equation can be inserted into equation 30 where electric neutrality is assumed in the 
diffusion layer. 
  
         
    
 
 
   
           
    
 
   
         
    
 
 
     
 
      
     
                                   
    
            
                
     (Eq. A30b) 
The chemical equilibrium in equations 1 and 2 were used to define all of the species at the 
surface of the tablet (x=0) in either terms of       or      .   
  
         
    
 
 
   
 
        
  
     
  
  
 
       
       
 
     
  
     
 
      
    
  1 2  3    2  3  +    3   3−   1    3+ +0   2  3      (Eq. A30c) 
The pH at the surface can be calculated by applying the boundary conditions to equation 30c. 
Boundary Conditions at X = h (bulk solution): 
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                    = Bulk pH 
                       = Known based on bulk pH and chemical equilibrium 
     
        
             = Experimental Buffer Concentration 
                          =                                   
                      = Analyzed with a CO2 monitor. 
Boundary Conditions at X = 0 (surface of the drug): 
                                                 
                      
                      
                        
     
        
               
                            
                        
 
  
         
    
 
 
   
 
        
  
     
  
  
 
  
       
 
     
  
     
 
      
     
                                   
    
            
                
     (Eq. A30d) 
Multiplying equation 30d by h and subtracting the right side of the equation from the  left side 
results in the following cubic equation to solve for       . 
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The total drug flux is dependent on the interfacial pH. 
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                   (Eq. A34c) 
Assuming the diffusion coefficient of the ionized form of the drug is equal to the unionized form 
of the drug simplifies equation 34c to equation 34d.  
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Tables 
 
Table 2. 1. The effect diffusion layer thickness (Ibuprofen used for h calculation) has on the time 
CO2 spends in the diffusion layer (tD) and how it compares to the reaction time (tr = 8s) 
h (µm) tD tr/tD 
61 (50 RPM) 0.76 11 
43 (100 RPM) 0.38 21 
27 (250 RPM) 0.15 53 
19 (500 RPM) 0.076 106 
14 (1000 RPM) 0.04 212 
 
 
Table 2. 2. Drug and buffer properties applied to the simultaneous diffusion and reaction model 
Species Solubility (M) pKa Diffusion Coefficient 
(cm
2
/s)  
 
Ibuprofen 3.30 x 10
-4  31
 4.43 
31
 7.93 x 10
-6  b 
Indomethacin 5.963 x 10
-6
 
c 
4.27 
33
 6.8 x 10
-6  
 
34
  
Ketoprofen 5.303 x 10
-4
 
c
 4.02
35,36
 9.3 x 10
-6  3
  
Bulk Bicarbonate  6.04 
c
 14.6 x 10
-6  37
 
Carbonic Acid  3.55
38 
14.6 x 10
-6  37
 
Carbon Dioxide 0.02403  24.9 x 10
-6
  
39
 
Values were taken from literature, estimated using the Wilke-Chang equation (b), or 
measured experimentally (c).  Table 3 average values (d) 
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Table 2. 3. Rotating disk dissolution experimental parameters applied to the weak acid drugs 
examined 
Drug Ibuprofen 
 
Indomethacin Ketoprofen 
Bulk pH 5.5 6.0 6.5 7.0 6.5 6.5 
Percent CO2 50 45 7-8, 14-16*, 21-22 5 7-8, 14-16, 21-22 7-8, 14-16, 24-26 
Total Buffer 
concentration  
[CO2(aq)]+[HCO3
-] 
(mM) 
15.5 20.7 6.5-7.5, 13-15*, 
19.5-20.5 
12.2 6.5-7.5, 13-15, 
19.5-20.5 
6.5-7.5, 13-15, 
22-24 
Bicarbonate 
Concentration 
[HCO3-]  (mM) 
3.5 9.9 5-5.5, 10-11*, 
14.5-15.5 
11 5-5.5, 10-11, 
14.5-15.5 
5-5.5, 10-11, 
16.5-18.0 
RPM 100 100 50, 100, 250, 500 100 100  100  
* = the concentration used for the ibuprofen experiments at 50, 250 and 500 RPM.  For ibuprofen at 
pH 6.5 and 100 RPM all buffer concentrations listed were used. 
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Figures 
 
Figure 2. 1. Total buffer and Bicarbonate buffer concentrations (mM) at physiologically relevant 
pH values as function of %CO2 in the solution (100% = 1atm) at 37
o
 C. Key  (             ) 5% CO2;     
(           ) 10% CO2; (          ) 20%  CO2; (          ) 40% CO2; (             ) 60% CO2; 
 
 
Figure 2. 2. Titration curve for a closed bicarbonate buffer system at 37
o
C and isotonic ionic 
strength (0.154M).  
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Figure 2. 3. The predicted surface pH of ibuprofen in 10mM bicarbonate buffer at pH 6.5 and 
different rotational speeds at 37
o
C. Key (           ) BCE Model Predictions;  (           ) IRR Model  
Predictions;  (             ) CAI Model Predictions; 
 
Figure 2. 4 The calculated Damkohler numbers for the hydration and dehydration reactions as a 
function of diffusion layer thickness. Key (           ) Damkohler numbers for the dehydration 
reaction;  (         ) Damkohler numbers for the hydration reaction; 
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Figure 2. 5. The experimental (50, 100, 250, and 500 RPM) and predicted flux of ibuprofen in 
10mM bicarbonate buffer at pH 6.5 and different rotational speeds at 37
o .  Key   •   
Experimental Flux;     (          ) BCE Model Flux Predictions;  (         ) IRR Model Flux 
Predictions;  (             ) CAI Model Flux Predictions; 
 
 
Figure 2. 6. The experimental and predicted flux of ibuprofen in bicarbonate buffer at multiple 
concentrations (at pH 6.5 and 37
o  .  Key   •   Experimental Flux;              B E Model Flux 
Predictions; (          ) IRR Model Flux Predictions;  (            ) CAI Model Flux Predictions; 
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Figure 2. 7. The experimental and predicted flux of ibuprofen in 10 mM bicarbonate buffer at 
bulk pH values of 5.3(3.5mM HCO3
-
), 6, 6.5 and 7 at 37
o .  Key   •   Experimental Flux;            
(          ) BCE Model Flux Predictions;  (         ) IRR Model Flux Predictions;  (           ) CAI 
Model Flux Predictions; 
 
Figure 2. 8. The experimental and predicted flux of Ketoprofen in bicarbonate buffer at multiple 
concentrations (at pH 6.5 and 37
o
C).  Key   •   Experimental Flux;               B E Model Flux 
Predictions;  (           ) IRR Model Flux Predictions;  (            ) CAI Model Flux Predictions 
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Figure 2. 9. The experimental and predicted flux of indomethacin in bicarbonate buffer at 
multiple concentrations (at pH 6.5 and 37
o
C).  Key   •   Experimental Flux;  (          ) BCE Model 
Flux Predictions;   (           ) IRR Model Flux Predictions;  (           ) CAI Model Flux Predictions; 
 
Figure 2. 10. The experimental (data interpolated from McNamara et al. 2003 figure 3) and 
predicted flux of indomethacin in bicarbonate buffer at multiple concentrations (at pH 6.8 and 
37
o
C).  Key   •   Experimental Flux;                IRR Model Flux Predictions based on 
indomethacin pKa = 4.17;    (        ) IRR Model Flux Predictions based on indomethacin pKa = 
4.27; 
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Chapter 3 
 
In Vivo Predictive Dissolution: Comparing the effect of bicarbonate and 
phosphate buffer on the dissolution of weak acids and weak bases 
 
Abstract 
Bicarbonate is the main buffer in the small intestine and it is well known that buffer 
properties such as pKa can affect the dissolution rate of ionizable drugs.  However, bicarbonate 
buffer is complicated to work with experimentally. Finding a suitable substitute for bicarbonate 
buffer may provide a way to perform more physiologically relevant dissolution tests. The 
dissolution of weak acid and weak base drugs was conducted in bicarbonate and phosphate 
buffer using rotating disk dissolution methodology. Experimental results were compared to the 
predicted results using the film model approach of Mooney et al. based on equilibrium 
assumptions as well as a model accounting for the slow hydration reaction, CO2 + H2O  
H2CO3. Assuming carbonic acid is irreversible in the dehydration direction: CO2 + H2O ← 
H2CO3, the transport analysis can accurately predicted rotating disk dissolution of weak acid and 
weak base drugs in bicarbonate buffer.  The predictions show that matching the dissolution of 
weak acid and weak base drugs in phosphate and bicarbonate buffer is possible.  The phosphate 
buffer concentration necessary to match physiologically relevant bicarbonate buffer (eg: 10 mM 
[HCO3
-
], pH=6.5) is typically in the range of <1-25mM and is very dependent upon drug 
solubility and pKa.. 
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Introduction 
Dissolution can be an important diagnostic tool for predicting the in vivo effects when a 
drug product administered orally.  The identification of an in vitro dissolution test that accurately 
predicts in vivo dissolution is therefore essential. Bicarbonate (HCO3
-
) is secreted by the 
pancreas and epithelial cells in the small intestine to neutralize gastric acid emptied into the 
duodenum and buffer the intestinal fluid maintaining intestinal pH . Conducting dissolution 
experiments in bicarbonate buffer would be more physiologically realistic.  However, the 
preparation of physiologically relevant bicarbonate buffer is more complex experimentally.  CO2 
gas must be constantly added to water to obtain a constant bicarbonate buffer concentration. This 
is generally a slow process that can also affect the hydrodynamics and dissolution of drug 
product/particles due to the potential presence of gas bubbles at solid liquid interfaces. Therefore 
using a buffer solution that produces equivalent buffer effect on drug dissolution as bicarbonate 
buffer would be preferred. 
Phosphate buffer is a logical buffer to consider matching the effects of bicarbonate buffer 
and creates a more physiologically relevant dissolution test. Phosphate buffer is commonly used 
in dissolution testing and is a buffer proposed in the guidance by the FDA to be used for in vivo 
biowaivers 
1
.  Additionally, phosphate has a pKa (6.8) that is within the pH range of the small 
intestine and the dissolution of weak acid drugs in phosphate buffer has been accurately 
predicted using the film model and reaction plane model 
2-4
.   
Phosphate buffer is currently used today as the buffer component in USP simulated 
intestinal fluid (SIF), and in fasted state simulated intestinal fluid (FASSIF) with concentrations 
of 50mM and 29mM respectively
5,6
. However, the average bicarbonate buffer concentration in 
the small intestine is ~6-20mM 
7
. The difference in physiological bicarbonate buffer 
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concentrations and typical phosphate buffer concentrations illustrates the variation between the 
dissolution media that is currently used versus the fluid present in the small intestine. These 
differences have been studied experimentally and significant differences in dissolution between 
physiologically relevant bicarbonate buffer and phosphate buffer have been observed
4,8-11
.  In 
order to accurately predict this difference and an equivalent phosphate buffer, the 
physicochemical properties of the drug and buffer must be taken account.  Additionally, Krieg 
and coworkers demonstrated the importance of reaction kinetics on the ability of bicarbonate to 
buffer the pH in the diffusion layer and at the surface of dissolving drug.  This reaction 
component introduces an additional complexity for matching the buffer capacities of bicarbonate 
and phosphate in the diffusion layer and for predicting an equivalent phosphate buffer for 
dissolution testing. A further complication is changes in bulk pH with low buffer capacities and 
low physiological volumes during dissolution usually requiring a pH-Stat to maintain bulk pH. 
This paper will experimentally examine the buffer effects of phosphate and bicarbonate 
using rotating disk dissolution of weak acid and weak base drugs.  The experimental data will be 
compared to predictions of the film model and the IRR model outlined in Krieg et al. that 
predicts the dissolution of drugs in bicarbonate buffer by incorporating the dehydration reaction 
rate and assuming that H2CO3 undergoes an irreversible reaction to form CO2 and H2O.  Results 
will show that the dissolution of both weak acid and weak base drugs can be accurately predicted 
in buffers with different physicochemical properties.  These results may provide the basis for 
predicting phosphate buffer concentrations that are more indicative of the buffer present in the 
luminal fluid of the intestine and offer a more physiologically relevant dissolution buffer.   
Applying a simultaneous diffusion and reaction model to phosphate buffer 
Phosphate buffer is determined by the following ionization reactions: 
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At physiologically relevant pH values of the small intestine, the only relevant pKa value is 6.8 
(pKa2  as demonstrated by Aunins et al. who incorporated buffers with multiple pKa’s into the 
simultaneous diffusion and chemical reaction model 
2
.  The values for pKa1 (1.86) and pKa3 
(11.5) are not in the range of the physiologically relevant intestinal pH and therefore have no 
significant buffer effect.  Therefore, the only species of relevance are monobasic phosphate and 
dibasic phosphate (Rxn 3.2).  The reaction rates for ionization are assumed to be occurring so 
fast that they occur instantaneously relative to diffusion and the film model accurately predicts 
the impact of phosphate buffer on the dissolution of weak acid drugs as described by Mooney et 
al. and Aunins
2,13
.  
The same film model procedure can be applied to weak base drugs.  A weak base drug 
will protonate at pH values below its pKa and consequently produce OH
-
 in solution.  As a 
result, the pH at the surface of a weak base drug will generally be higher than that of the bulk 
solution pH.  The addition of a buffer will act to decrease the surface pH.  Hence the chemical 
equilibrium reactions must take this into account when solving for the flux of weak base drugs.  
The equilibrium reactions are shown below.  
 
      
  
  
          (Rxn. 3.4) 
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Where B
-
 is deprotonated form of the weak base drug, BH is the protonated form of the weak 
base drug. 
The assumptions made in the film model for weak acids are applied to weak bases with 
the chemical equilibrium adjusted accordingly. A cubic equation can be obtained for the OH
-
 
concentration at the surface of the tablet which allows for the pH at the surface of the tablet to be 
calculated. This cubic equation is shown below.   
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This same transport analysis that assumes instantaneous chemical equilibrium was 
applied to bicarbonate buffer through two different approaches. The BCE model (bulk chemical 
equilibrium) assumes that the hydration and dehydration reactions in the formation of 
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bicarbonate are fast enough to reach chemical equilibrium instantaneously (pKa =6.04). The CAI 
model (carbonic acid ionization) assumes that the hydration and dehydration reactions are too 
slow to occur at all in the diffusion layer (pKa = 3.55).  A more thorough explanation of these 
models is given in Krieg et al
14
. 
Applying a simultaneous diffusion and reaction model to with an irreversible chemical 
reaction to weak base drugs 
 
The same IRR model scheme from Krieg, et al. to model weak acid dissolution was used 
to model the impact of the slow hydration and dehydration reactions on bicarbonate buffer by 
assuming that H2CO3 undergoes an irreversible chemical reaction to form CO2 and H2O
14
. The 
chemical reactions that were considered for the analysis are shown below. 
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The role the dehydration reaction rate (kd) plays in the calculation for the hydroxide ion 
concentration at the surface of the dissolving drug is evident when comparing equation 3.1 to 
equation 3.2 shown below. 
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Materials and Methods 
 
Benzoic acid (Sigma Aldrich - St. Louis, Missouri, USA;  > 99.5%, Lot# MKBG2270V), 
ibuprofen (Albermarle – Baton Rouge, Louisiana, USA; Lot#11550-0005), indomethacin (Alexis 
Biochemicals – San Diego,  alifornia, USA;  ≥ 98%, Lot# L 5666 ,   -napthoic acid (Sigma 
Aldrich- St. Louis, Missouri, USA;  Lot #14709KHV), ketoprofen (Sigma Aldrich- St. Louis, 
Missouri, USA; Lot# 044K0790), and Haloperidol (TCI Portland, Oregon, USA; >98.0%  
Lot#D6C3D-R1) were used as received.  All other chemicals used were of analytical grade.  
Distilled water was used for all experiments.  All dissolution runs were performed in a jacketed 
beaker at 37
o
C.  Two runs were done for each experimental condition described below. Samples 
were analyzed using a UV spectrophotometer (Agilent Technologies -  Santa Clara, California, 
USA; Model# 61103A).  The samples were obtained using a flow through system that recycled 
the analyzed solution back into the dissolution vessel.  The standard curves were also made using 
the UV flow through system.   
The solubility of 2-naphthoic acid was measured by agitating the suspension in 0.1N 
hydrochloric acid solution while being kept at 37
o
C. Samples were filtered before dilution in pH 
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6.5 50 mM phosphate buffer.  The pKa and solubility of the other compounds studied are shown 
in Table 3. 
Dissolution experiments using phosphate buffer were performed in duplicates at pH 6.5 
at several different phosphate concentrations and medium volumes. The exact experimental 
parameters can be seen in tables 1 and 2. Solutions were made using sodium monobasic 
phosphate, sodium hydroxide, and sodium chloride to make it isotonic. A disc of compressed 
drug with a tablet diameter of 1cm was used for ibuprofen, indomethacin, ketoprofen, and 
haloperidol. A compressed disc with a tablet diameter of 0.472cm was used for benzoic acid and 
2-naphthoic acid.  Differences in volume and tablet diameter used for these experiments were 
made according to the solubility and predicted flux of each drug to achieve desirable 
experimental conditions (sink conditions and adequate sensitivity for UV analysis). All 
experiments were carried out at 100RPM. 
For the rotating disk dissolution experiments in bicarbonate buffer, different bicarbonate 
buffer concentrations were prepared by continuously flowing quantities of 100% dry compressed 
air and 100% carbon dioxide in a 0.9%NaCl solution at appropriate ratios. The %CO2(aq) in 
solution was determined using a CO2 monitor (YSI 8500 – Yellow Springs, Ohio, USA) and pH 
was monitored using a pH meter (Beckman   40 – Brea, California, USA).   Solid sodium 
hydroxide and 5N NaOH was added to adjust pH.  The exact experimental parameters can be 
seen in tables 3.1 and 3.2.  Note that the buffer concentration may be defined either as the 
bicarbonate concentration or the sum of bicarbonate and CO2 as shown in tables 3.1 and 3.2. 
The flux of the drugs was predicted by applying the mathematical models outlined in this paper 
and Krieg et al. and the parameters given in Table3.3 using MATLAB (Mathworks – Natick, 
Massachusetts, USA). 
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Results  
Ibuprofen Results 
Figure 3.1 shows the flux of ibuprofen in bicarbonate and phosphate buffer over a range 
of buffer concentrations along with theoretical predictions at pH 6.5.  The data for the flux of 
ibuprofen, indomethacin, and ketoprofen in bicarbonate buffer was shown and explained in 
Krieg et al.
14
. The rotating disk flux of ibuprofen in phosphate buffer is accurately predicted by 
the simultaneous diffusion and chemical reaction model as expected.  The predictions show that 
an increase in phosphate buffer concentration results in a significant increase in the flux but 
ibuprofen still serves as a self-buffer and influences surface pH under the conditions studied.  
The figure 1 plot shows that the phosphate buffer concentrations needed to match 
physiologically relevant bicarbonate buffer are 4-8mM. 
 Indomethacin Results 
Figure 3.2 shows the flux of indomethacin in bicarbonate and phosphate buffer over a 
range of buffer concentrations along with theoretical predictions at pH 6.5.  The simultaneous 
diffusion and chemical reaction model accurately predicts the experimental flux of indomethacin 
in phosphate buffer.   The calculated pH at the surface of indomethacin approaches the bulk pH 
at low concentrations of phosphate buffer as expected due to the low intrinsic solubility of 
indomethacin which makes it a poor self-buffer. Bicarbonate is not able to buffer the surface pH 
of indomethacin as effectively as phosphate buffer.  Therefore very low phosphate buffer 
concentrations (1-2mM) are needed to match physiologically relevant bicarbonate buffer. As was 
seen for ibuprofen, the slow hydration reaction rate has a significant impact on the buffer 
capacity of bicarbonate and only the IRR model can accurately predict the flux of indomethacin 
in bicarbonate buffer. 
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Ketoprofen Results 
Figure 3.3 shows the flux of ketoprofen in bicarbonate and phosphate buffer over a range 
of buffer concentrations along with theoretical predictions at pH 6.5.  The predictions show that 
an increase in buffer concentration results in a significant increase in the flux.  The predicted flux 
matches the experimental flux in phosphate buffer. The experimental flux of ketoprofen in 
bicarbonate buffer is only accurately predicted when the dehydration reaction rate is incorporated 
by applying the IRR model.  Figure 3shows phosphate buffer concentrations needed to match 
physiologically relevant bicarbonate buffer are ~5-12mM 
2-Napthoic Acid Results 
Figure 3.4 shows the flux of 2-Napthoic acid in bicarbonate and phosphate buffer over a 
range of buffer concentrations along with theoretical predictions at pH 6.5.  The predictions 
show that an increase in buffer concentration results in a significant increase in the flux.  The 
solubility of 2-naphthoic acid is similar to ibuprofen.  Therefore 2-napthoic acid acts similarly as 
a self-buffer at the dissolving surface. The predicted flux matches the experimental flux in 
phosphate buffer. As was seen for all of the weak acids previously, the experimental flux of 2-
naphthoic acid in bicarbonate buffer is not predicted accurately by the BCE and CAI models and 
is only accurately predicted when the dehydration reaction rate is incorporated by applying the 
IRR model. Figure 3.4 shows phosphate buffer concentrations needed to match physiologically 
relevant bicarbonate buffer are similar to ibuprofen (3-10mM). 
Benzoic Acid Results 
Figure 3.5 shows the flux of benzoic acid in bicarbonate and phosphate buffer over a 
range of buffer concentrations at pH 6.5.  The flux of benzoic acid in phosphate buffer is 
accurately predicted by the simultaneous diffusion and chemical reaction model.  The predictions 
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and results show that a large increase in buffer concentration does not cause a significant 
increase in the flux.  This is due to the high solubility of benzoic acid which is apparent in the 
large flux value for benzoic acid at zero buffer concentration.  A highly soluble weak acid drug 
will lead to a high concentration of drug at the surface and a high [H
+
] that limits the pH change 
at the surface even in the presence of high buffer concentration.  In effect, benzoic acid solubility 
very effectively serves as a self-buffer and controls surface pH under the conditions studied.   
As observed with all of the weak acid drugs, the BCE and CAI models do not accurately 
predict the flux of benzoic acid in bicarbonate buffer.  However unlike the other weak acid drugs 
the IRR model did not accurately predict the flux of benzoic acid in bicarbonate buffer.  In the 
case of benzoic acid dissolution in bicarbonate buffer, it was observed throughout these 
experiments that gas bubbles continuously formed at the surface of the dissolving tablet.  This 
likely affected the hydrodynamics and effective surface area of the dissolving drug available for 
dissolution. Therefore, the experimental flux would not be expected to match the predicted flux 
for the dissolution of benzoic acid in bicarbonate buffer for any of the models that were used.  
The gas bubbles at the dissolving surface were likely carbon dioxide.  The concentration of CO2 
at the surface depends on the [H
+
] concentration (Equation 3).  When [H
+
] is sufficiently high, 
the CO2 (aq) concentration can exceed its solubility causing CO2 to come out of solution. 
                                                              
          
  
   
                                     (Eqn. 3.3) 
The IRR model does not calculate concentration of CO2 (aq) at the surface of the tablet.  
However, the BCE model predicts similar surface pH values and enables the calculation of the 
concentration of carbon dioxide at the surface of the tablet.  At the highest experimental CO2 
partial pressure (37% CO2) the BCE model predicts a nearly saturated solution (98% saturated) 
of CO2 at the surface of the tablet. The assumptions made in the IRR model are consistent with 
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the buildup of carbon dioxide in the diffusion layer even though the predictions were not 
accurate.  The IRR model assumes that the concentration of carbon dioxide will only increase in 
the diffusion layer without an ability to be transformed into carbonic acid. Additionally, the high 
solubility of benzoic acid leads to a low pH in the diffusion layer that will generate more carbon 
dioxide and could cause the concentration of carbon dioxide to increase to a point where it comes 
out of solution. So, while not precisely quantitative, these predictions are very consistent with the 
hypothesis that the bubbles formed at the dissolving benzoic acid compact surface are due to 
saturated CO2 conditions in the diffusion layer and at the dissolving surface.   
Haloperidol Results 
Figure 3.6 shows haloperidol flux, a weak base, in bicarbonate and phosphate buffer over 
a range of buffer concentrations at pH 6.5. The predictions show that an increase in buffer 
concentration results in a significant increase in the flux.  The solubility of haloperidol is similar 
to indomethacin and, in the same way, the low solubility of the drug prevents it from effectively 
self-buffering the surface pH.  As was seen with the weak acid drugs, rotating disk experimental 
flux in phosphate buffer is predicted accurately by the simultaneous diffusion and chemical 
reaction model.  The predictions for bicarbonate buffer also match what was seen for the weak 
acid drugs.  The experimental flux of haloperidol in bicarbonate buffer falls between predictions 
assuming instantaneous hydration/dehydration reactions (BCE model : pKa = 6.04) or no 
hydration/dehydration reactions (CAI model:  pKa = 3.55).  Experimental flux of haloperidol in 
bicarbonate buffer is only accurately predicted when the IRR model is used for the predictions. 
The experimental data and predictions in bicarbonate and phosphate buffer show that phosphate 
is much better at buffering the surface pH. Therefore very low concentrations of phosphate 
buffer would be needed to match bicarbonate (<1mM)  
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Figure 3.7 shows the experimental and predicted flux of haloperidol in 10mM 
bicarbonate buffer with bulk pH values of 6, 6.5, and 7.  As the bulk pH decreases, the 
experimental and predicted flux in bicarbonate increases.  This is due to an increase in H
+
 in the 
solution and consequently a decrease the surface pH and an increase the ionized form of the drug 
in the diffusion layer, leading to an increase in the overall flux of the weak base drug.  The BCE 
model overestimates and the CAI model underestimates the effect that changing the bulk pH will 
have on the surface pH and the flux of the drug. The IRR model accurately predicts experimental 
flux of haloperidol in bicarbonate buffer.  
Discussion 
The importance the reaction rates play in the buffering capacity of bicarbonate is 
apparent when comparing all of the experimental results in bicarbonate and phosphate buffer.  
The drug flux data further confirms the accuracy of the film model to predict the dissolution of 
weak acid drugs in phosphate buffer and it also shows that it can be successfully applied to weak 
base drugs.  The IRR model accurately predicts the experimental flux of weak acid and weak 
base drugs in bicarbonate buffer.  Furthermore, the experimental data for haloperidol and the 
data presented in Krieg, et al. demonstrates the ability of the IRR model to be used under various 
experimental conditions (eg: different bulk pH, drug solubilities, rotational speeds).  The results 
also give good approximations of the phosphate buffer concentrations needed to match 
physiologically relevant bicarbonate buffer concentrations for rotating disk dissolution of drugs 
with varying physiochemical properties.  For the drugs studied in this paper, the phosphate buffer 
concentrations needed to match physiologically relevant bicarbonate buffer were ~1-15mM 
based on the experimental data and the IRR model predictions.   
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The dynamic nature of bicarbonate buffer can be observed by comparing the IRR model 
predictions to the BCE model predictions. If the hydration and dehydration reactions were fast 
enough that chemical equilibrium was achieved instantaneously, as seen in the BCE model, 
bicarbonate would be a very good buffer in the diffusion layer. According to the BCE model, a 
10mM bicarbonate buffer would provide the same buffering ability in the diffusion layer as 
~50mM phosphate buffer at a bulk of pH 6.5.  Therefore when the reaction time is unlimited (i.e. 
in the bulk solution) and the rates of the hydration and dehydration reactions do not play a 
limiting role in buffering capacity (i.e. the BCE model), bicarbonate acts as a strong buffer. 
However, when the reaction time is finite, (i.e. in the diffusion layer using the IRR model), the 
buffer capacity of bicarbonate is much lower but this lower buffer capacity is partially 
compensated for by the dehydration reaction of H2CO3. 
Predicting Physiologically Relevant Phosphate Buffer Concentrations 
While there have been recent advancements in preparing bicarbonate buffer and 
controlling buffer concentration
15
 , the process of making bicarbonate buffer is not ideal for 
performing dissolution experiments.  The experimental data in this paper and the data in Krieg et 
al. demonstrate that the IRR model can accurately predict the effect bicarbonate has on buffering 
surface pH of weak acid and weak base drugs under rotating disk dissolution conditions.  This 
paper and previous work illustrates the ability to accurately predict rotating disk drug dissolution 
in phosphate buffer using the film model that assumes chemical equilibrium is achieved 
instantaneously 
2,4
.  Therefore applying each of these models to their respective buffer system 
will give accurate estimations for phosphate buffer concentrations that will simulate 
physiologically relevant bicarbonate buffer.  
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To estimate phosphate buffer concentrations that would match  physiologically relevant 
bicarbonate buffer, the physicochemical properties of ibuprofen were used (see table 3.3) with 
the exception of drug pKa and solubility which were varied, and the IRR model was applied.  
For weak acids, the drug pKa was varied from 3-8 and for weak bases the drug pKa was varied 
from 5-10.  The drug solubility was varied from 10
-1
 M to 10
-6
 M.  The physiologically relevant 
bicarbonate buffer chosen for the predictions was 15% CO2 (10.4 mM bicarbonate concentration) 
at pH 6.5 as representative of GI conditions
16
.  The diffusion layer thickness for these predictions 
was chosen as 30µm based on the work of Hintz and Johnson
17. 
The relationship between equivalent phosphate buffer concentration and the pKa of weak 
acid drugs, pKw-pKa for weak base drugs, and log(drug solubility) is shown in Figure 3.8.  For 
weak acid drugs, when the pKa - log(drug solubility) is plotted versus the equivalent phosphate 
buffer concentration necessary to match physiologically relevant bicarbonate buffer a single 
curve is obtained as shown in Figure 3.8. The same is true for weak base drugs when the when 
(pKw-pKa- log(drug solubility) is plotted versus equivalent phosphate buffer as shown in Figure 
3.8.  This is due to the relationship between the weak acid drug Ka (for a weak base: Kw-Ka) 
and the solubility of the drug in the cubic equation of the film model.  These two parameters only 
appear in the cubic equation as being multiplied together. Therefore if one parameter is 
decreased by an order of magnitude while the other is increased by an order of magnitude, this 
will result in the same solution for the cubic equation and pH at the surface of the drug.  
Predictions at bulk pH of 6.0, 6.5 and 7.0 show that phosphate buffer concentrations 
needed to match physiologically relevant bicarbonate buffer are higher for both weak acid and 
weak base drugs at a pH of 6 and the lower at pH 7.  This is due to the low pKa for the ionization 
reaction of carbonic acid (3.55) which is used in the IRR model.  As the bulk pH is lowered, the 
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buffering capacity increases.  This is evident in the case of weak acid drugs. There is a wide 
range of equivalent phosphate buffer concentrations needed to match weak acid drugs (~1 to 
95mM) depending on the bulk pH and drug properties (ie: solubility and pKa).  As the drug pKa 
increases and the drug solubility decreases for weak acid drugs, the phosphate buffer 
concentration needed to provide the same buffer effect decreases.  However, a more 
representative BCS class 2a drug range would lead to the equivalent phosphate buffer 
concentration becoming much more condensed over the bulk pH’s tested and results in 
equivalent phosphate concentrations of 1mM  to 25mM range. For example, ibuprofen is 
predicted to require an equivalent phosphate buffer concentration of ~11mM at pH 6 and ~2mM 
at pH 7. 
In the case of weak base drugs, the matching phosphate buffer concentration for 
physiologically relevant bicarbonate buffer is less than 2mM for all drug pKa values and 
solubilities evaluated. This is due to weak base drugs forming OH
-
 at the surface of the 
dissolving drug which increases the pH and makes the bicarbonate buffer relatively ineffective. 
The carbonic acid ionization reaction pKa is much lower than the pH at the surface so the 
irreversible reaction provides only a minor increase in buffer capacity and makes bicarbonate a 
very poor buffer for weak base drugs.  Therefore very little phosphate buffer is needed to 
decrease the pH at the surface of the dissolving weak base drug to have the same effect as 
physiologically relevant bicarbonate buffer. 
The predictions of phosphate buffer concentrations that match physiologically relevant 
bicarbonate buffer offer a dissolution medium that can better simulate the buffer capacity in the 
small intestine.  However, there are additional considerations that must be taken into account 
when dealing with the dissolution of a dosage form.  The first is that, as a weak acid or weak 
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base drug dissolves, the bulk pH may be changing which will cause the pH at the surface to 
change.  This problem could be overcome by maintaining a relatively constant bulk pH through 
titration (eg: pH-Stat). Another consideration is that, as a drug particle is dissolving, the diffusion 
layer thickness of the particle may be considered to change
17-19
.  The bicarbonate buffer model 
and the data for flux of ibuprofen at different rotational speeds (different diffusion layer 
thickness) in Krieg et al. shows that the predicted pH at the surface of the drug is dependent on 
the diffusion layer thickness. This aspect makes the selection of an appropriate diffusion layer 
thickness a significant parameter for particle dissolution in bicarbonate buffer. Of course, the 
dosage form and excipients could affect disintegration and dissolution which could have a 
significant impact on the phosphate buffer concentration that best simulates physiologically 
relevant bicarbonate buffer. 
Conclusions 
The experimental data obtained from rotating disk dissolution shows that the 
simultaneous diffusion and chemical reaction model accurately predicts drug flux where 
“instantaneous” chemical reactions occur as is the case for phosphate buffer.  In the case of 
bicarbonate buffer, the predicted flux and experimental results show the importance of reaction 
kinetics in buffering the pH in the diffusion layer and at the surface of the dissolving drug.  The 
results for the weak acids ibuprofen, indomethacin, 2-naphthoic acid, ketoprofen, and the weak 
base haloperidol dissolution demonstrates  that the experimental flux in bicarbonate buffer 
cannot be predicted accurately by assuming that chemical equilibrium is instantly achieved and 
the  reaction rates must be taken into account.  Due to the slow reaction rate between CO2 and 
H2O, the BCE model overestimates and the CAI model underestimates the impact of bicarbonate 
buffer throughout the convective-diffusion layer and at the surface of the tablet. We show that 
107 
 
the slow hydration and dehydration reactions can be accounted for by assuming that CO2 does 
not react with H2O in the convective-diffusion layer while H2CO3 undergoes an irreversible 
chemical reaction forming CO2 and H2O in the convective-diffusion layer. This unique attribute 
of the bicarbonate buffer-diffusion-reaction system can accurately predict drug dissolution in 
bicarbonate buffer.  
Matching the dissolution rate (flux) of weak acid and weak base drugs in phosphate and 
bicarbonate buffer systems is possible but it is a complex function of buffer pH and pKa, drug 
pKa and solubility, and diffusion layer thickness. The accuracy of the IRR model to predict 
rotating disk dissolution in bicarbonate buffer allowed for predictions of equivalent phosphate 
buffer concentrations that matched physiologically relevant bicarbonate buffer for both weak 
acid and weak base drugs. An important conclusion of this work is that, while it is possible to 
identify an equivalent phosphate buffer for a drug, a precise match for dosage form testing is 
difficult because of the complex nature mentioned above.  A second important conclusion of  this 
work is that low phosphate buffer concentrations (1-25mM) appear to be more physiologically 
relevant and may better simulate the impact of bicarbonate buffer on the dissolution of weak acid 
drugs.  For weak base drugs, extremely low phosphate buffer concentrations (less than 2 mM) 
would be needed to match physiologically relevant bicarbonate buffer.  These predicted 
equivalent phosphate buffer concentrations suggest that the current phosphate buffer 
concentrations used for dissolution testing (often 50 mM) likely do not accurately reflect the 
dissolution media and conditions that a drug will experience in the intestine.    
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Tables  
Table 3. 1. Rotating disk dissolution experimental parameters applied to the weak acid drugs 
examined 
Drug Ibuprofen 
 
Indomethacin Ketoprofen 2-Naphthoic 
Acid 
Benzoic 
Acid 
Bulk pH 6.5 6.5 6.5 6.5 6.5 
Percent CO2 7-8, 14-16, 
21-22 
7-8, 14-16, 
21-22 
7-8, 14-16, 
24-26 
7-8, 14-16, 
22-25 
13,  26, 
and 37 
Total Buffer 
concentration 
[CO2(aq)]+[HCO3
-
] (mM) 
6.5-7.5, 13-
15, 19.5-
20.5 
6.5-7.5, 13-
15, 19.5-20.5 
6.5-7.5, 13-
15, 22-24 
6.5-7.5, 13-
15, 20.5-
23.5 
12.5, 21.5, 
29.1 
Bicarbonate 
Concentration 
[HCO3-]  (mM) 
5-5.5, 10-
11, 14.5-
15.5 
5-5.5, 10-11, 
14.5-15.5 
5-5.5, 10-
11, 16.5-
18.0 
5-5.5, 10-11, 
15-17 
9, 18, and 
25.6 
Phosphate Buffer 
Concentration 
[H2PO4-+HPO4
-2] 
  (mM) 
3.5, 5.2, 
6.95, 13, 
25, and 
43.5 
2.5, 13, 25, 
and 43.5 
10, 25, and 
50 
10, 25, and 
50 
13, 25, and 
43.5 
Volume of 
Dissolution 
Medium (ml) 
150 100 300 200 300 
RPM 100 100 100 100 100 
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Table 3. 2. Rotating disk dissolution experimental parameters applied to the weak base 
drug Haloperidol 
Drug Haloperidol 
Bulk pH 6.0 6.5 7.0 
Percent CO2 45 7-8, 14-16*, 22 5 
Total Buffer concentration 
[CO2(aq)]+[HCO3
-] (mM) 
20.7 6.5-7.5, 13-15*, 
20.5 
12.2 
Bicarbonate Concentration  
[HCO3-]  (mM) 
9.9 5-5.5, 10-11*, 15 11 
Phosphate Buffer Concentration 
[H2PO4-+HPO4
-2]  (mM) 
NA 2.5, 13, 25, and 
43.5 
NA 
Volume of Dissolution Medium (ml) 75 75 75 
RPM 100 100 100 
* denotes the experimental parameters that were used for pH 6.5 in bicarbonate buffer in 
Figure 7 
 
Table 3. 3. Drug and buffer properties at 37oC that were applied to the simultaneous 
diffusion and reaction model 
Species Solubility (M) pKa Diffusion Coefficient 
(cm
2
/s)  
 
Benzoic Acid 0.0334 
20
 4.19 
21
 12.0 x 10
-6  b 
Ibuprofen 3.30 x 10
-4  22
 4.43 
22
 7.93 x 10
-6  b 
Indomethacin 5.963 x 10
-6
 
c 
4.27 
23
 6.8 x 10
-6  
 
24
  
Ketoprofen 5.303 x 10
-4
 
c
 4.02
25
 9.3 x 10
-6  2
  
2-napthoic acid 3.044 x 10
-4
 
c
 4.22
26
 9.86 x 10
-6  b
  
Haloperidol 8.514 x 10
-6
  
24
 8.0   
27
 6.6 x 10
-6  
 
24
  
Phosphate  6.8 
12
 11.5 x 10
-6  2
 
Bicarbonate  6.04 
c
 14.6 x 10
-6  28 
Carbonic Acid  3.55
29 
14.6 x 10
-6  28 
Carbon Dioxide 0.02403 6.04 
c
 24.9 x 10
-6
  
30
 
Values were taken from literature (2,31-38), estimated using the Wilke-Chang equation (b), or 
measured experimentally (c).  
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Figures 
 
Figure 3. 1 The experimental and predicted flux of ibuprofen in bicarbonate and phosphate buffer 
at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux in Phosphate 
Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental Flux in 
Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
 
 
Figure 3. 2 The experimental and predicted flux of indomethacin in bicarbonate and phosphate 
buffer at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux in 
Phosphate Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental Flux 
in Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
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Figure 3. 3. The experimental and predicted flux of ketoprofen in bicarbonate and phosphate 
buffer at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux in 
Phosphate Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental Flux 
in Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
 
 
 
 
Figure 3. 4. The experimental and predicted flux of 2-napthpoic acidin bicarbonate and 
phosphate buffer at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux 
in Phosphate Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental 
Flux in Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
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Figure 3. 5. The experimental and predicted flux of benzoic acid in bicarbonate and phosphate 
buffer at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux in 
Phosphate Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental Flux 
in Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
 
 
 
 
Figure 3. 6. The experimental and predicted flux of haloperidol in bicarbonate and phosphate 
buffer at multiple concentrations (at pH 6.5 and 37
o
C).   Key (     ) Experimental Flux in 
Phosphate Buffer; (           )  Predicted Flux in Phosphate Buffer (BCE);  (    ) Experimental Flux 
in Bicarbonate Buffer;  (           ) BCE Model Flux Predictions; (            ) IRR Model Flux 
Predictions;  (            ) CAI Model Flux Predictions; 
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Figure 3. 7. The experimental and predicted flux of haloperidol in 10 mM bicarbonate buffer at 
bulk pH values 6, 6.5, and 7 at 37
o .  Key   •   Experimental Flux;              B E Model Flux 
Predictions;  (         ) IRR Model Flux Predictions;  (           ) CAI Model Flux Predictions; 
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Figure 3. 8. The predicted equivalent phosphate buffer concentration needed to match 10.5mM 
bicarbonate buffer for weak acid drugs with drug pKa’s of 3-8 and weak base drugs with pKa’s 
of 5-10 and drug solubilities of 0.1M-10
-6
M for both.   Key: (               ) Equivalent buffer 
predictions at pH 6 (h=30µm).  (            ) Equivalent buffer predictions at pH 6.5 (h=30µm);        
(             ) Equivalent buffer predictions at pH 7 (h=30µm); (    ) Equivalent buffer predictions for 
benzoic acid; (    ) Equivalent buffer predictions for ketoprofen; (     ) Equivalent buffer 
predictions for ibuprofen; (    ) Equivalent buffer predictions for indomethacin; ( X) Equivalent 
buffer predictions for haloperidol 
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Chapter 4 
 
Transport analysis to match Bicarbonate and Phosphate buffer for suspension 
and tablet dosage form dissolution 
 
Abstract 
 
Predicting and matching the dissolution of drugs in different buffer systems requires the 
evaluation of both drug and buffer properties that will impact dissolution.  Chapters 2 and 3 have 
presented work using the rotating disk dissolution methodology to show that matching the buffer 
strengths of different buffer species is possible when applied to a well-defined hydrodynamic 
system and diffusion layer thickness. However, this analysis becomes more complicated when a 
suspension or tablet dosage form is introduced into the experimental study. Factors that can be 
neglected using the rotating disk methodology must be accounted for such as a change in particle 
size, change in bulk pH, and tablet disintegration.  
All of the experimental work presented was done using ibuprofen and the USP 2 
dissolution apparatus in 900ml of buffer solution with a paddle rotational speed of 50RPM.  
Initial experiments were performed on ibuprofen powder with a defined particle size to allow for 
the particle diffusion layer thickness parameter to be defined which would be the driving force 
for all of the surface pH predictions for bicarbonate buffer. It was assumed that matching surface 
pH values between bicarbonate and phosphate buffer would provide a matching dissolution 
profile. The experimental work shows that this assumption is correct if other factors such as 
disintegration or changing bulk pH are minimized. 
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 Additionally an assessment of the added value of using both bicarbonate buffer and the 
predicted equivalent phosphate buffer were studied by evaluating the bioequivalence of 600mg 
ibuprofen reference and test tablets. These tablets were shown to not be bioequivalent based on 
in vivo results given by Alvarez et al. in 2011 
1
. However, Alvarez et al. also illustrated that in 
vitro dissolution studies in recommended dissolution media (pH 6.8 50mM phosphate buffer) 
could not discriminate between the dissolution rates to allow for the same conclusion. Therefore 
dissolution was performed in physiologically relevant bicarbonate buffer and the predicted 
equivalent phosphate buffer in this chapter to evaluate the ability of the buffers to provide in vivo 
predictive results. The dissolution data indicates that these buffers can provide meaningful 
information about dissolution rank order and statistically significant results to predict that the 
two formulations are not equivalent.  
Introduction 
Performing dissolution testing of oral dosage forms that are intended to be marketed or 
already on the market should provide the best determination of how that drug will dissolve in the 
gastro-intestinal tract when it is taken orally. Alvarez et al. showed the limitations of relying on 
the recommended WHO and USP monograph buffer systems for determining the bioequivalence 
of drug products 
1
. Therefore making a dissolution test more predictive of in vivo results must 
emphasize the most important physiological parameters. For BCS class 2a (BCS Class 2 weak 
acid) drugs, the potential rate limiting factor after the drug has emptied into the intestine is 
dissolution 
2
. Therefore an emphasis should be placed on BCS class 2a drugs using a dissolution 
medium that simulates the fluid of the intestines. A dissolution test that uses bicarbonate buffer 
or one that can replicate the same buffer effect as bicarbonate should provide more meaningful in 
vivo results.   
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As has been discussed, the preparation of physiologically relevant bicarbonate buffer is 
complicated and not an ideal process to perform on a large scale experimentally
3-6
.  Using a 
phosphate buffer solution that dissolves drug particles and the active pharmaceutical ingredient 
(API) in a dosage form at the same rate as physiologically relevant bicarbonate buffer would be 
preferable. Phosphate buffer systems that match bicarbonate buffer and are easy to implement 
may be expected to offer a more in vivo predictive dissolution test for drugs in early development 
and can possibly be helpful in determining the bioequivalence of generic and reference drug 
products. 
Rotating disk dissolution data has confirmed that transport analysis can accurately predict 
the flux of a drug in bicarbonate buffer (IRR model) and phosphate buffer (film model) under 
conditions of a constant well-defined diffusion layer thickness, constant drug surface area, and 
constant bulk pH
3,7,8
.  When drug particles or dosage forms are being dissolved in a USP 2 
apparatus, the diffusion layer thickness is not well defined, the surface area of the particle will 
decrease, and the bulk pH of the dissolution medium can either increase or decrease as the weak 
acid or weak base drug dissolves
9-11
.  Therefore it is important to examine if the rotating disk 
dissolution transport analysis can be applied to suspension formulations (ie: drug particles) and 
tablet dosage forms in order to predict a phosphate buffer that matches bicarbonate buffer. 
As previously shown, the diffusion layer thickness can have a significant impact on the 
pH at the surface of the drug when the drug is dissolved in bicarbonate buffer 
3
. There have been 
numerous studies examining the diffusion layer thickness for particle dissolution in a USP 2 
apparatus
9,11-14
.  These models often use the concept of a critical diffusion layer thickness 
surrounding a dissolving spherical particle that represents the region adjacent to the dissolving 
surface where there is a large concentration gradient between the dissolving drug and the bulk 
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solution.  This diffusion layer thickness is effectively constant at large particle sizes (ie: critical 
diffusion layer thickness) but once the particle is dissolved to the point of the critical radius, the 
diffusion layer thickness is equal to the particle size radius.  These critical diffusion layer 
thickness values have varied in literature to be ~20-40µm in thickness.  This variation in possible 
diffusion layer thickness values could have a significant impact on the predicted matching 
phosphate buffer. For example, the surface pH would vary in an 11mM bicarbonate buffer 
solution from a surface pH of 5.28 at a 40µm diffusion layer thickness to a surface pH of 5.15 at 
a 20µm diffusion layer thickness. This would decrease the solubility of ibuprofen from 
0.549mg/ml to 0.425mg/ml, corresponding to a 23 percent decrease in solubility which could 
have a significant effect on the drug dissolution rate depending on the particle size of the drug. 
This work will investigate the dissolution of ibuprofen particles and MotrinIB coated 
tablets in bicarbonate buffer in order to test if the CO2-bicarbonate transport analysis (IRR 
model) can predict an equivalent phosphate buffer.  The dissolution profiles will be compared to 
determine if the IRR model developed by Krieg et al. for rotating disk dissolution can be applied 
to drug particles and dosage forms that a person would take orally. Additionally bicarbonate and 
the equivalent phosphate buffer will be examined to determine whether a physiologically 
relevant buffer system will provide meaningful in vitro results that offer a more discriminating 
dissolution test for test and reference 600mg ibuprofen tablets. This evaluation of in vitro 
dissolution data will be used to assess the usefulness of physiologically relevant buffers as both a 
qualitative and quantitative tool to predict failures in bioequivalence.  
Theoretical 
The USP 2 apparatus particle dissolution data in bicarbonate buffer was used to estimate 
the correct diffusion layer thickness to apply to the IRR model to predict the correct surface pH 
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of the dissolving particles. This surface pH could then be matched by applying the film model of 
Mooney et al. to phosphate buffer to predict an equivalent phosphate buffer concentration to 
match the dissolution profile in bicarbonate buffer
7
.  The pH at the surface was calculated for a 
range of diffusion layer thickness values as high as 40µm and as low as 15 µm.  The surface pH 
at each diffusion layer thickness was used to calculate the solubility of the drug at the surface. 
The surface pH and solubility were assumed to be constant at the predicted surface pH for the 
initial diffusion layer thickness throughout the experiment even though the IRR model 
demonstrates that this is not the case. In the case of a 235um particle this is a safe assumption 
since the diffusion layer thickness changes very little before >90% of the particle has dissolved.  
The diffusion layer thickness used and corresponding solubility were applied to the Wang and 
Flanagan model for predicting particle dissolution shown in equation 4.1. 
  
  
       
 
         
 
 
  
              Equation 4.1 
The diffusion layer thickness is a function of the radius of the dissolving particle (rp) and 
a critical diffusion layer thickness (hcritical) values. To predict the dissolution profile for 235µm 
ibuprofen particles (assumed a monodisperse system) the best fit critical diffusion layer thickness 
and corresponding drug solubility was determined by calculating the residual sum of squares for 
the different predicted dissolution profiles compared to the experimental dissolution profile.  
This statistical analysis determined that a diffusion layer thickness that was equal to 18µm which 
would correspond to a surface pH calculation of 5.13 was the best fit dissolution profile.  
  
  
       
 
    
 
 
  
              Equation 4.2 
This critical diffusion layer thickness was used for all surface pH calculations which were used 
to predict the equivalent phosphate buffer concentration needed to match the same surface pH as 
bicarbonate buffer.   
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Materials and Methods: 
   All of the dissolution experiments were performed in single cell jacketed USP 2 
apparatus in 900ml of dissolution media that was kept at 37
o
C and the paddle was rotated at 
50RPM. Ibuprofen was the API studied in all of the dissolution experiments. Ibuprofen 
dissolution was studied through the dissolution of ibuprofen particles (Albermarle – Baton 
Rouge, Louisiana, USA; Lot#11550-0005) which were placed directly into the USP 2 apparatus. 
The particle size was characterized by sieving and then using optical microscopy to determine 
the mean particle size.  Dissolution was also performed on commercially available 200mg 
MotrinIB coated tablets (McNeil-PPC, INC – Fort Washington, PA, USA; NDC – 50580-110-
07). The MotrinIB tablets were added as both intact tablets directly into the USP 2 apparatus and 
they were also predisintegrated in 20ml of 0.01N HCl solution.  The entire suspension of the 
20ml of 0.01N HCl solution and disintegrated tablet was added to the USP 2 apparatus to make 
900ml of solution.  The Motrin tablets did not easily disintegrate in the 0.01N HCl so a spatula 
was used to break the tablet into particles in the acid solution. All of the particle dissolution and 
MotrinIB tablet results reported were done in triplicate.  
 Dissolution was also performed on 600mg ibuprofen tablets utilized in the published 
research by Alvarez et al. The tablets studied were the Test 1 (batch S-10), Test 2 (batch V-1), 
Reference 1 (Abbot Laboratories, Madrid, Spain; Batch R-210) and the Reference 2 tablets 
(Abbot Laboratories, Madrid, Spain; Batch 134578D).  All of the studies involving the 600mg 
tablets were done with the tablets pre-disintegrated.  All of the test and reference dissolution 
results shown were done in duplicate.  
For the dissolution experiments in bicarbonate buffer, the bicarbonate buffer was 
prepared by continuously flowing quantities of 100% dry compressed air and 100% carbon 
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dioxide in a 0.9%NaCl solution at appropriate ratios directly into the distilled water. The 
%CO2(aq) in solution was determined using a CO2 monitor (YSI 8500 – Yellow Springs, Ohio, 
USA) and pH was monitored using a pH meter (Beckman   40 – Brea, California, USA).   Solid 
sodium hydroxide and 5N NaOH was added to adjust pH.  The exact experimental parameters 
can be seen in Table 4.1.   
Dissolution experiments using phosphate buffer were made using sodium monobasic 
phosphate, sodium hydroxide, and sodium chloride to make the buffer solution isotonic. The 
exact experimental parameters can be seen in Table 4.1. 
Samples for all of the dissolution studies were taken manually using a syringe and filtered 
(13mm Acrodisc 0.45µm filter). The samples were analyzed using a UV spectrophotometer 
(Agilent Technologies -  Santa Clara, California, USA; Model# 61103A).   
Results 
Ibuprofen Particle Dissolution Results: 
The analysis of particle dissolution in bicarbonate buffer was performed to estimate the 
size of the diffusion layer around the particle (ie: hcritical).  This information allowed for 
calculation of the proper pH at the surface of the particle.  This information was then used to 
predict the corresponding equivalent phosphate buffer concentration.  This was achieved by 
performing dissolution experiments on 200mg of 235µm ibuprofen particles.  In the case of the 
particle dissolution data this equivalent phosphate buffer concentration was predicted to be 
3.5mM. The data shown in figure 4.1 shows that the predicted equivalent phosphate buffer 
(3.5mM) matches the dissolution data in bicarbonate buffer very well. However, the bulk pH 
must be kept constant throughout the experiment by titrating in 5N NaOH solution for this to 
occur.  When no base is titrated into the bulk solution, the dissolution of the ibuprofen particles 
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in the predicted equivalent phosphate buffer is slower than the dissolution in bicarbonate buffer.  
This is due to the bulk pH changing to a much greater extent in the 3.5mM phosphate buffer 
solution than the bicarbonate buffer solution.  The pH in the bicarbonate buffer solution never 
varied more than ±0.03 pH units during the dissolution experiments.  However, if the equivalent 
phosphate buffer solution was not titrated, the pH would decrease almost 0.5 pH units over the 
course of the experiments.  This is a significant drop in pH and would cause the predicted surface 
pH to decrease from 5.13 to 4.83 over the course of the experiment.  Therefore this dictated the 
procedure of titrating 5N NaOH for all other experiments that involved the equivalent phosphate 
buffer. 
Ibuprofen Tablet Dissolution Results: 
Based on the accurate results for predicting an equivalent phosphate buffer for the 
dissolution of ibuprofen particles, the same dissolution procedure for dissolution of MotrinIB 
tablets in bicarbonate buffer and equivalent phosphate buffer was used. The results in Figure 4.2 
show that a dosage form that must disintegrate before the dissolution can occur  makes 
predicting an equivalent phosphate buffer a more challenging procedure. The coated MotrinIB 
tablet appeared to disintegrate faster in bicarbonate buffer which led to a faster dissolution rate 
than when the tablet was dissolved in the equivalent phosphate buffer. The hypothesis of 
disintegration being a rate-limiting factor was tested by pre-disintegrating the MotrinIB tablet in 
0.01N HCl to eliminate the disintegration step but preventing the drug particles from dissolving 
to a significant extent.  This data is shown for bicarbonate buffer and phosphate buffer in figure 
4.3. When the coated MotrinIB tablet is pre-disintegrated in 0.01N HCl before being introduced 
into the USP 2 apparatus, the dissolution profiles are very similar. The equivalent phosphate 
buffer actually dissolves the pre-disintegrated MotrinIB tablet slightly faster than bicarbonate 
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buffer. This increase in dissolution rate is minimal but becomes more apparent after 50% percent 
of the drug has dissolved.  
Bioequivalence Dissolution Study Results: 
Preliminary results for the dissolution of the 600mg ibuprofen tablets in bicarbonate 
buffer showed that disintegration was a factor in the dissolution rate. Therefore the tablets were 
pre-disintegrated in 0.01NHCl before being added to the USP 2 dissolution apparatus to assess 
only the dissolution rate of the tablets and  studies were performed on the pre-disintegrated 
tablets following the USP monograph dissolution protocol (900ml, 50RPM, pH 6.8 50mM 
phosphate buffer) to verify that disintegration was not the only factor in the in vitro dissolution 
outcome under these conditions. These studies showed that the pre-disintegrated tablets in pH 
6.8 50mM buffer dissolved completely in 5 minutes. This illustrated that a high concentration of 
phosphate buffer can be a very non-discriminating buffer and led to a focus on the effect 
bicarbonate and the equivalent phosphate buffer have on dissolution.   
Figures 4.4-4.7 show that the pre-disintegrated reference products dissolved faster in both 
the bicarbonate buffer and the equivalent phosphate buffer than the pre-disintgrated test 
products. These results followed the correct rank order based on the in vivo results from the 
Alvarez et al. study that showed a higher Cmax and lower Tmax for the reference products 
compared to the corresponding test products. Additionally, an f2 analysis of the dissolution 
results in bicarbonate buffer (figures 4.4 and 4.5) was performed and in each case the dissolution 
profiles through the first 30 minutes (where 85% of the dissolution occurred) gave f2 value that 
were <50.  This analysis supports the conclusion that these two drug products are not equivalent. 
The bicarbonate concentration was higher in these experiments (11.5mM) so a higher 
predicted phosphate buffer concentration (4mM) was predicted to match the dissolution in 
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bicarbonate buffer. The dissolution results in phosphate buffer (Figures 4.6 and 4.7) were similar 
to the dissolution results in bicarbonate buffer. However, they also followed the same trend as 
the pre-disintegrated MotrinIB tablets and the equivalent phosphate buffer had a faster dissolution 
rate that became much more noticeable after 50% of the ibuprofen had dissolved. In the case of 
the equivalent phosphate buffer, the correct rank order of the test and reference compounds was 
observed. However, the f2 value was only less than 50 (20.1) when comparing the dissolution 
profiles for the Reference 1 and Test 1 products (figure 4.6).  The f2 value for the Reference 2 
and Test 2 dissolution profile comparison (figure 4.7) was 51.3 with an average difference in 
percent dissolved at each time point of 9.4%. Therefore the percent difference is very close to the 
cutoff point for the two products to be considered not equivalent (10% difference at each time 
point).  In each case it should be noted that two dissolution runs were performed at each 
experimental condition. Therefore if additional dissolution runs had been performed, a more 
meaningful f2 statistical comparison would likely have been achieved.   
Discussion 
The particle and drug product dissolution results show both the advantages and 
disadvantages to using a predicted equivalent phosphate buffer to match the dissolution in 
bicarbonate buffer. When the drug product has no effect on the dissolution of the particles, the 
dissolution in bicarbonate can be matched by applying the IRR transport model.  However, in 
many cases the excipients of the dosage form can impact the product performance (e.g. MotrinIB 
and disintegration). The effect of the excipients on dissolution is a very important parameter that 
the IRR model does not take into account as it is constructed currently.   
The bioequivalence dissolution studies show that dissolution cannot be the only 
consideration when comparing dosage forms to determine whether they are bioequivalent.  The 
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dissolution data in bicarbonate buffer and the equivalent phosphate buffer indicates that the 
tablets are disintegrating in the stomach in vivo. The drug particles are then emptied into the 
intestine where they undergo dissolution and the reference product drug particles will dissolve 
faster in the intestine.  In order to distinguish between the dissolution rates of the test and 
reference compounds in vitro, a buffer that provides a slower dissolution rate must be used. A 
50mM phosphate buffer at pH 6.8 will dissolve the disintegrated ibuprofen tablets so fast that a 
noticeable difference in dissolution profiles would be difficult to distinguish. Therefore 
bicarbonate and the equivalent phosphate buffers would provide dissolution results that are more 
discriminating.  However, the results in the bicarbonate and phosphate buffers in the USP 2 
apparatus with 900ml of buffer at pH 6.5 still only offer the opportunity for a qualitative 
assessment for bioequivalence at this point. The experimental dissolution profiles in these buffer 
systems do not offer a quantitative assessment of the in vivo parameters. More physiological 
parameters must be considered before the quantitative assessment can be expected. 
The faster dissolution rate that was noticeable in the equivalent phosphate buffer 
dissolution for the pre-disintegrated MotrinIB tablets and the 600mg ibuprofen tablets compared 
to the dissolution in bicarbonate can be attributed to two possibilities.  The first possibility is that 
the bulk pH decreased to a greater extent in bicarbonate buffer because of the addition of 20ml of 
0.01N HCl and the high dose of ibuprofen. When the 600mg pre-disintegrated tablet was being 
dissolved, the bulk pH in bicarbonate buffer decreased to ~6.35 and stayed constant at that pH 
throughout the dissolution experiment. The bulk pH during the dissolution in the equivalent 
phosphate buffer was kept at a constant pH of 6.5 throughout the experiments with titration.  The 
other possibility for the dissolution in the equivalent phosphate buffer being faster is the 
changing diffusion layer thickness as the particle dissolved and its effect on the surface pH using 
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bicarbonate buffer.  As the diffusion layer thickness decreases when the particle radius becomes  
 18µm , then the pH at the surface will also decrease which will cause the dissolution in 
bicarbonate buffer to slow down. Phosphate reaches a chemical equilibrium instantaneously so 
this phenomenon is only occurring with bicarbonate buffer.  
Conclusion 
The data shows that the IRR model can be accurately applied to the dissolution of 
particles or drug suspensions.  However, the pH must be controlled in the equivalent phosphate 
buffer solution as the drug is being dissolved especially in the case of a large dose of a weak acid 
drug.  A key component that seems to impact the use of the IRR model for tablets is the rate of 
disintegration.  In the case of the MotrinIB coated tablets that were used, the tablet took some 
time to disintegrate and this lag time affected the dissolution rate which made the equivalent 
buffer predictions not applicable.  
When the ibuprofen was introduced as particles or the dosage form as a suspension, then 
the model accurately predicts the same dissolution profiles for bicarbonate and phosphate.  This 
would also presumably be the case if the tablet were a very fast disintegrating tablet.  However, 
more work would need to be done to determine the accuracy of this assumption.  Based on the 
dosage form restrictions and the limitations that come with using low buffer concentrations, 
performing dissolution in bicarbonate buffer would provide the best guidance for how an 
ionizable drug would dissolve in vivo. However, the equivalent phosphate buffer concentration 
can still be useful and provide a better substitute to the high phosphate concentration buffers that 
are currently used for dissolution testing.   
The data suggests that using bicarbonate buffer and the equivalent phosphate offers a 
more discriminating dissolution test than the current dissolution testing protocols. These buffer 
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systems provide an opportunity to make accurate qualitative assessments to evaluate 
bioequivalence.  However, more physiologic parameters need to be incorporated before an 
accurate quantitative assessment of bioequivalence can be made.  This could possibly be done by 
incorporating more complex dissolution systems. One example would be using a multi-
compartment dissolution system.  In the case of acidic drugs, a compartment that mimics the 
stomach media and hydrodynamics could disintegrate the tablet allowing for dissolution of drug 
particles to occur in the intestinal compartment at physiologically relevant volumes.  The 
predicted equivalent phosphate buffer could be used in the intestinal compartment to match 
bicarbonate buffer and provide a more in vivo predictive dissolution test.  However, more work 
needs to be done to assess the viability of these more complex systems. 
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Tables 
Table 4. 1. USP 2 apparatus experimental parameters applied to the different ibuprofen 
dosage forms 
 
Drug Ibuprofen 235µm 
Particles 
200mg Motrin IB 
Coated Tablet 
600mg Ibuprofen 
Test and Reference 
Products 
Bulk pH 6.5 6.5 6.5 
Percent CO2 15-16.5 15-16.5 16-17.5 
Total Buffer concentration 
[CO2(aq)]+[HCO3
-] (mM) 
10.5-11.5 10.5-11.5 11-12 
Bicarbonate Concentration 
[HCO3-]  (mM) 
14-15.5 14-15.5 14.5-16 
Phosphate Buffer 
Concentration [H2PO4-
+HPO4-2]  (mM) 
3.5 3.5 4 
Volume of Dissolution 
Medium (ml) 
900 900 900 
RPM 50 50 50 
 
Figures: 
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Figure 4. 1. USP 2 apparatus dissolution results of 235µm ibuprofen particles in 11mM 
bicarbonate buffer and 3.5mM phosphate buffer at pH 6.5 and at 37
o
C.   Key (    ) Dissolution in 
bicarbonate buffer; (    ) Dissolution in phosphate buffer bulk pH kept constant; (    ) Dissolution 
in phosphate buffer bulk pH not kept constant; (         ) predictions in bicarbonate buffer based on 
h = 18µm which gives a surface pH of 5.13;  
 
 
 
Figure 4. 2. USP 2 apparatus dissolution results of 200mg Motrin IB intact tablets in 11mM 
bicarbonate buffer and 3.5mM phosphate buffer at pH 6.5 and at 37
o
C.   Key (    ) Dissolution in 
bicarbonate buffer; (    ) Dissolution in phosphate buffer bulk pH kept constant. 
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Figure 4. 3. USP 2 apparatus dissolution results of 200mg Motrin IB pre-disintegrated tablets in 
11mM bicarbonate buffer and 3.5mM phosphate buffer at pH 6.5 and at 37
o
C.   Key (    ) 
Dissolution in bicarbonate buffer; (    ) Dissolution in phosphate buffer bulk pH kept constant. 
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Figure 4. 4. USP 2 apparatus dissolution results of 600mg ibuprofen pre-disintegrated tablets test 
1 and reference 1 drug products in 11.5 mM bicarbonate buffer at pH 6.5 and at 37
o
C.   Key (    ) 
Dissolution results of the reference 1 drug product; (    ) Dissolution results of the test 1 drug 
product; 
 
Figure 4. 5. USP 2 apparatus dissolution results of 600mg ibuprofen pre-disintegrated tablets test 
2 and reference 2 drug products in 11.5 mM bicarbonate buffer at pH 6.5 and at 37
o
C.   Key (    ) 
Dissolution results of the reference 2 drug product; (    ) Dissolution results of the test 2 drug 
product; 
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Figure 4. 6. USP 2 apparatus dissolution results of 600mg ibuprofen pre-disintegrated tablets test 
1 and reference 1 drug products in 4 mM bicarbonate buffer at a bulk pH kept constant at 6.5 and 
at 37
o
C.   Key (    ) Dissolution results of the reference 1 drug product; (    ) Dissolution results of 
the test 1 drug product; 
 
 
Figure 4. 7. USP 2 apparatus dissolution results of 600mg ibuprofen pre-disintegrated tablets test 
2 and reference 2 drug products in 4 mM bicarbonate buffer at a bulk pH kept constant at 6.5 and 
at 37
o
C.   Key (    ) Dissolution results of the reference 2 drug product; (    ) Dissolution results of 
the test 2 drug product; 
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Chapter 5 
 
USP 4 Particle Dissolution: The impact of fluid velocity on the dissolution of 
drug particles using dimensionless numbers 
 
Abstract: 
Dissolution testing is typically done in the USP 2 apparatus which has a broad velocity 
and hydrodynamic profile that is typically not in the range of that which a drug particle would 
encounter as it is being dissolved in the gastrointestinal tract.  Therefore making predictions in 
the USP 2 apparatus for the hydrodynamic impact on dissolution is difficult and it may not be a 
meaningful tool to assess the impact of hydrodynamics in vivo. However, the USP 4 apparatus 
has a more well-defined velocity profile that can be adjusted to be kept in a physiologically 
relevant range by altering the flow rate of the fluid in the apparatus.  This allows for the 
capability of modeling the impact of fluid velocity on particle dissolution using dimensionless 
numbers such as the Reynolds (Re), Schmidt (Sc), and the Sherwood (Sh) number. 
Experimental work was performed in the USP 4 apparatus for three different particle size 
sieve factions of ibuprofen. These sieve fractions were analyzed using optical microscopy to 
characterize the particle size and obtain a mean particle diameter for each sieve cut. The 
dissolution of each ibuprofen sieve cut was evaluated at various flow rates (6, 11 and 25ml/min) 
to evaluate the impact of velocity and Re number on the dissolution of the particles.   
This data was used to determine a mass transfer relationship that would provide the best 
explanation for defining the Sh number that could be used to predict particle dissolution at lower 
and more narrow Re number range (0.06<Re<2).  This approach was accomplished by 
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successfully applying the mass transfer model of Nelson and Galloway with the Rowe 
modification
1,2
. The model was able to accurately predict the impact of velocity on particle 
dissolution for the different particle sizes and fluid velocities when the void fraction in the area 
around the particles could be estimated.  However, there was a significant variation in the USP 4 
dissolution data which was typically seen at the lower flow rates possibly due to particle 
agglomeration or packed bed formation. 
Lastly the USP 4 data was compared to dissolution of the same sieve cuts in the USP 2 
apparatus.  The comparison of dissolution profiles showed much less experimental variation in 
the USP 2 apparatus and the average results for all of the sieve cuts were very similar to the USP 
4 experimental data at 11ml/min. Therefore the USP 4 apparatus presents the opportunity to 
model the impact of velocity but the USP 2 apparatus provides a robust dissolution test that 
offers a hydrodynamic environment similar to the environment the particles would see at low 
flow rates and at in vivo relevant velocities. 
Introduction  
Dissolution in all of the USP apparatuses has shown that varying the hydrodynamics can 
impact the rate at which a drug dissolves and this is particularly true for the most commonly used 
USP 2 apparatus
3-7
.  One of the main hydrodynamic components that can be elucidated from in 
vivo data is the flow rate and velocity in the gastrointestinal tract (GI). One of the disadvantages 
of the USP 2 apparatus, which is the most commonly used dissolution methodology, is the wide 
variation in velocities observed throughout the apparatus
8-11
. Also, the peak and bulk velocities 
(10-20cm/s) in the USP 2 apparatus are much larger than those seen in the intestinal tract (0.02-
1cm/s)
8,12-14
.  A dissolution test that can reduce the magnitude and variation in velocities would 
be preferred to understand the impact of hydrodynamics on particle dissolution and could offer a 
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more in vivo predictive dissolution test. For example, Katori et al. showed that very low 
rotational speeds in the USP 2 apparatus and low flow rates in the USP 4 apparatus can provide a 
IVIVC for controlled release tablets
15
.  
The USP 4 apparatus allows for a predictable and uniform fluid velocity profile 
throughout the cell
16-19
.  The flow rates can be made to be very low in the USP 4 apparatus (i.e. 
4ml/min) which would equate to an average fluid velocity of 0.06cm/s in the 12mm powder cell 
USP 4 apparatus. These low velocities are good approximations of intestinal velocities which 
would help to create a more meaningful hydrodynamic dissolution test experimentally. However, 
these low velocities may not be efficient at dispersing the particles which can cause the particles 
to agglomerate and form larger particles that will take longer to dissolve
20
. 
The ability to control the velocity that a particle experiences during the dissolution 
process allows for a better understanding of the impact of hydrodynamics on particle dissolution.  
Previous work has shown that changing the hydrodynamics in the different USP dissolution 
apparatuses can have a significant impact on both tablet and particle dissolution
4,21-24
.  Being 
able to predict the impact that changing the velocity will have on particle dissolution would 
provide a significant benefit when trying to predict how the different flows in the GI tract will 
impact dissolution.  Also, having a known velocity using the USP 4 apparatus creates the 
opportunity to expand on the particle dissolution models which rely on a diffusion layer 
thickness based on assumptions of the diffusion layer thickness being equal to the particle radius 
or a critical diffusion layer thickness 
24-29
. The USP 4 apparatus can provide an experimental 
fluid velocity (particle velocity = ((flow rate/area for flow) + settling velocity)/2) that can be 
incorporated into the predictions for dissolution through non-dimensional numbers (eg: 
Sherwood number).   
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Dimensionless Number Analysis of Dissolution Results  
The particle dissolution was predicted by using the Sherwood number (Sh #) which is a 
dimensionless number used to describe mass transfer. The Sh # is a parameter in the mass 
transfer coefficient for dissolution of a particle. It plays a role in defining the diffusion layer 
thickness (heff) of a dissolving particle 
30
.  
  
  
   
     
    
                                     
           
   
  
                              
     
  
  
   
       
  
                         
The dimensionless number approach to quantify dissolution using the USP 4 apparatus is 
not a novel idea. This approach has been previously applied to both tablet and particle 
dissolution
20,22,31
.  However, the definition for the Sh number for these dissolution studies has 
generally been based on the Ranz and Marshal model which will be discussed below. The Sh # is 
typically defined by the Reynolds number (Re #), and the Schmidt number (Sc #). Additionally 
there is usually a diffusion component that is a constant and set to equal = 2.The basic format of 
the Sh # for single particle solutions assuming infinite dilution is shown in equation 5.8. 
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The ∆U term is the velocity that the drug particles are assumed to be experiencing as they 
are dissolving. The α and x terms in the Sh # vary in the literature with the experimental systems 
and conditions
32-38
.  However, the Sh # that is most identifiable is the one proposed by Frossling 
and experimentally verified through the work of Ranz and Marshall who define it as  
Sh=2+0.6Re
0.5
Sc
1/3
 
32,39
.  However, this work dealt with the evaporation of a single sphere of 
liquid into air and does not necessarily translate to many drug particles that could be interacting 
with each other as they are dissolving in liquid.  This was specifically examined by D’arcy and 
Persoons who defined the diffusion layer thickness through the Ranz and Marshall model for 
their particle dissolution work.  Their approach assumed that the dissolution would be not be 
affected by increasing the flow rate in a USP 4 apparatus. This assumption applied to the Ranz 
and Marshall Model did not accurately account for the dissolution data they observed at different 
flow rates.  However, including the increasing fluid velocities they applied experimentally to the 
Ranz and Marshall approach does allow for more accurate predictions of dissolution (according 
to our calculations).   
Therefore the Ranz and Marshall theory was first applied to the particle dissolution data 
in the USP 4 apparatus to test the accuracy for our dissolution system.  However, this approach 
and several other Sh # variations in the literature did not accurately account for the experimental 
results in our system
33-36
.  Much of the past experimental work of mass transfer focused on either 
ideal systems with a single particle or solid pellet or the focus was also on modeling a large 
variation in Re numbers where Re # <1 to Re # >1,000 
33-36,40
.  These situations are quite 
different from those that a dissolving drug tablet or particle would typically experience in the 
intestinal tract or USP 4 apparatus (Re < 30)
41
. Therefore other work was evaluated to analyze 
141 
 
models studying the mass transfer of solid into liquids at low Sh # and Re #
1,2,40,42-45
.  Many of 
these models differ from one another but there was a unifying trend in much of the mass transfer 
work modeling fluidized beds.  The work by Nelson and Galloway offered an approach to 
calculate the Sh # when dealing with a packed or fluidized bed at low Re #’s.  This approach is 
given in Equation 5.9-5.10. 
   
   
 
 
 
        
 
 
        
 
  
   
 
 
 
     
 
       
 
 
      
                    
   
 
     
 
 
   
 
 
                                   
  The solution derived by Nelson and Galloway provides two rate limiting cases. The first 
limiting case is when the system has a void fraction of 1 (ie. single particle – infinite dilution) 
where the derivation reverts to the Ranz and Marshal model. The second limiting case is where 
the Sh # goes to zero as the Re # goes to zero in the presence of a packed or fluidized bed. This is 
shown in equation 5.11. 
   
 
     
 
 
 
 
     
 
 
    
  
 
                             
However, this approach did not adequately account for mass transfer at higher Re 
numbers that may be seen in fluidized beds. Therefore Rowe proposed a modification to the 
Nelson and Galloway approach (shown in equation 5.12) to accurately describe mass transfer 
when dealing with higher Re # that exceeds the mass transfer predictions using the Ranz and 
Marshall theory. 
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The   symbol is the void fraction in the system. The definition for  is the same as it 
appears in Equation 5.10 and the α term is still hypothesized to be equal to 0.6 just as it is in the 
Ranz and Marshall model.  A plot using the approach applied in equation 12 is shown in figure 
5.2 with the experimental data. This figure supports the use of the Rowe modification for fitting 
the USP 4 particle dissolution data.  However, one of the unknown parameters in applying the 
Nelson and Galloway approach with the Rowe modification to the USP 4 system is quantifying 
the void fraction without understanding the conditions the particles are experiencing while they 
are being dissolved. 
Additionally, the Re # for the particles was assumed to be equal to the fluid velocity 
during the flow portion of the pumping pulse and equal to the particle settling velocity during the 
no flow portion of the pulse.  Therefore the velocity is dependent on particle size and density. 
The equation for settling velocity shows that this dependence is at its greatest for large particle 
sizes and at low flow rates. However, as the particle dissolves, the particle velocity becomes 
more dependent on the fluid flow rate. This can be observed in figure 5.1which shows the 
velocity profiles for the particles sizes and flow rates used for the experiments.  
The main goal of this chapter was to use the USP 4 apparatus to accurately determine the 
impact that fluid velocity has on the dissolution of drug particles under physiologically relevant 
velocities as well as compare the dissolution in the USP 4 apparatus to dissolution in the USP 2 
apparatus. This work has shown that the dissolution of different particle sizes at different flow 
rates can be predicted accurately with the Nelson and Galloway approach that was modified by 
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Rowe as long as the void fraction is known or can be estimated. Additionally this work evaluated 
the viability of using the USP 4 apparatus to obtain meaningful hydrodynamic results in 
comparison to the USP 2 apparatus. 
Materials and Methods:  
The dissolution of 10mg of ibuprofen (Albermarle – Baton Rouge, Louisiana, USA; 
Lot#11550-0005) particles was studied using the Sotax CE-7 USP apparatus 4 with the 12mm 
powder cells.  Three different sieve cuts of ibuprofen were analyzed through optical microscopy 
to determine the particle size.  The mean particle diameter of the three different sieve cuts were 
45µm, 111µm, and 235µm. The true density of the ibuprofen particles was measured to be 
1.118mg/ml.  Each of the sieve cuts was studied at flow rates of 11 and 25ml/min.  Additionally, 
the 45µm and 111µm sieve cuts were also studied at 6ml/min.  Ten milligrams of the ibuprofen 
particles were introduced into the USP 4 Cells as part of a suspension composed of 50mM 
Acetate buffer ~pH4.00 and composed of Avicel RC-591microcrystalline cellulose powder 
(FMC BioPolymer – Philadelphia, Pennsylvania, USA; Lot#13825182) and sodium dodecyl 
sulfate (Fisher Scientific – Fair Lawn, New Jersey, USA; Lot # 125937) 20mg/ml 
ibuprofen/1.5% Avicel/0.75mM sodium dodecyl sulfate (SDS) suspension. The dissolution 
medium for the USP 4 dissolution tests consisted of 550ml of 0.75mM SDS, pH 4.5, 50mM 
acetate buffer (ibuprofen solubility =0.15mg/ml).  A closed system was used for the USP 4 set 
up so the fluid was continually recycled from the USP 4 cells to the 550ml of bulk fluid. Each 
cell had its own 550ml of bulk fluid.  The samples were taken using a peristaltic pump to pull 
2ml from the bulk solution of all the samples individually and all at the same time.   
Additionally dissolution of the 45, 111, and 235µm diameter ibuprofen particle sieve cuts 
was performed in the USP 2 apparatus.  The same suspensions were used for each but 20mg of 
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ibuprofen was added for each dissolution test. The dissolution medium composition was that was 
used for the USP4 but the volume used in the USP 2 apparatus was 900ml. The paddle was 
rotated at 50 RPM.  The 3ml samples were pulled manually using a syringe and filtered using a 
0.45µm acrodisc syringe filter. 
All of the dissolution samples were analyzed using a UV spectrophotometer (Agilent 
Technologies, Model# 61103A).  
 MATLAB was used for dissolution simulations. The ibuprofen particles sieve cuts were 
assumed to be monodisperse for all of the dissolution simulations and equal to the mean particle 
size that was measured. 
Results  
Figure 5.2 shows the calculations for Sh/Sc
1/3
 based on the results for each experimental 
condition as well as the theoretical values based on the Rowe Modification to the Nelson and 
Galloway approach for Sh #’s at different Re #’s assuming varying void fractions. The 
experimental results were evaluated from zero to 50% dissolved to calculate the experimental 
Sh/Sc
1/3
.  The experimental Sh/Sc
1/3
 values are consistent with the Rowe modification to the 
Nelson and Galloway approach for low Re numbers in packed or fluidized bed situations 
1,2,45
. 
The experimental data is in good agreement with the assumption that there is a void fraction of 
0.25 applying the Rowe approach. Therefore all of the experimental dissolution profiles were 
predicted utilizing the Rowe modification while assuming a void fraction of 0.25.   
Figure 5.3 shows how the Sh # changes with particle size and flow rate based on the 
Rowe approach assuming a void fraction of 0.25.  A large particle at a high flow rate will have a 
large Sh # due to a large Re #.  When assuming the presence of a void fraction due to a packed or 
fluidized bed, the Rowe model calculates a Sh number that goes to zero as the particle size and 
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fluid flow go to zero (Re goes to 0). This is different than the Ranz and Marshall model which 
states that the Sh number will become a constant equal to two when the Re number equals zero.  
The reason for the difference in these models is that the Ranz and Marshall model assumes the 
spherical particle is undergoing mass transfer in an infinite stagnant fluid which leads to a steady 
state solution that equals two when the Re # is equal to zero. However, the Nelson and Galloway 
model which was modified by Rowe assumes that the drug particle is a part of a collection of 
particles that no longer conform to a non-zero steady state solution and therefore the Sh # goes to 
zero as the Re # goes to zero. 
Figure 5.4 shows the impact of velocity and particle size on the diffusion layer thickness 
when applying the Rowe modification to the Nelson and Galloway approach while assuming a 
void fraction of 0.25.  Increasing the velocity decreases the size of the diffusion layer. However, 
as the particle radius goes to zero, so too does the Sh # as shown in figure 5.3. This leads to the 
diffusion layer thickness either staying relatively constant throughout the dissolution process as 
seen in the predictions at a 25ml/min flow rate or the diffusion layer thickness increasing as the 
particle is dissolving at flow rates of 6ml/min and 11ml/min flow rates. This is due to the 
relationship of diffusion layer thickness, Sh #, and particle size given in equation 2.  At flow 
rates of 6ml/min and 11ml/min the Sh # is decreasing faster than the particle size because of the 
lower Re numbers which leads the diffusion layer thickness to increase as the particle is 
dissolving. However, for a the faster flow rate (larger Re number) of 25ml/min the particle size 
and Sh # are decreasing at similar rates which is why there is a fairly constant diffusion layer 
thickness. 
Figure 5.4 also displays the initial diffusion layer thickness necessary to fit the data using 
an assumption of a critical diffusion layer thickness when applied to the experimental data. 
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These values were calculated for each dissolution experiment for the different particle sizes and 
flow rates used. The calculations followed the Wang and Flanagan approach which assumes the 
diffusion layer thickness is a function of a critical diffusion layer thickness value and the radius 
of the particle  
 
    
  
 
         
 
 
  
 .  These calculated values for diffusion layer thickness 
depended on the particle size and the fluid flow rate.  The values are in good agreement with the 
calculations using dimensionless numbers while assuming a void fraction of 0.25.  Therefore if 
an accurate characterization of the particle’s velocity and void fraction are known, then the 
dimensionless numbers approach will provide accurate predictions for the dissolution of drug 
particles based on physical properties of the dissolution system. However, if these properties of 
the system are unknown, then there is no benefit to using the dimensionless number approach. In 
cases with limited knowledge of the system, an average critical diffusion layer thickness 
approach may be a more practical way to predict particle dissolution. 
Figure 5.5 shows the experimental and predicted results for the dissolution of 45µm 
ibuprofen particles in the USP 4 apparatus at flow rates of 6ml/min, 11ml/min, and 25ml/min.  
The experimental and predicted results show that as the flow rate is increased, the dissolution 
rate of the particles increases as well. The experimental data shows a large variation in the 
results. The predictions do a fairly good job at predicting the data at all of the flow rates. The 
large variation in the percent dissolved at the low flow rate could be due to the particles not 
being dispersed well enough which could lead to the particles agglomerating and forming larger 
particles which take longer to dissolve. The data and predictions correspond well with the Rowe 
modification to the Nelson and Galloway model assuming a void fraction of 0.25. 
Figure 5.6 shows the experimental and predicted results for the dissolution of 111µm 
ibuprofen particles in the USP 4 apparatus at flow rates of 6ml/min, 11ml/min, and 25ml/min. 
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The predictions using the Rowe approach do a good job of accurately predicting the dissolution 
of the particles at all of the flow rates.  The 6ml/min flow rate data displays a lot of variation 
similar to the 45um data and again this could be caused by particles agglomerating which is 
likely more prevalent at lower flow rates. 
Figure 5.7 shows the experimental and predicted results for the dissolution of 235µm 
ibuprofen particles in the USP 4 apparatus at flow rates of 11ml/min and 25ml/min.  The 
experimental results show a large amount of variation. This could be due to particle 
agglomeration but also a packing of particles at the top of the cell which corresponds well with 
the assumption that there is a void fraction of 0.25. The Avicel was insoluble and would 
accumulate at the top of the cell which made it necessary to incorporate glass wool at the top of 
the cell before the filter in order to prevent the flow from being disrupted by catching the 
particles. Therefore the glass wool and the suspension particles could be two sources of the low 
void fraction that is being seen.   
Figures 5.8-5.10 show the dissolution results of the three different sieve cuts in the USP 2 
apparatus in the same dissolution medium composition as the USP 4 apparatus dissolution work 
but in 900ml of fluid. The paddle was stirred at a rate of 50RPM. The dissolution results show 
very little variation between dissolution runs unlike the USP 4 apparatus dissolution work.  Also 
the results are compared to the dissolution data in the USP 4 apparatus at 11ml/min and the 
dissolution profiles are very similar for each of the three different sieve cuts. 
Discussion 
The USP 4 data shows that particle dissolution is a function of particle size and fluid 
velocity. This relationship can be accurately approximated using dimensionless numbers but it 
does not conform to an infinite dilution approach of Ranz and Marshall. This leads to the 
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application of the Rowe modification to the Nelson and Galloway model which applies to 
particles in packed or fluidized beds. When it was assumed that there was a void fraction of 0.25, 
the predictions were able to accurately account for the experimental data.  The presence of a void 
fraction is most likely due the particles being localized to a small area in the USP 4 cells, the 
presence of glass wool, and the large number of Avicel particles that are insoluble in the 
dissolution media.   
This adjusted equation to calculate the experimental Sh # is consistent with other mass 
transfer data at low Re #’s in a packed bed and it does a accurate job of fitting all of the USP 4 
dissolution data presented 
1,2,45
.  However, applying this approach a priori adds the complexity of 
estimating the void fraction to solve for the dissolution of particles in the USP 4 apparatus. This 
approach cannot be accurately applied to the USP 4 apparatus without being able to estimate or 
calculate the void fraction that the particles are encountering in the USP 4 system before the 
experiment is undertaken.   Therefore this is not an ideal experimental system and would require 
more experimental work to determine an approach to quantify the fluid velocity and void 
fraction.  This approach could be applied to more data with glass wool to evaluate its robustness. 
Also, studies could be done on a low dose suspension without insoluble excipients to determine 
if the results conform to the Ranz and Marshall approach for predicting the mass transfer of drug 
particles. 
When comparing dissolution in the USP 2 apparatus at 50 RPM to dissolution in the USP 
4 apparatus at an 11ml/min flow rate with a low void fraction, there is little difference observed 
in the dissolution profiles. The particles in the USP 2 apparatus settled to the bottom of the 
vessel, where there is limited fluid flow, for the majority of the dissolution runs. Therefore the 
hydrodynamics experienced by the ibuprofen particles in the USP 4 apparatus experiments and at 
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the bottom of the USP 2 apparatus are similar. This suggests that there may be little benefit to 
using the USP 4 apparatus when there is a large dose of drug or large amount of insoluble 
excipient in an effort to obtain a better simulation of in vivo fluid velocities. However, this 
would depend on the density of the drug and the dosage form used. If the drug particles stay 
suspended in the bulk solution and do not settle to the bottom of the apparatus, the dissolution 
would be expected to occur much quicker in the USP 2 apparatus. Also, if a low dose suspension 
was formed that only contained well dispersed solid drug particles, the dissolution in the USP 4 
apparatus should conform to the Ranz and Marshall model. This would predict slower 
dissolution than the model proposed in this chapter and the dissolution would likely be slower 
than the dissolution of the particles that settled to the bottom of the USP 2 apparatus (see figure 
5.2). 
Conclusions 
The USP 4 apparatus offers a more well-defined fluid velocity profile that is in the range 
of what is physiologically relevant and allows for accurate predictions to be made. However, 
there is significant experimental variation caused by possible particle agglomeration or particles 
forming a packed or fluidized bed at the top of the cell. Additionally for accurate predictions to 
be made, an accurate estimate for void fraction in the USP 4 cell must be made because of the 
large impact it can have on the dissolution data. The Avicel particles in the suspension were 
insoluble in the dissolution media and therefore were present in the USP 4 cells throughout the 
dissolution runs. The drug and Avicel particles were pushed by the fluid flow to the top of the 
cell where glass wool was placed to prevent the particles from impeding flow.  These two factors 
and the dissolution data suggest that there was a significant decrease in the porosity around the 
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solid particles which leads to a low void fraction of 0.25 being an accurate assessment of the 
experimental conditions. 
The experimental and predicted data shows that fluid velocity has a signficant impact on 
dissolution (and diffusion layer thickness). However, more work is needed to assess how 
effectively this model can be applied to other dosage forms and particles with different densities 
and solubilities.  The major problem with using the dimensionless number approach for 
predicting dissolution in the USP 4 apparatus is the presence of too many unknown experimental 
variables in the USP 4 cells to accurately describe the conditions the drug particles are 
experiencing as they dissolve.  Depending on the dosage form and location of the particles in the 
USP 4 cells, it is difficult to accurately assess the void fraction in the apparatus and how the 
particle surface area and velocity is being affected. The dimensionless number approach a priori 
will not be accurate unless these parameters are known with relative accuracy before the 
dissolution test is performed.  
The dissolution profiles in the USP 2 apparatus were very similar to the dissolution 
profiles in the USP 4 apparatus at an 11ml/min flow rate and the results were much less variable.  
This illustrates that although the fluid velocity can be much greater and highly variable in the 
bulk fluid of the USP 2 apparatus, the actual velocities that the drug particle experiences when it 
is dissolving is not much different than that seen in the USP 4 apparatus in conditions of packed 
or fluidized beds.  This is likely due to the particles settling at the bottom of the USP 2 apparatus 
shortly after being introduced into the system.  Bai et al. showed that computational fluid 
dynamic (CFD) predictions of velocity at the bottom of the USP 2 vessel are < 1cm/s which is 
much less than what the particles would experience in the bulk solution.  Therefore if the 
particles settle to the bottom of the vessel fast enough, the velocities they will experience during 
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dissolution are similar to what a particle may experience in the USP 4 apparatus when the 
particles encounter conditions of packed or fluidized beds.   
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Figures 
 
Figure 5. 1. The calculated velocity profiles for the different experimental flow rates and 
pparticle sizes.  Key (         ) Calculated velocity profile for a flow rate of 6ml/min; (         ) 
Calculated velocity profile for a flow rate of 11ml/min; (         ) Calculated velocity prfile for a 
flow rate of 25 ml/min; (            ) Calculated settling velocity for a 235µm particle; (           ) 
Calculated settling velocity for a 111µm particle; (         ) Calculated settling velocity for a 45µm 
particle; 
 
Figure 5. 2. Calculated Sh/Sc
1/3
 based on the Nelson and Galloway approach with the Rowe 
modification at different void fractions and the experimental Sh/Sc
1/3
 and as a function of Re #.   
Key              alculated Sh #’s based on the Ranz and Marshall ;  (              alculated Sh #’s with 
void fraction = 0.999 ;              alculated Sh #’s void fraction = 0.90;               alculated Sh #’s 
void fraction = 0.50;              alculated Sh #’s void fraction = 0.25; 
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Figure 5. 3.  alculated Sh #’s based on the best fit data and as a function of particle size and 
flow rate.   Key              alculated Sh #’s for a flow rate of 6ml/min;              alculated Sh #’s 
for a flow rate of 11ml/min;              alculated Sh #’s for a flow rate of  5 ml/min;   
 
Figure 5. 4. Predictions for diffusion layer thickness using the best fit Sh# based on the 
dissolution data.   Key (         ) predictions for diffusion layer thickness at flow rate of 6ml/min;   
(         ) predictions for diffusion layer thickness at flow rate of 11ml/min; (         ) predictions for 
diffusion layer thickness at flow rate of 25ml/min; (    ) calculated diffusion layer for the particle 
sizes tested at a flow rate of 6 ml/min; (    ) calculated diffusion layer for particle sizes tested at a 
flow rate of 11 ml/min; (    ) calculated diffusion layer for particle sizes tested at a flow rate of 25 
ml/min; 
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Figure 5. 5. USP 4 dissolution results of 45µm ibuprofen particles in 50mM Acetate buffer at pH 
4.5 and at 37
o
C.   Key (    ) experimental dissolution at a flow rate of 6ml/min; (    ) experimental 
dissolution at a flow rate of 11ml/min; (    ) experimental dissolution at a flow rate of 25ml/min;  
(         ) predicted dissolution at 6ml/min; (         ) predicted dissolution at 11ml/min;  (          ) 
predicted dissolution at 25ml/min; 
 
Figure 5. 6. USP 4 dissolution results of 111µm ibuprofen particles in 50mM Acetate buffer at 
pH 4.5 and at 37
o
C.   Key (    ) experimental dissolution at a flow rate of 6ml/min; (    ) 
experimental dissolution at a flow rate of 11ml/min; (    ) experimental dissolution at a flow rate 
of 25ml/min;  (         ) predicted dissolution at 6ml/min; (         ) predicted dissolution at 
11ml/min;  (          ) predicted dissolution at 25ml/min; 
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Figure 5. 7. USP 4 dissolution results of 235µm ibuprofen particles in 50mM Acetate buffer at 
pH 4.5 and at 37
o
C.   Key (    ) experimental dissolution at a flow rate of 6ml/min; (    ) 
experimental dissolution at a flow rate of 11ml/min; (    ) experimental dissolution at a flow rate 
of 25ml/min;  (         ) predicted dissolution at 6ml/min; (         ) predicted dissolution at 
11ml/min;  (          ) predicted dissolution at 25ml/min; 
 
 
Figure 5. 8. USP 4 and USP2 dissolution results of 45µm ibuprofen particles in 50mM Acetate 
buffer at pH 4.5 and at 37
o
C.   Key (    ) experimental dissolution in the USP 4 apparatus at a 
flow rate of 11ml/min; (    ) experimental dissolution in the USP 2 apparatus 
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Figure 5. 9. USP 4 and USP2 dissolution results of 111µm ibuprofen particles in 50mM Acetate 
buffer at pH 4.5 and at 37
o
C.   Key (    ) experimental dissolution in the USP 4 apparatus at a 
flow rate of 11ml/min; (    ) experimental dissolution in the USP 2 apparatus. 
 
 
Figure 5. 10. USP 4 and USP2 dissolution results of 235µm ibuprofen particles in 50mM Acetate 
buffer at pH 4.5 and at 37
o
C.   Key (    ) experimental dissolution in the USP 4 apparatus at a 
flow rate of 11ml/min; (    ) experimental dissolution in the USP 2 apparatus  
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Chapter 6 
 
The Impact of In Vivo Relevant Fluid Velocity on In vitro HPMC Tablet 
Erosion and In Vitro – In Vivo Correlation  
 
Abstract 
The hydrodynamics and fluid velocity experienced by an eroding hydroxypropyl 
methylcellulose (HPMC) extended release tablet can have a significant effect on the rate at 
which the tablet erodes. An in vitro test that accurately simulates the in vivo environment should 
be a better predictor of in vivo erosion rate and drug release. The USP 4 apparatus was chosen to 
evaluate the impact of using an in vivo relevant velocity on tablet erosion and to assess its 
effectiveness in developing an in vitro/in vivo correlation.  In this work the tablet erosion rates 
were measured in the USP 4 apparatus and were compared to the erosion rates of the same 
HPMC tablet formulations that were determined by Jain et al. in humans and using the USP 2 
apparatus
1
.  
The tablet erosion studies done in the USP 4 apparatus utilized the 22.6mm flow through 
cell at a 25ml/min flow rate (0.1 cm/s velocity).  The in vivo erosion rate measured in humans by 
Jain et al. was significantly greater compared to the in vitro erosion rate using the USP 4 
apparatus. The erosion rate of the tablets in the USP 4 apparatus was also significantly less than 
the erosion rates observed using the USP 2 apparatus (50RPM ~ 10cm/s velocity).   
The erosion rate data in the USP 2 apparatus provided a better correlation for the erosion 
rate data in vivo. Therefore, it appears that, while the USP 4 apparatus does provide a more well-
defined erosion environment, it may not incorporate all of the physiological parameters that may 
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impact tablet erosion to provide a good IVIVC.  To develop an in vitro erosion test that can 
provide meaningful insight into the in vivo erosion process, additional physiological parameters 
that impact erosion may need to be considered. 
Introduction 
Hydroxypropyl methylcellulose (HPMC) formulations have been widely studied to 
observe their controlled release behavior and to understand how the different formulations erode 
under different hydrodynamic conditions, in different dissolution apparatus, and in different 
media
2-7
. All of these parameters can contribute significantly to the erosion rate of the HPMC 
tablet formulation. Additionally, the formulation of HPMC and the excipients chosen can have a 
large impact on tablet erosion
7,8
.  
The erosion medium will not be a major focus in this study but the composition of the 
medium can have an impact on the erosion rate but this is a function of the HMPC form being 
studied
2,4,6
.  The ionic strength and the concentration of surfactants are the two erosion medium 
parameters that have the most significant impact on HPMC tablet erosion
2,4,6,9
. However, the pH 
of the solution can also have an effect if there are wide variations in pH being studied. This 
would be most noticeable when analyzing erosion in simulated gastric fluid compared to 
simulated intestinal fluid 
4-6
.   
The main focus of this study will be the in vitro hydrodynamic impact on the erosion of 
HPMC tablets and if making the conditions more in vivo relevant in terms of fluid velocity will 
offer a better in vitro/in vivo correlation. Adjusting the agitation rate or the RPM of the different 
dissolution apparatus can have a large effect on tablet erosion. Increasing the agitation rate will 
increase the erosion rate for HPMC tablets
10-12
.  Also, the hydrodynamics of different dissolution 
methods have been shown to have a significant impact on the erosion process and the erosion 
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rate
10-15
.  Therefore employing different dissolution methodologies that apply different 
hydrodynamic stresses on the tablet can lead to a wide variation in tablet erosion results. This 
makes it necessary to have all of the experimental parameters be relevant based on in vivo 
conditions when performing an erosion study on tablets made with different HPMC formulations 
to provide a meaningful IVIVC. 
In vitro erosion studies have been done to develop an IVIVC using both the USP 2 and 
the USP 3 apparatus
1,3,12,16,17
. This has typically been done by examining the in vitro percent 
drug dissolved and the in vivo plasma concentration
12,16,17
.  These correlations between the in 
vitro and in vivo parameters were typically done by using a Levy plot to display how the in vitro 
percent dissolved correlates to the fraction of the drug absorbed in vivo
12,17
. However, work has 
also been done to specifically correlate the in vitro and in vivo erosion rates 
1,3
. This in vitro 
work typically involves the USP 2 apparatus and a marker (charcoal or magnetic moment) whose 
change is correlated to the in vitro erosion and this change in the marker is measured in vivo. The 
correlations between in vitro and in vivo tablet erosion following this method are the best when 
the polymer concentration is above the percolation threshold.  However, these studies gave no 
consideration to the hydrodynamics and fluid velocity in the in vitro studies to correlate with the 
same parameters in vivo. 
The goal of this study was to measure the erosion rate of the HPMC controlled release 
tablets using the USP 4 apparatus at an average velocity of 0.1cm/s in the USP 4 cell. This fluid 
velocity is what the tablets would likely encounter throughout the erosion process in the small 
intestine
18,19
. These in vitro erosion rates would then be compared to the in vivo small intestine 
erosion rates in humans that were observed for the same formulations by Jain et al.  Additionally 
the erosion rate using the USP 4 apparatus was compared to the erosion rate using the USP 2 
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apparatus based on the work of Jain et al. The impact velocity has on the erosion of different 
HMPC tablet formulations and how much it contributes to the in vivo erosion rate will be 
presented and discussed. This study will help to assess the use of the USP 4 apparatus as an 
evaluation tool for in vivo erosion rates in humans. 
Materials and Methods 
HPMC Tablets were made using four different formulations that were used as supplied 
from AstraZeneca.  The components for the four different formulations and their %w/w are 
given in table 6.1 which was reproduced from Jain et al. 2014.  
The tablets were made by weighing 350mg of the powder for each of the different 
formulations and using direct compression via a carver tablet press and a 1cm diameter convex 
punch and die. A compression pressure of 170 MPa was applied for 30 seconds and then the 
pressure was slowly released  over 30 seconds. The tablet thickness and weight was recorded. 
The tablet thickness ranged from 3.65mm to 3.90mm which is similar to the tablet thickness of 
3.7mm measured by Jain et al for the same tablet formulations.   
To ensure that the tablets were similar to those made by Jain et al., the tablet hardness 
was measured for each formulation. This was done by placing the tablets in a tablet hardness 
tester ( Schleunger  Tablet Tester 6D)to measure the breaking force of the tablets.  The tablet 
hardness ranged from 61Nto107N and is in the range of reported values by Jain et al.  
The tablet erosion study was performed using the Sotax CE7 USP 4 dissolution 
apparatus.  The 22.6 mm cells were used with the 5mm red bead at the bottom of cell and filled 
with 1mm glass beads to have laminar flow throughout the cell. The tablets were placed with the 
long axis horizontally on the tablet holder. The erosion medium used was 500ml of pH 6.8 
50mM phosphate buffer that was made isotonic with NaCl. A closed system was used so the 
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erosion medium was pumped into the cells and pumped back into the same bulk solution. Each 
USP 4 cell had its own bulk solution that was pumped into the cell and recycled back. The flow 
rate used for the experiments was 25ml/min.  Experiments were done in duplicate for each tablet 
formulation at each time point. 
The tablets were taken out at a specific time point and placed in a 9 well glass pyrex dish 
which was then placed in an oven (VWR BIO model) at 85
o
C for at least 48 hours. The dried 
tablets were then weighed to calculate the percent weight loss  that occurred.  Whole tablets of 
each formulation that were not eroded were dried in the same way to determine the percent water 
that was contained in each formulation to account for the percentage of water in the tablet. 
Results 
Figure 6.1 shows the erosion data in the USP 4 apparatus. The data displays the same 
rank order erosion that was observed in the in vitro USP 2 study and the in vivo study by Jain et 
al.  This also correlates well with past work based on the percent of the HPMC’s in each of the 
formulations.  Figure 6.1 also shows that the USP 4 erosion results display a linear increase over 
the duration of the study which was similar to the USP 2 erosion data by Jain et al. There was 
only minor variation in the percent erosion between each of the tablets at each time point.   
The erosion rates throughout the duration of the experiment are shown in figure 6.2. Figure 6.2 
also shows there was minor variation in the erosion rate over the entire timeframe of the 
experiment. Therefore even as the tablet swells in the USP 4 apparatus, which would cause a 
change in the velocity profile around the tablet due to the area available for fluid flow, there is 
little impact on the erosion rate for the tablet.     
Figure 6.3 shows the impact of in vitro hydrodynamics by comparing the erosion rate 
data from the USP 4 apparatus to the USP 2 apparatus. The same buffer concentration and pH 
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was used for each erosion study. However, the ionic strength was made to be isotonic in the USP 
4 test while the USP 2 erosion tests were done at an ionic strength that was based exclusively on 
50mM phosphate buffer at pH 6.8. This difference could impact the data by slightly increasing 
the USP 4 erosion rates based on past work that examined the impact of ionic strength on tablet 
erosion
4,6
. This was also confirmed by preliminary work that replicated the USP 2 erosion work 
of Jain et al. that compared erosion in both isotonic and non-isotonic 50Mm phosphate buffer at 
pH 6.8. However, the major difference in these studies was the hydrodynamics in the USP 2 
apparatus and the USP 4 apparatus. Comparing the erosion rates in the USP 4 apparatus to the 
erosion rates the in the USP 2 apparatus shows the erosion rate is around 3.5-4.5 times greater in 
the USP 2 apparatus than in the USP 4 apparatus. The greatest difference in erosion rates was 
seen for formulation 1 which contains the largest amount of methocel K4M. The smallest 
difference was seen for formulation 4 which contains the smallest percentage of HPMC and the 
faster eroding HPMC form K100LV.    
Figure 6.4 compares the in vitro erosion rate using a physiologically relevant velocity in 
the USP 4 apparatus to the in vivo erosion rate data in the small intestine of humans. The erosion 
rate was much more variable in vivo but the mean erosion rate values were significantly higher 
than the USP 4 in vitro erosion rate. The in vivo erosion rates were 2-4.5 times greater than the in 
vitro erosion rates in the USP 4 apparatus. Again, formulation 1 showed the largest difference in 
erosion rates and formulation 4 showed the smallest difference. 
Discussion  
The impact of hydrodynamics on extended release polymer tablet erosion is significant 
when comparing the erosion data in the USP 4 apparatus to that of the USP 2 apparatus. Thus 
identifying the correct hydrodynamic environment an extended release tablet would see in vivo is 
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a key component for developing an accurate IVIVC for tablet erosion.  The experimental data 
suggests that this is more significant in the case of slower eroding HPMC forms such as 
methocel K4M. The velocity chosen for the USP 4 experiment was 0.1 cm/s which is in the 
range of what the extended release tablet could expect to encounter in the small intestine of 
humans. However, the in vivo erosion was much faster than the in vitro erosion in the USP 4 
apparatus. Therefore even though the velocity the tablet experiences is an important component 
of hydrodynamics it is not the only one that is involved in the tablet erosion in vivo.  The shear 
rate is a very important hydrodynamic component that is not likely to be similar to in vivo 
conditions. The tablet is held in place by a tablet holder throughout the duration of the 
experiment and this setup would likely not account for the differences in shear the tablet would 
experience as it is traveling through the intestinal tract. 
In addition to the hydrodynamics of the in vitro study not characterizing the in vivo 
environment, there are other factors that could limit the IVIVC based on the methods used. One 
of these factors could be the erosion medium used during the in vitro test. The erosion rate could 
be significantly increased in the USP 4 apparatus by adding more salt to the buffer solution or 
bile acids. However, this would still have to be done within the limits of physiologically relevant 
in vivo fluid of the gastrointestinal tract.  Another possible parameter that cannot be taken into 
account in the USP 4 experiment is the sloughing off of the wetted tablet as it is traveling 
through the gastrointestinal tract and coming into contact with the wall of the intestine.  Once the 
polymer tablet begins to swell in the erosion medium, it is easy for the outer portion of the tablet 
to rub off when it comes into contact with another object. This mechanism for release could 
possibly be observed using the USP 3 apparatus since the tablet would continually be coming 
into contact with the top and bottom mesh of the apparatus.   
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Conclusion: 
The data shows that matching the in vitro velocities to the in vivo velocities in the 
intestinal tract is not enough to accurately correlate the in vitro erosion rate data to the in vivo 
erosion rate data in humans.  This is likely due to the many other factors than can impact tablet 
erosion that were not simulated in the USP 4 in vitro study. The in vitro study did not account for 
parameter such as in vivo relevant media, in vivo shear rates, and the rubbing off of the tablet 
against the intestinal wall.  
The bulk velocity (~10cm/s) the tablets saw in the USP 2 apparatus in the study by Jain et 
al. is a great deal larger than what is seen in the in the GI tract.  However, the results in the USP 
2 apparatus are a much better predictor of the in vivo erosion rates than the results in the USP 4 
apparatus.  This was not true however for formulation 4 and there is no physiological basis for 
performing in vitro erosion studies under the hydrodynamic conditions of the USP 2 apparatus 
with the tablet in a stationary basket. Therefore the USP 2 apparatus is not an ideal erosion 
methodology for developing an in vitro extended release polymer tablet erosion study that can 
better predict in vivo results.  The next step in developing a better IVIVC methodology for 
eroding tablets would be to include physiologically relevant parameters that impact the erosion 
of the polymer tablets. This could be done by incorporating the parameters into either the USP 4 
apparatus or a novel apparatus to better simulate the conditions the tablets would be seeing in 
vivo. 
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Tables 
Table 6. 1. HPMC powder components for each tablet formulation 
 Tablet Formulation 
Component #1 #2 #3 #4 
Methocel K4M % (w/w) 23.0 10.0 - - 
Methocel K100LV % (w/w) 17.0 30.0 40.0 20.0 
DI-TAB % (w/w) 57.6 57.6 57.6 77.6 
Sicovit % (w/w) 1.4 1.4 1.4 1.4 
Pruv % (w/w) 1.0 1.0 1.0 1.0 
 
Figures 
Figure 6. 1. Experimental tablet erosion profiles of the 4 different formulations tested using the 
USP 4 apparatus at a flow rate of 25ml/min 
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Figure 6. 2. Experimental erosion rates of the 4 different formulations tested using the USP 4 
apparatus at a flow rate of 25ml/min 
 
 
Figure 6. 3. Comparison of the tablet erosion rates for the 4 different formulations tested in vitro 
using the USP 4 apparatus and the USP 2 apparatus 
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Figure 6. 4. Comparison of the tablet erosion rates for the 4 different formulations tested in vitro 
using the USP 4 apparatus and in vivo in the small intestine. 
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